FedInvent™ Patent Applications
Application Details for Thursday, September 08, 2022
This page was updated on Thursday, September 08, 2022 at 04:31 PM GMT
Department of Health and Human Services (HHS)
| US 20220279767 | SYKES et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of Columbia University in the City of New York (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Megan SYKES (New York, New York); Robert J. HAWLEY (New York, New York) |
| ABSTRACT | The present disclosure provides for transgenic swine, comprising one or more nucleotide sequences encoding one or more HLA I polypeptides and/or one or more HLA II polypeptides inserted into one or more native SLA loci of the swine genome, methods of making and methods of using. The present disclosure also provides for improved methods of making human immune system mice. |
| FILED | Monday, April 18, 2022 |
| APPL NO | 17/722697 |
| CURRENT CPC | Animal Husbandry; Care of Birds, Fishes, Insects; Fishing; Rearing or Breeding Animals, Not Otherwise Provided For; New Breeds of Animals A01K 67/0278 (20130101) Original (OR) Class A01K 2207/12 (20130101) A01K 2217/052 (20130101) A01K 2227/105 (20130101) A01K 2227/108 (20130101) A01K 2267/025 (20130101) A01K 2267/0387 (20130101) Preparations for Medical, Dental, or Toilet Purposes A61K 35/26 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220279777 | MOSKOWITZ et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CELLPHIRE INC. (Rockville, Maryland) |
| ASSIGNEE(S) | CELLPHIRE INC. (Rockville, Maryland) |
| INVENTOR(S) | Keith Andrew MOSKOWITZ (Westfield, Indiana); Braden Carl ISHLER (Gaithersburg, Maryland); William Matthew DICKERSON (Washington, District of Columbia); Amber Nicole LEE (Rockville, Maryland); Shan XU (Rockville, Maryland); Stephon Edward AMOS (Buckeystown, Maryland); Rafael JORDA (Merignac, France); Michael Alexander MATHEWS (Arlington, Virginia) |
| ABSTRACT | Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein. |
| FILED | Thursday, February 17, 2022 |
| APPL NO | 17/674831 |
| CURRENT CPC | Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators A01N 1/0221 (20130101) Original (OR) Class Preparations for Medical, Dental, or Toilet Purposes A61K 35/19 (20130101) A61K 38/363 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 7/04 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0644 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/86 (20130101) G01N 33/96 (20130101) G01N 33/6893 (20130101) G01N 2333/705 (20130101) G01N 2800/224 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280043 | Baran |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Rochester (Rochester, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Timothy M. Baran (Rochester, New York) |
| ABSTRACT | The present invention provides an optical probe system that allows for determination of optical properties at the wall of a hollow cavity and photosensitizer uptake at the time of photodynamic therapy (PDT). In one embodiment, this system provides for rigorous treatment planning to maximize efficacy and minimize risk to patients by optimizing the concentration of the scattering emulsion infused into the cavity and the delivered laser power. |
| FILED | Friday, March 04, 2022 |
| APPL NO | 17/687052 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/0071 (20130101) Original (OR) Class A61B 5/0084 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 5/062 (20130101) A61N 5/067 (20210801) A61N 5/0603 (20130101) A61N 2005/0626 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 20/40 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280062 | DeMauro et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Edward P. DeMauro (Hamilton, New Jersey); German Drazer (Skillman, New Jersey); Hao Lin (Montgomery, New Jersey); Mehdi Javanmard (West Windsor, New Jersey) |
| ABSTRACT | A system and associated method for capturing and detecting a target analyte in a sample comprising an aerosol include a capture device, to capture a sample comprising an aerosol including a target analyte. The capture device includes an input to receive the sample, an output to release the sample for capturing, and a channel to flow the sample from the input toward the output. The channel is configured to accelerate the flowing sample to allow capturing of particles from the flowing sample, to thereby generate a captured sample including the target analyte. A sensor device is coupled to the capture device to receive at least a portion of the captured sample including the target analyte, to detect the target analyte in the captured sample based on an impedance measurement. The capture device can include a nozzle and an impact plate coupled with the nozzle and the sensor device. |
| FILED | Friday, March 04, 2022 |
| APPL NO | 17/653621 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/082 (20130101) Original (OR) Class A61B 5/097 (20130101) A61B 5/742 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280066 | Chu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California); MAKANI SCIENCE INC. (lrvine, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael Chu (Irvine, California); William E. Saltzstein (Irvine, California); Michelle Khine (Irvine, California) |
| ABSTRACT | A wearable strain sensor for measuring respiration volume and respiration rate is described herein. The wearable strain sensor includes a flexible yet not stretchable connector that connects soft electronics to hard electronics. The flexible and non-stretch able connector removes stress/strain from the soft/hard interface, thereby preventing damage to sensor components and maintaining electrical connection. |
| FILED | Wednesday, September 16, 2020 |
| APPL NO | 17/760608 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/091 (20130101) Original (OR) Class A61B 5/0816 (20130101) A61B 5/6832 (20130101) A61B 2562/164 (20130101) A61B 2562/227 (20130101) A61B 2562/0261 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280079 | Kim et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Curators of the University of Missouri (Columbia, Missouri) |
| ASSIGNEE(S) | The Curators of the University of Missouri (Columbia, Missouri) |
| INVENTOR(S) | Chang-Soo Kim (Rolla, Missouri); William Stoecker (Rolla, Missouri); Paul Nam (Rolla, Missouri); Mousumi Bose (Rolla, Missouri); Jason Hagerty (Rolla, Missouri) |
| ABSTRACT | Improved sensor compositions comprising a dye are provided. The compositions are generally characterized by at least partially immobilizing the dye on polymeric microparticles and dispersing in a dispersion medium. The dye may comprise an oxygen, humidity, carbon dioxide, temperature, or pH-responsive dye. Also provided is a sensor patch comprising a substrate and the sensor composition comprising a dye. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/685609 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/6833 (20130101) A61B 5/14552 (20130101) Original (OR) Class A61B 5/14556 (20130101) A61B 2562/046 (20130101) Organic Dyes or Closely-related Compounds for Producing Dyes; Mordants; Lakes C09B 47/04 (20130101) C09B 67/009 (20130101) C09B 67/0097 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280081 | ANDESHMAND et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | TALIS BIOMEDICAL CORPORATION (Menlo Park, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sayeed ANDESHMAND (Dublin, California); Thomas H. CAULEY, III (Redwood City, California); John DIXON (Moss Beach, California); David GLADE (San Ramon, California); Hédia MAAMAR (El Dorado Hills, California); Michael John McADAMS (Los Gatos, California); Dzam-Si Jesse NG (Fremont, California); David Alexander ROLFE (San Francisco, California) |
| ABSTRACT | Methods and systems are provided for point-of-care nucleic acid amplification and detection. One embodiment of the point-of-care molecular diagnostic system includes a cartridge and an instrument. The cartridge can accept a biological sample, such as a urine or blood sample. The cartridge, which can comprise one or more of a loading module, lysis module, purification module and amplification module, is inserted into the instrument which acts upon the cartridge to facilitate various sample processing steps that occur in order to perform a molecular diagnostic test. |
| FILED | Monday, August 17, 2020 |
| APPL NO | 17/635044 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/150755 (20130101) A61B 5/150961 (20130101) Original (OR) Class Chemical or Physical Laboratory Apparatus for General Use B01L 3/502761 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/689 (20130101) C12Q 1/6888 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280114 | Bhagavatula et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sharath Krishna Bhagavatula (Cambridge, Massachusetts); Kunj Bhaveshkumar Upadhayaya (Calgary, Canada); Alex Andrew Lammers (Cambridge, Massachusetts); Oliver Jonas (Weston, Massachusetts); Devon Michael Thompson (Ben Lomond, California) |
| ABSTRACT | An anchoring apparatus for a medical microdevice and a method of selectively maintaining the medical microdevice in a predetermined position within a body tissue are provided. The medical microdevice includes a body having longitudinally spaced proximal and distal device ends and a guidewire extending proximally from the proximal device end. The anchoring apparatus includes a selectively expandable anchor having longitudinally spaced proximal and distal anchor ends. A selected one of the proximal and distal anchor ends is connected to the distal or proximal device end, respectively. The anchor self-expands from a collapsed insertion condition to an expanded anchoring condition after insertion into a body tissue to resist post-implantation motion of the microdevice. |
| FILED | Wednesday, August 19, 2020 |
| APPL NO | 17/637145 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/6839 (20130101) Original (OR) Class A61B 10/0233 (20130101) A61B 17/0057 (20130101) A61B 17/3468 (20130101) A61B 18/1492 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280126 | Altunbas |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, a body corporate (Denver, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Cem Altunbas (Denver, Colorado) |
| ABSTRACT | The present invention relates generally to X-ray detectors and more particularly to a system and a method for integrating an anti-scattering grid with scintillators to significantly enhance the performance of flat panel X-ray detector. In particular, the performance of a flat panel X-ray detector may be enhanced by photon counting detector pixels configured underneath the septa of a 2D antiscatter grid. |
| FILED | Tuesday, January 11, 2022 |
| APPL NO | 17/572718 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 6/4035 (20130101) A61B 6/4216 (20130101) A61B 6/4283 (20130101) A61B 6/4291 (20130101) Original (OR) Class Measurement of Nuclear or X-radiation G01T 1/2002 (20130101) G01T 1/2006 (20130101) G01T 7/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280188 | Bhagavatula et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sharath Krishna Bhagavatula (Cambridge, Massachusetts); Kunj Bhaveshkumar Upadhayaya (Calgary, Canada); Alex Andrew Lammers (Cambridgge, Massachusetts); Oliver Jonas (Weston, Massachusetts); Devon Michael Thompson (Ben Lomond, California) |
| ABSTRACT | A microdevice includes a body having longitudinally spaced proximal and distal device ends and a guidewire extending proximally from the proximal device end. An anchoring apparatus includes an anchor having longitudinally spaced proximal and distal anchor ends. The anchoring apparatus is selectively expandable between a collapsed insertion condition and an expanded anchoring condition within the body tissue. A retrieval apparatus for selectively retrieving the medical microdevice and its associated anchoring apparatus from a target implantation site of a body tissue is described. The retrieval apparatus includes a stylet having proximal and distal stylet ends longitudinally separated by a stylet lumen configured to selectively accept the guidewire. A retrieval sheath has proximal and distal sheath ends longitudinally separated by a sheath lumen. The sheath lumen is configured to selectively and concurrently laterally surround the microdevice and the stylet therewithin for removal from the body tissue. |
| FILED | Wednesday, August 19, 2020 |
| APPL NO | 17/637182 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 17/3468 (20130101) Original (OR) Class A61B 17/32053 (20130101) A61B 2017/22049 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280423 | Nedergaard et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Rochester (New York, New York) |
| ASSIGNEE(S) | University of Rochester (New York, New York) |
| INVENTOR(S) | Maiken Nedergaard (Rochester, New York); Benjamin Plog (New York, New York); Humberto Mestre (New York, New York); Tuomas O. Lilius (Helsinki, Finland); Andreas I. Jensen (Virum, Denmark); Steven A. Goldman (Webster, New York) |
| ABSTRACT | This invention relates to improving delivery of agents (e.g., one or more nanoparticles) to the central nervous system. |
| FILED | Monday, March 21, 2022 |
| APPL NO | 17/699953 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0085 (20130101) Original (OR) Class A61K 9/5115 (20130101) A61K 9/5146 (20130101) A61K 47/02 (20130101) Peptides C07K 16/18 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280428 | ZINGER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Methodist Hospital (Houston, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Assaf Yosef ZINGER (Houston, Texas); Francesca TARABALLI (Houston, Texas) |
| ABSTRACT | Disclosed are liposomal formulations and biomimetic proteolipid nanoparticles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. Leukocyte-based biomimetic nanoparticles are disclosed that incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here it is shown that, while increasing the protein:lipid ratio to a maximum of 1:20 (w/w) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. The combined use of a microfluidic, bottom-up approach and tuning of key synthesis parameter enabled the synthesis of reproducible, enhanced biomimetic nanoparticles that have the potential to improve treatment of inflammatory-based conditions through targeted nanodelivery, including particular cancers such as human breast cancer, and TNBC in particular. |
| FILED | Friday, March 04, 2022 |
| APPL NO | 17/686406 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/1271 (20130101) A61K 9/1277 (20130101) Original (OR) Class A61K 31/713 (20130101) A61K 45/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280429 | Zinger et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Methodist Hospital (Houston, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Assaf Yosef Zinger (Houston, Texas); Francesca Taraballi (Houston, Texas) |
| ABSTRACT | Disclosed are liposomal formulations and biomimetic proteolipid nanoparticles that possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types. Leukocyte-based biomimetic nanoparticles are disclosed that incorporate cell membrane proteins to transfer the natural tropism of leukocytes to the final delivery platform. However, tuning the protein integration can affect the in vivo behavior of these nanoparticles and alter their efficacy. Here it is shown that, while increasing the protein:lipid ratio to a maximum of 1:20 (wt./wt.) maintained the nanoparticle's structural properties, increasing protein content resulted in improved targeting of inflamed endothelium in two different animal models. The combined use of a microfluidic, bottom-up approach, and the tuning of key synthesis parameters enabled the synthesis of reproducible, biomimetic nanoparticles for the improved targeted nanodelivery of a variety of inflammatory-based conditions, including particular cancers such as human breast cancer, and TNBC, in particular. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/803152 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/1277 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 5/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280452 | Zou et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Yimin Zou (La Jolla, California); John Scott (La Jolla, California); Sonal Thakar (La Jolla, California) |
| ABSTRACT | The present invention is based on the finding that subanesthetic doses of N-methyl-D-aspartate (NMDA) receptor antagonists alleviate social interaction deficits associated with behavioral disorders, such as Smith-Magenis Syndrome (SMS). The invention therefore provides methods and compositions for treating SMS. Also provided are methods of selecting NMDA receptor agonists useful in alleviating social interaction deficits associated with such behavioral disorders. |
| FILED | Friday, June 26, 2020 |
| APPL NO | 17/622027 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/13 (20130101) A61K 31/135 (20130101) Original (OR) Class A61K 31/439 (20130101) A61K 31/451 (20130101) A61K 31/485 (20130101) A61K 33/00 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280460 | JACKSON et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Edwin Kerry JACKSON (Pittsburgh, Pennsylvania); Theresa L. WHITESIDE (Pittsburgh, Pennsylvania); Nils LUDWIG (Regensburg, Germany) |
| ABSTRACT | Disclosed herein are methods for improving exosome production or stimulating exosome secretion by cells. The methods comprise inhibiting at least one step of the glycolytic pathway by contacting the cells with at least one glycolytic inhibitor and/or inhibiting mitochondrial function by contacting the cells with at least one inhibitor of mitochondrial function. |
| FILED | Friday, August 07, 2020 |
| APPL NO | 17/637881 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/06 (20130101) A61K 31/19 (20130101) Original (OR) Class Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6886 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/57488 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280513 | Liu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Qi Liu (Milbrae, California); Chaitan Khosla (Stanford, California); Amita Gupta (Stanford, California) |
| ABSTRACT | Compounds and methods are provided for the treatment of pathogenic virus infections. Compositions and methods are provided for inhibiting RNA viruses. |
| FILED | Tuesday, July 14, 2020 |
| APPL NO | 17/625592 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 31/513 (20130101) Original (OR) Class A61K 31/7064 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/14 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280514 | VERKMAN |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Alan S. VERKMAN (Oakland, California) |
| ABSTRACT | The disclosure is directed to methods of treating bile acid diarrhea by administering a CFTR chloride channel inhibitor (CFTR-CCI). The CFTR chloride channel inhibitor can be benzopyrimido-pyrrolo-oxazine-dione-CFTR-CCI (e.g., BPO-27), a PPQ-CFTR-CCI, a thiazolidinone-CFTR-CCI, or a glycine hydra-zide-CFTR-CCI. |
| FILED | Monday, June 08, 2020 |
| APPL NO | 17/596502 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/44 (20130101) A61K 31/64 (20130101) A61K 31/165 (20130101) A61K 31/196 (20130101) A61K 31/417 (20130101) A61K 31/426 (20130101) A61K 31/437 (20130101) A61K 31/451 (20130101) A61K 31/519 (20130101) Original (OR) Class A61K 31/575 (20130101) A61K 31/785 (20130101) A61K 31/787 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 1/12 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280522 | Luo et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Research Foundation for the State University of New York (Albany, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Juntao Luo (Jamesville, New York); Dandan Guo (Syracuse, New York); Changying Shi (Jamesville, New York) |
| ABSTRACT | Provided herein are compositions and nanocarriers comprising linear-dendritic telodendrimers (TD) containing riboflavin. The nanocarriers and compositions have desirable loading properties and stabilized structure and can be used for efficient in vivo delivery. |
| FILED | Thursday, May 19, 2022 |
| APPL NO | 17/748566 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0014 (20130101) A61K 9/0019 (20130101) A61K 9/0043 (20130101) A61K 9/146 (20130101) A61K 31/75 (20130101) A61K 31/525 (20130101) Original (OR) Class A61K 31/704 (20130101) A61K 47/34 (20130101) A61K 47/56 (20170801) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280525 | BORRERO-GARCÍA et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF PUERTO RICO (San Juan, Puerto Rico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Luis D. BORRERO-GARCÍA (San Juan, Puerto Rico); Suranganie DHARMAWARDHANE FLANAGAN (San Juan, Puerto Rico) |
| ABSTRACT | Targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), however acquired or intrinsic resistance often confounds therapy success. Common mechanisms of therapy resistance involve activating receptor point mutations and (or) upregulation of signaling downstream of EGFR/HER2 to Akt and (or) mitogen activated protein kinase (MAPK) pathways. However, additional pathways of resistance may exist thus, confounding successful therapy. To determine novel mechanisms of EGFR/HER2 therapy resistance in breast cancer, Gefitinib® or Lapatinib® resistant variants were created from SKBR3 breast cancer cells. Syngenic therapy sensitive and resistant SKBR3 variants were characterized for mechanisms of resistance by mammosphere assays, viability assays, and western blotting for total and phospho proteins. Combinations of treatments focused on RGFR/HER2 and Rac inhibitors (1,5-disubstituted 1, 2, 3-triazoles, e.g. Ehop-16 and MBQ-167) are proposed as viable strategies for treatment of EGFR/HER2 targeted therapy resistant breast cancer. |
| FILED | Wednesday, March 02, 2022 |
| APPL NO | 17/685174 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/517 (20130101) A61K 31/4192 (20130101) A61K 31/5377 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280535 | ADAMS et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF IOWA RESEARCH FOUNDATION (Iowa City, Iowa); THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (Washington, District of Columbia) |
| ASSIGNEE(S) | UNIVERSITY OF IOWA RESEARCH FOUNDATION (IOWA CITY, Iowa); THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (WASHINGTON, District of Columbia) |
| INVENTOR(S) | Christopher M. ADAMS (Rochester, Minnesota); Steven D. KUNKEL (West Richland, Washington); Michael WELSH (Riverside, Iowa) |
| ABSTRACT | The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula: or a stereoisomer, solvate, or pharmaceutically acceptable salt thereof, thereby accomplishing one or more of (a)-(f). |
| FILED | Monday, May 17, 2021 |
| APPL NO | 17/321923 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/36 (20130101) A61K 31/56 (20130101) A61K 31/58 (20130101) Original (OR) Class A61K 31/215 (20130101) A61K 31/352 (20130101) A61K 31/353 (20130101) A61K 31/382 (20130101) A61K 31/404 (20130101) A61K 31/407 (20130101) A61K 31/435 (20130101) A61K 31/436 (20130101) A61K 31/437 (20130101) A61K 31/438 (20130101) A61K 31/473 (20130101) A61K 31/565 (20130101) A61K 31/4164 (20130101) A61K 31/4166 (20130101) A61K 31/4355 (20130101) A61K 31/4365 (20130101) A61K 31/4375 (20130101) A61K 31/4706 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6809 (20130101) C12Q 2600/136 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5023 (20130101) G01N 2800/10 (20130101) G01N 2800/52 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280538 | LOWE et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | MEMORIAL SLOAN KETTERING CANCER CENTER (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Scott LOWE (New York, New York); John P. MORRIS, IV (New York, New York); Scott E. MILLMAN (New York, New York); Lydia FINLEY (New York, New York) |
| ABSTRACT | The present technology relates generally to methods and compositions for treating, preventing, and/or ameliorating p53-mutant cancers in a subject in need thereof, including acute myeloid leukemia (AML), pancreatic cancer, and liver cancer, by administration of a therapeutically effective amount of a 2-oxoglutarate dehydrogenase (OGDH) inhibitor. |
| FILED | Thursday, August 13, 2020 |
| APPL NO | 17/634775 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/47 (20130101) A61K 31/198 (20130101) A61K 31/282 (20130101) A61K 31/506 (20130101) A61K 31/513 (20130101) A61K 31/517 (20130101) A61K 31/519 (20130101) A61K 31/573 (20130101) A61K 31/655 (20130101) Original (OR) Class A61K 31/662 (20130101) A61K 31/704 (20130101) A61K 31/4745 (20130101) A61K 31/7068 (20130101) A61K 39/3955 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1137 (20130101) C12N 2310/11 (20130101) C12N 2310/14 (20130101) C12N 2310/531 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280543 | Ambati et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Virginia Patent Foundation (Charlottesville, Virginia) |
| ASSIGNEE(S) | University of Virginia Patent Foundation (Charlottesville, Virginia) |
| INVENTOR(S) | Jayakrishna Ambati (Charlottesville, Virginia); Shao-bin Wang (Charlottesville, Virginia); Kameshwari Ambati (Charlottesville, Virginia) |
| ABSTRACT | Provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with NLR family CARD domain containing 4 (NLRC4) inflammasome biological activities. In some embodiments, the method include administering to a subject in need thereof a composition that includes a nucleoside reverse transcriptase inhibitor (NRTI). Also provided are methods for inhibiting NLRC4-induced caspase-1 activation in cells, methods for inhibiting NLRC4-induced IL-Iβ release from cells, methods for inhibiting Alu-induced retinal pigmented cell (RPE) degeneration in subjects, and compositions for use in the presently disclosed methods. |
| FILED | Monday, August 24, 2020 |
| APPL NO | 17/637557 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/513 (20130101) A61K 31/675 (20130101) A61K 31/685 (20130101) A61K 31/708 (20130101) A61K 31/7068 (20130101) A61K 31/7072 (20130101) A61K 31/7076 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 27/02 (20180101) Peptides C07K 16/18 (20130101) C07K 16/40 (20130101) C07K 16/2866 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280550 | Machielse et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mandos LLC (West Hollywood, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernardus Nicolaas Machielse (North Potomac, Maryland); Allan Darling (North Potomac, Maryland) |
| ABSTRACT | This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/745464 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/08 (20130101) A61K 9/0019 (20130101) A61K 9/0085 (20130101) A61K 31/724 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280551 | Machielse et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mandos LLC (West Hollywood, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernardus Nicolaas Machielse (North Potomac, Maryland); Allan Darling (North Potomac, Maryland) |
| ABSTRACT | This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/745487 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/08 (20130101) A61K 9/0019 (20130101) A61K 9/0085 (20130101) A61K 31/724 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280552 | Machielse et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mandos LLC (West Hollywood, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernardus Nicolaas Machielse (North Potomac, Maryland); Allan Darling (North Potomac, Maryland) |
| ABSTRACT | This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/745491 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/08 (20130101) A61K 9/0019 (20130101) A61K 9/0085 (20130101) A61K 31/724 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280553 | Machielse et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mandos LLC (West Hollywood, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernardus Nicolaas Machielse (North Potomac, Maryland); Allan Darling (North Potomac, Maryland) |
| ABSTRACT | This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/745497 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/08 (20130101) A61K 9/0019 (20130101) A61K 9/0085 (20130101) A61K 31/724 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280554 | Machielse et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mandos LLC (West Hollywood, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernardus Nicolaas Machielse (North Potomac, Maryland); Allan Darling (North Potomac, Maryland) |
| ABSTRACT | This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/745505 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/08 (20130101) A61K 9/0019 (20130101) A61K 9/0085 (20130101) A61K 31/724 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280560 | Neuwelt |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Oregon Health and Science University (Portland, Oregon) |
| ASSIGNEE(S) | Oregon Health and Science University (Portland, Oregon) |
| INVENTOR(S) | Edward A. Neuwelt (Portland, Oregon) |
| ABSTRACT | Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity. |
| FILED | Monday, May 09, 2022 |
| APPL NO | 17/740109 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 33/04 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 27/16 (20180101) A61P 39/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280580 | Pascual et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Montana State University (Bozeman, Montana) |
| ASSIGNEE(S) | Montana State University (Bozeman, Montana) |
| INVENTOR(S) | David Pascual (Gainesville, Florida); Massimo Maddaloni (Gainesville, Florida) |
| ABSTRACT | The present disclosure relates generally to therapeutic compositions comprising recombinant bacteria. Further, the disclosure elaborates upon methods of utilizing the herein described therapeutic compositions to treat autoimmune and inflammatory disease. The present teachings also relate to the disclosed recombinant bacteria and methods of producing the recombinant bacteria utilized in the compositions and methods. Further taught herein are dietary supplements and food additive compositions comprising the taught recombinant bacteria. |
| FILED | Friday, August 28, 2020 |
| APPL NO | 17/637987 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/20 (20130101) A61K 35/744 (20130101) Original (OR) Class A61K 38/00 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 37/06 (20180101) Peptides C07K 14/54 (20130101) C07K 2319/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280590 | Yi et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Georgetown University (Washington, District of Columbia) |
| ASSIGNEE(S) | Georgetown University (Washington, District of Columbia) |
| INVENTOR(S) | Chunling Yi (Washington, District of Columbia); Shigekazu Murakami (Bethesda, Maryland) |
| ABSTRACT | Methods of inducing apoptosis and inhibiting proliferation in YAP-dependent cancer cells, involving contacting the cells with one or more inhibitors of YAP and one or more inhibitors of SOX2. In addition, methods of treating or preventing YAP-dependent cancer in subjects, involving administering to the subject one or more inhibitors of YAP and one or more inhibitors of SOX2. |
| FILED | Thursday, August 20, 2020 |
| APPL NO | 17/636735 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/138 (20130101) A61K 31/437 (20130101) A61K 38/005 (20130101) Original (OR) Class Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 1/18 (20180101) A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280597 | Urish et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Pittsburgh - Of the Commonwealth System of Higher Education (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kenneth Urish (Sewickley, Pennsylvania); Jonathan Brendan Mandell (Pittsburgh, Pennsylvania) |
| ABSTRACT | A method of treating or preventing a microbial infection in a patient is provided, along with a wound irrigation system and a composition in the form of an irrigation liquid for reducing microbial load or preventing microbial infection in a wound. |
| FILED | Friday, May 20, 2022 |
| APPL NO | 17/749731 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/546 (20130101) A61K 38/10 (20130101) Original (OR) Class A61K 38/1729 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280607 | Kuhn et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Pittsburgh - Of the Commonwealth System of Higher Education (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Bernhard Kuhn (Pittsburgh, Pennsylvania); Honghai Liu (Pittsburgh, Pennsylvania) |
| ABSTRACT | Provided herein are methods of treating congenital heart disease in a patient, such as tetralogy of Fallot, with beta blockers to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient. Also provided herein are uses for beta blockers for treating congenital heart disease, such as tetralogy of Fallot, in a patient to increase cardiomyocyte endowment in the patient and/or to reduce risk of developing complications originating later from heart diseases, such as myocardial infarction, in the patient. |
| FILED | Monday, July 13, 2020 |
| APPL NO | 17/625270 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/138 (20130101) A61K 38/1709 (20130101) A61K 38/1825 (20130101) Original (OR) Class A61K 38/1883 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 9/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280614 | WEISS et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CASE WESTERN RESERVE UNIVERSITY (Cleveland, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Michael A. WEISS (Indianapolis, Indiana); Faramarz ISMAIL-BEIGI (Shaker Heights, Ohio) |
| ABSTRACT | A premixed acidic solution contains two single-chain insulin analogues. One has isoelectric point between 6.5 and 8.0 (SCI-A) and the other has isoelectric point between 4.5 and 6.0 (SCI-B), such that biphasic basal and prandial insulin activity is provided on subcutaneous injection. Each protein is an analogue of a mammalian insulin, such as human insulin, with insertion of engineered C domain of length 5-11 residues; the respective C domains of SCI-A and SCI-B may be different. SCI-A contains a Glycine, Alanine, Serine or Glutamine substitution at position A21 and may contain a basic residue at position A8 and Glutamine at position B13. SCI-B may contain a non-beta-branched substitution at position A8, either Alanine or Glutamic Acid at position A14, and substitutions at positions B28 and/or B29 to confer rapid action. A method of treating a patient comprises administering the insulin analogue or a physiologically acceptable salt thereof to a patient. |
| FILED | Monday, August 03, 2020 |
| APPL NO | 17/632193 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/28 (20130101) Original (OR) Class A61K 47/02 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 3/10 (20180101) Peptides C07K 14/62 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280628 | Sun |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Albany Medical College (Albany, New York) |
| ASSIGNEE(S) | Albany Medical College (Albany, New York) |
| INVENTOR(S) | Wei Sun (Glenmont, New York) |
| ABSTRACT | A vaccine platform using a Yersinia pestis mutant synthesizing an adjuvant form lipid A (monophosphoryl lipid A, MPLA) for the increased biogenesis of bacterial outer membrane vesicles (OMVs). To enhance the immunogenicity of the OMVs, an Asd-based balanced-lethal host-vector system was constructed to oversynthesize the LcrV antigen of Y. pestis, raise the amounts of LcrV enclosed in OMVs by Type II secretion system, and eliminate harmful factors like plasminogen activator (Pla) and murine toxin from the OMVs. Vaccination with OMVs containing MPLA and increased amounts of LcrV with diminished toxicity afforded complete protection in mice against subcutaneous challenge and intranasal challenge and was significantly superior to that resulting from vaccination with LcrV/alhydrogel. Additionally, the Yersinia OMV can be used as a platform to deliver the heterologous antigens of Bacillus anthraces. Vaccination with multiantigenic self-adjuvanting bionanoparticles from Pseudomonas was also successfully tested in connection with Pseudomonas aeruginosa. |
| FILED | Thursday, September 23, 2021 |
| APPL NO | 17/482527 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/104 (20130101) A61K 39/0291 (20130101) Original (OR) Class A61K 2039/55594 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/04 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280630 | MASSARI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Trustees of Tufts College (Medford, Massachusetts) |
| ASSIGNEE(S) | Trustees of Tufts College (Medford, Massachusetts) |
| INVENTOR(S) | Paola MASSARI (Cambridge, Massachusetts); Caroline GENCO (Medford, Massachusetts) |
| ABSTRACT | Described herein are vaccine compositions and methods of selecting an antigen or fragment thereof for the preparation of a vaccine composition. The methods and vaccine compositions described herein are based, in part, on the discovery that certain polypeptides not previously identified or considered for potential use as antigens from pathogenic microorganisms (e.g., N. gonorrhoeae) can provoke an immune response in a subject. The methods of identifying and selecting the antigens described herein rely, in part, on approaches that identify polypeptides (e.g., hypothetical proteins) predicted to be immunogenic. |
| FILED | Thursday, July 30, 2020 |
| APPL NO | 17/631694 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/095 (20130101) Original (OR) Class A61K 2039/575 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/689 (20130101) Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology G16B 30/10 (20190201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280640 | FOX |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | ACCESS TO ADVANCED HEALTH INSTITUTE (Seattle, Washington) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Christopher B. FOX (Sumner, Washington) |
| ABSTRACT | Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided. |
| FILED | Thursday, April 28, 2022 |
| APPL NO | 17/731671 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/76 (20130101) A61K 39/04 (20130101) A61K 39/12 (20130101) A61K 39/39 (20130101) Original (OR) Class A61K 45/06 (20130101) A61K 2039/57 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/06 (20180101) A61P 31/12 (20180101) A61P 33/04 (20180101) A61P 35/00 (20180101) Peptides C07K 14/705 (20130101) C07K 14/70596 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280644 | Peterson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (Salt Lake City, Utah); IMPERIAL COLLEGE INNOVATIONS LIMITED (London, United Kingdom) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Randall Theodore Peterson (Salt Lake City, Utah); Pui Ying Lam (Salt Lake City, Utah); Matthew J. Fuchter (London, United Kingdom); Aditya Raymond Thawani (London, United Kingdom) |
| ABSTRACT | Described herein are photoswitchable compounds that can activate TRPA1 channels in neuronal and non-neuronal cells. The TRPswitch molecules allow for optical control of both the activation and deactivation of TRPA1 channels. Such compounds can be used as research tools or therapeutics. |
| FILED | Friday, August 07, 2020 |
| APPL NO | 17/632332 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 41/0057 (20130101) Original (OR) Class Heterocyclic Compounds C07D 307/68 (20130101) C07D 333/38 (20130101) C07D 405/14 (20130101) C07D 409/14 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280658 | Zolotukhin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Florida Research Foundation, Incorporated (Gainesville, Florida) |
| ASSIGNEE(S) | University of Florida Research Foundation, Incorporated (Gainesville, Florida) |
| INVENTOR(S) | Sergei Zolotukhin (Gainesville, Florida); Sean M. Crosson (Gainesville, Florida); Cedrick Shawn Dotson (Gainesville, Florida); Seth Currlin (Gainesville, Florida); Andres Acosta (Rochester, Minnesota) |
| ABSTRACT | The present application provides methods and compositions for AAV-mediated delivery of PYY and Glucagon-like Peptide 1 or an analog thereof (e.g., Exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of Ex-4 and PYY peptides also are provided. Methods and compositions are useful to promote weight loss and/or altered lipid taste sensitivity, as well as for the treatment of diabetes. |
| FILED | Friday, March 18, 2022 |
| APPL NO | 17/698433 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0053 (20130101) A61K 38/22 (20130101) A61K 38/26 (20130101) A61K 38/2207 (20130101) A61K 48/0058 (20130101) A61K 48/0075 (20130101) Original (OR) Class Peptides C07K 14/47 (20130101) C07K 14/575 (20130101) C07K 14/605 (20130101) C07K 14/57563 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/86 (20130101) C12N 2750/14142 (20130101) C12N 2750/14143 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280661 | Evans et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Michael Evans (Oakland, California); Yangjie Huang (Oakland, California); Christopher Drake (Oakland, California) |
| ABSTRACT | Disclosed herein are compounds useful for detection of glucocorticoid receptor expression and activity via positron emission tomography and related techniques. Methods for preparation and use of the compounds are also described. |
| FILED | Thursday, May 05, 2022 |
| APPL NO | 17/737649 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 51/0455 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280792 | GANGULY et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); U.S. Government Represented by the Department of Veterans Affairs (Washington, District of Columbia); LightSide MD, LLC (Los Altos, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Karunesh GANGULY (San Francisco, California); Adelyn TSU (San Francisco, California); Nikhilesh NATRAJ (San Francisco, California); Gabriel Philip HOWLES-BANERJI (Oakland, California); Rajiv DOSHI (Los Altos, California); Kondapavulur T. VENKATESWARA-RAO (San Jose, California) |
| ABSTRACT | Methods and apparatuses for sensory electrical stimulation of the peripheral nervous system to improve human motor function and performance are described. Methods and devices may be used to enhance physical performance of athletes, professionals, and gamers or improve motor function (hand, finger and limb movement) in patients rehabilitating from neurological deficits and impairments caused by stroke, traumatic brain injury and other neurologic or non-neurologic conditions. These apparatuses and methods may be used for physical training and mental training (to improve memory and functional performance including motor coordination, limb-eye coordination, occupational and recreational skills) through periodic or sustained sensory electrical stimulation. Treatment plans may be based on biomarkers and may be used alone or in combination with other apparatuses. Learning and feedback techniques individualize treatment parameters depending on the subject's neurologic and motor function in diseased patients and healthy users. |
| FILED | Wednesday, March 23, 2022 |
| APPL NO | 17/702621 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/002 (20130101) A61B 5/30 (20210101) A61B 5/375 (20210101) A61B 5/4047 (20130101) A61B 5/4824 (20130101) A61B 5/4848 (20130101) A61B 5/7275 (20130101) A61B 5/7455 (20130101) A61B 2505/09 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 1/378 (20130101) A61N 1/0456 (20130101) A61N 1/0484 (20130101) A61N 1/0492 (20130101) A61N 1/36021 (20130101) A61N 1/36031 (20170801) Original (OR) Class A61N 1/36034 (20170801) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280815 | BRUZA et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF DARTMOUTH COLLEGE (Hanover, New Hampshire); DOSEOPTICS, LLC (Lebanon, New Hampshire) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Petr BRUZA (Lebanon, New Hampshire); Brian POGUE (Hanover, New Hampshire); Michael JERMYN (Lebanon, New Hampshire); Venkataramanan KRISHNASWAMY (Lebanon, New Hampshire) |
| ABSTRACT | A system for performing radiation treatment of a patient with a proton beam from a particle accelerator uses a high-sensitivity camera to capture dose images of patient surface, a video processor that integrates the dose images, beam-on detection apparatus, and apparatus to eliminate interference of room lighting. In embodiments, the system registers dose images to a surface model of the patient derived from stereo image pairs captured by a stereo camera. In embodiments, the surface model is registered to three-dimensional images of the patient from MRI or CT, and an integrated three-dimensional energy deposition map of the patient is prepared. |
| FILED | Friday, July 10, 2020 |
| APPL NO | 17/626488 |
| CURRENT CPC | Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 5/1071 (20130101) Original (OR) Class A61N 2005/1059 (20130101) A61N 2005/1087 (20130101) Measurement of Nuclear or X-radiation G01T 1/1603 (20130101) G01T 1/2921 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281802 | PRADHAN-NABZDYK et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Beth Israel Deaconess Medical Center, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Leena PRADHAN-NABZDYK (Rochester, Minnesota); Lijun SUN (Harvard, Massachusetts); Philip LOGERFO (Cambridge, Massachusetts); Finith JERNIGAN (Brookline, Massachusetts); Gabriel BIRANNE (Lynn, Massachusetts); Frank W. LOGERFO (Cambridge, Massachusetts) |
| ABSTRACT | Compounds, pharmaceutical compositions, and methods are disclosed for inhibiting interaction between IL18 and IL18R. |
| FILED | Friday, July 31, 2020 |
| APPL NO | 17/631972 |
| CURRENT CPC | Acyclic or Carbocyclic Compounds C07C 211/45 (20130101) Original (OR) Class C07C 279/18 (20130101) C07C 2601/16 (20170501) Heterocyclic Compounds C07D 249/18 (20130101) C07D 401/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281816 | Luesch et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Florida Research Foundation, Incorporation (Gainesville, Florida); Smithsonian Institution (Washington, District of Columbia) |
| ASSIGNEE(S) | University of Florida Research Foundation, Incorporation (Gainesville, Florida); Smithsonian Institution (Washington, District of Columbia) |
| INVENTOR(S) | Hendrik Luesch (Gainesville, Florida); Xiao Liang (Gainesville, Florida); Susan Matthew (Houston, Texas); Jason C. Kwan (Gainesville, Florida); Qi-Yin Chen (Gainesville, Florida); Valerie J. Paul (Fort Pierce, Florida) |
| ABSTRACT | The invention is directed towards compounds (e.g., Formulae (I)-(IX)), their mechanism of action, processes to prepare the compounds, methods of activating quorum sensing signaling activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formulae (I)-(IX)). |
| FILED | Friday, July 24, 2020 |
| APPL NO | 17/630138 |
| CURRENT CPC | Heterocyclic Compounds C07D 207/38 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281824 | Kolluri et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Oregon State University (Corvallis, Oregon) |
| ASSIGNEE(S) | Oregon State University (Corvallis, Oregon) |
| INVENTOR(S) | Siva Kumar Kolluri (Corvallis, Oregon); Nancy I. Kerkvliet (Corvallis, Oregon); Sebastian Bernales (San Francisco, California); Jit Chakravarty (Edmond, Oklahoma); Brahmam Pujala (Greater Noida, India); Pasha Khan (New Delhi, India); Varun Kumar (New Delhi, India); Abhinandan Danodia (Greater Noida, India); Gonzalo Ureta (Santiago, Chile) |
| ABSTRACT | Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed. |
| FILED | Thursday, July 30, 2020 |
| APPL NO | 17/630763 |
| CURRENT CPC | Heterocyclic Compounds C07D 209/12 (20130101) C07D 235/06 (20130101) Original (OR) Class C07D 307/80 (20130101) C07D 401/04 (20130101) C07D 401/06 (20130101) C07D 403/04 (20130101) C07D 405/04 (20130101) C07D 405/06 (20130101) C07D 409/04 (20130101) C07D 471/06 (20130101) C07D 471/16 (20130101) C07D 487/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281825 | McCormack et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Arisan Therapeutics Inc. (Carlsbad, California) |
| ASSIGNEE(S) | Arisan Therapeutics Inc. (Carlsbad, California) |
| INVENTOR(S) | Kenneth McCormack (Oceanside, California); Michael Bruno Plewe (San Diego, California); Nadezda Sokolova (San Diego, California); Gregory Henkel (Carlsbad, California); Eric Brown (Santee, California); Vidyasagar Reddy Gantla (San Diego, California); Young-Jun Shin (San Diego, California) |
| ABSTRACT | The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of |
| FILED | Thursday, April 21, 2022 |
| APPL NO | 17/726096 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/52 (20130101) A61K 31/53 (20130101) A61K 31/416 (20130101) A61K 31/423 (20130101) A61K 31/437 (20130101) A61K 31/439 (20130101) A61K 31/454 (20130101) A61K 31/519 (20130101) A61K 31/713 (20130101) A61K 31/4184 (20130101) A61K 31/4192 (20130101) A61K 31/4439 (20130101) A61K 31/4985 (20130101) A61K 31/5025 (20130101) A61K 31/5377 (20130101) A61K 31/7056 (20130101) A61K 31/7105 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/14 (20180101) Heterocyclic Compounds C07D 235/06 (20130101) Original (OR) Class C07D 235/20 (20130101) C07D 249/18 (20130101) C07D 413/00 (20130101) C07D 471/04 (20130101) C07D 471/08 (20130101) C07D 473/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281826 | Schug et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Wistar Institute (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Zachary Schug (Philadelphia, Pennsylvania); Joseph Salvino (Philadelphia, Pennsylvania) |
| ABSTRACT | The present disclosure provides compounds, which in certain embodiments are ACSS2 inhibitors. In certain embodiments, the compounds of the disclosure are useful for treating, ameliorating, and/or preventing certain types of cancer. |
| FILED | Friday, June 12, 2020 |
| APPL NO | 17/618397 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/437 (20130101) A61K 31/496 (20130101) A61K 31/4184 (20130101) A61K 31/4545 (20130101) A61K 31/5377 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Heterocyclic Compounds C07D 235/12 (20130101) Original (OR) Class C07D 401/12 (20130101) C07D 403/12 (20130101) C07D 471/04 (20130101) C07D 471/10 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281828 | Betts et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Brian Betts (Tampa, Florida); Said M. Sebti (Tampa, Florida); Harshani Lawrence (Tampa, Florida); Nicholas Lawrence (Tampa, Florida); Claudio Anasetti (Tampa, Florida); Joseph Pidala (Tampa, Florida) |
| ABSTRACT | Disclosed herein are compounds and methods for reducing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V. |
| FILED | Monday, December 20, 2021 |
| APPL NO | 17/555786 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/505 (20130101) A61K 31/506 (20130101) A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Heterocyclic Compounds C07D 239/48 (20130101) Original (OR) Class C07D 401/12 (20130101) C07D 403/12 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281862 | Liu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | KUDA Therapeutics, Inc. (Salt Lake City, Utah) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Xiaohui Liu (Salt Lake City, Utah); Mei Yee Koh (Salt Lake City, Utah) |
| ABSTRACT | Novel substituted imidazopyridine and oxazolopyridine compounds that are useful as inhibitors of HIF-2α and inducers of ferroptosis through perturbations in iron metabolism, synthetic methods for making said compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat disorders associated with dysfunction of HIF-2α or iron metabolism. |
| FILED | Friday, February 14, 2020 |
| APPL NO | 16/791148 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Heterocyclic Compounds C07D 417/12 (20130101) Original (OR) Class C07D 471/04 (20130101) C07D 487/04 (20130101) C07D 498/04 (20130101) C07D 513/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281874 | Zhang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Dana-Farber Cancer Institure, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | Dana-Farber Cancer Institure, Inc. (Boston, Massachusetts) |
| INVENTOR(S) | Tinghu Zhang (Brookline, Massachusetts); Nicholas Paul Kwiatkowski (Brookline, Massachusetts); Nathanael S. Gray (Stanford, California); Zhixiang He (Brookline, Massachusetts); Yanke Liang (Belmont, Massachusetts) |
| ABSTRACT | The present disclosure provides compounds of Formula (I), (II-1), (II-2), (II-3), or (II-4). The compounds of the present disclosure may be inhibitors of kinases (e.g., a cyclin-dependent kinase (CDK) (e.g., CDK7)). In some embodiments, the compounds disclosed herein are selective for inhibiting the activity of a kinase (e.g., CDK7) over certain other kinases (e.g., CDK2, CDK9, CDK12). In certain embodiments, the compounds do not bind or inhibit a 5-hydroxytryptamine (5-HT) receptor. Also provided are pharmaceutical compositions, kits, methods of use, and uses that involve the compounds disclosed herein. In some embodiments, the compounds are useful in inhibiting the activity of a kinase, inhibiting the growth of a cell, inducing apoptosis of a cell, treating a disease, and/or preventing a disease (e.g., proliferative disease, cystic fibrosis). |
| FILED | Wednesday, July 22, 2020 |
| APPL NO | 17/628794 |
| CURRENT CPC | Heterocyclic Compounds C07D 487/04 (20130101) Original (OR) Class C07D 519/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281913 | Gunther et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | YALE UNIVERSITY (New Haven, Connecticut) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Erik Gunther (Branford, Connecticut); Mikhail Kostylev (New Haven, Connecticut); Stephen Strittmatter (Durham, Connecticut) |
| ABSTRACT | The present invention provides a protein separation micro el having a first plate having a first opening; a second plate; a gel substrate formed between the first plate and the second plate; and a plurality of wells positioned at a first non-zero distance from a first edge of the gel and at a second non-zero distance from a second edge of the gel; wherein the first and second edge of the gel are opposite edges of the gel. |
| FILED | Wednesday, August 12, 2020 |
| APPL NO | 17/634657 |
| CURRENT CPC | Separation B01D 57/02 (20130101) Peptides C07K 1/26 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281919 | Reshetnyak et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Rhode Island Board of Trustees (Kingston, Rhode Island) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Yana K. Reshetnyak (Saunderstown, Rhode Island); Oleg A. Andreev (Saunderstown, Rhode Island); Keykavous Parang (Irvine, California) |
| ABSTRACT | The present subject matter provides pH triggered peptides, as well as compositions methods, devices, and systems comprising the same. The pH triggered peptides include cyclic and short linear peptides, and may have higher affinity to a membrane lipid bilayer at low pH than at neutral or high pH. |
| FILED | Monday, March 14, 2022 |
| APPL NO | 17/694478 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 8/44 (20130101) A61K 8/64 (20130101) A61K 38/00 (20130101) A61K 45/06 (20130101) A61K 49/0043 (20130101) A61K 49/0056 (20130101) Specific Use of Cosmetics or Similar Toilet Preparations A61Q 17/005 (20130101) A61Q 19/08 (20130101) Peptides C07K 7/08 (20130101) C07K 7/64 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281920 | PEI |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Ohio State Innovation Foundation (Columbus, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dehua PEI (Columbus, Ohio) |
| ABSTRACT | The present disclosure provides a large combinatorial library of cell-permeable bicyclic peptides. The bicyclic peptides described herein include the first ring consisted of randomized peptide sequences for potential binding to a target of interest while the second ring featured a family of different cell-penetrating motifs, for both cell penetration and target binding. The library was screened against the IκB kinase α/β (IKKα/β)-binding domain of NF-κB essential modulator (NEMO), resulting in the discovery of several cell-permeable bicyclic peptides which inhibited the NEMO-IKKβ interaction, thereby selectively inhibiting canonical NF-κB signaling in mammalian cells and the proliferation of cisplatin-resistant ovarian cancer cells. |
| FILED | Monday, May 23, 2022 |
| APPL NO | 17/750966 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 7/64 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281930 | Liedtke |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | DUKE UNIVERSITY (Durham, North Carolina) |
| ASSIGNEE(S) | DUKE UNIVERSITY (Durham, North Carolina) |
| INVENTOR(S) | Wolfgang Liedtke (Durham, North Carolina) |
| ABSTRACT | The present disclosure provides, in part, composition and methods for the treatment of pathological pain and itch. |
| FILED | Monday, August 24, 2020 |
| APPL NO | 17/637760 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 31/55 (20130101) A61K 31/167 (20130101) A61K 31/335 (20130101) A61K 31/404 (20130101) A61K 31/426 (20130101) A61K 31/433 (20130101) A61K 31/497 (20130101) A61K 31/506 (20130101) A61K 31/517 (20130101) A61K 31/5377 (20130101) A61K 31/5517 (20130101) A61K 33/24 (20130101) A61K 38/00 (20130101) A61K 45/06 (20130101) A61K 48/0058 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 25/04 (20180101) Peptides C07K 14/005 (20130101) C07K 14/465 (20130101) C07K 14/4702 (20130101) Original (OR) Class Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 7/00 (20130101) C12N 15/86 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281931 | EBERT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts); Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (Heidelberg, Germany) |
| ASSIGNEE(S) | Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts); Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (Heidelberg, Germany) |
| INVENTOR(S) | Benjamin EBERT (Boston, Massachusetts); Mikolaj SLABICKI (Boston, Massachusetts); Eric S. FISCHER (Boston, Massachusetts); Hojong YOON (Boston, Massachusetts); Jonas KOEPPEL (Heidelberg, Germany) |
| ABSTRACT | The invention features methods for characterizing a cancer as sensitive or resistant to Bcl6 therapies, as well as compositions and methods for inducing the degradation or polymerization of a polypeptide of interest. |
| FILED | Friday, May 20, 2022 |
| APPL NO | 17/750061 |
| CURRENT CPC | Peptides C07K 14/4702 (20130101) Original (OR) Class C07K 2319/95 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/68 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281937 | Wong et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Altor BioScience LLC (Culver City, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Hing C. Wong (Culver City, California); Peter Rhode (Culver City, California); Xiaoyun Zhu (Culver City, California); Kai-Ping Han (Culver City, California) |
| ABSTRACT | The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention. |
| FILED | Friday, April 08, 2022 |
| APPL NO | 17/716986 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/1774 (20130101) A61K 38/1793 (20130101) A61K 38/2086 (20130101) Peptides C07K 14/5443 (20130101) Original (OR) Class C07K 14/7051 (20130101) C07K 14/7155 (20130101) C07K 16/18 (20130101) C07K 16/28 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/09 (20130101) C12N 15/62 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/56977 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281940 | Kumar |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, a body corporate (Denver, Colorado) |
| ASSIGNEE(S) | |
| INVENTOR(S) | T. Rajendra Kumar (Aurora, Colorado) |
| ABSTRACT | The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing, and methods of using the hypo-glycosylated FSH as disclosed herein. These methods of use include methods of treating infertility, methods of inducing follicle growth and/or maturation, methods of inducing oocyte/egg growth and/or maturation, methods of stimulating sex steroid secretion, methods of treating or preventing bone density loss, and methods of treating or preventing fatty tissue accumulation. |
| FILED | Friday, May 06, 2022 |
| APPL NO | 17/662312 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 3/00 (20180101) A61P 5/06 (20180101) A61P 15/08 (20180101) Peptides C07K 14/59 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281944 | POWELL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Daniel POWELL (Bala Cynwyd, Pennsylvania); Andrew TSOURKAS (Bryn Mawr, Pennsylvania) |
| ABSTRACT | The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor that comprises a protein or peptide tag, such as a SpyCatcher or a SpyTag moiety, bound to an extracellular hinge region, a transmembrane domain, and an intracellular domain for T cell activation. |
| FILED | Thursday, May 19, 2022 |
| APPL NO | 17/748983 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/17 (20130101) Peptides C07K 14/7051 (20130101) Original (OR) Class C07K 14/70521 (20130101) C07K 2319/02 (20130101) C07K 2319/03 (20130101) C07K 2319/20 (20130101) C07K 2319/60 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281958 | CROWE, JR. et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Vanderbilt University (Nashville, Tennessee) |
| ASSIGNEE(S) | Vanderbilt University (Nashville, Tennessee) |
| INVENTOR(S) | James E. CROWE, JR. (Nashville, Tennessee); Seth ZOST (Nashville, Tennessee); Robert CARNAHAN (Nashville, Tennessee); Pavlo GILCHUK (Nashville, Tennessee) |
| ABSTRACT | The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof. |
| FILED | Friday, March 18, 2022 |
| APPL NO | 17/655503 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/14 (20180101) Peptides C07K 16/10 (20130101) Original (OR) Class Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/56983 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281962 | WANG et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Feinstein Institutes For Medical Research (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Haichao WANG (Edison, New Jersey); Weiqiang CHEN (Garden City, New York); Jian Hua LI (New York, New York); Kevin J. Tracey (Old Greenwich, Connecticut) |
| ABSTRACT | Provided are anti-tetranectin domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments. |
| FILED | Wednesday, August 12, 2020 |
| APPL NO | 17/634430 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 19/02 (20180101) A61P 29/02 (20180101) A61P 39/00 (20180101) Peptides C07K 16/18 (20130101) Original (OR) Class C07K 2317/24 (20130101) C07K 2317/76 (20130101) C07K 2317/92 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281986 | NGUYEN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Research Foundation for The State University of New York (Amherst, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Juliane NGUYEN (Buffalo, New York); Michael DECI (Amherst, New York) |
| ABSTRACT | Provided are composition comprising antibodies directed to the N-terminal domain of CXCR4. The antibody may be a scFv and can be fused to a RNA binding peptide. The fusion protein can be complexed to RNAi, such as micro RNA. The complexes can be used for targeting delivery of RNAi molecules to CXCR4 expressing cancer cells, as well as inhibiting the binding of CXCR4 to CXCL12. |
| FILED | Monday, July 13, 2020 |
| APPL NO | 17/626477 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 14/46 (20130101) C07K 16/2866 (20130101) Original (OR) Class C07K 2317/21 (20130101) C07K 2317/33 (20130101) C07K 2317/56 (20130101) C07K 2317/76 (20130101) C07K 2317/94 (20130101) C07K 2317/622 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281996 | Desir et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Yale University (New Haven, Connecticut) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Gary Desir (Woodbridge, Connecticut); Abigail Hunt (Alameda, California); Jessica O-Rear (Redwood City, California); Peter Flynn (San Francisco, California) |
| ABSTRACT | The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics. |
| FILED | Monday, May 09, 2022 |
| APPL NO | 17/739691 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/39558 (20130101) A61K 2039/505 (20130101) Peptides C07K 16/40 (20130101) Original (OR) Class Enzymes C12Y 106/03 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/573 (20130101) G01N 2333/90209 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282200 | Murthy |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northeastern University (Boston, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shashi K. Murthy (Newton, Massachusetts) |
| ABSTRACT | Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease. |
| FILED | Monday, May 23, 2022 |
| APPL NO | 17/664532 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/0008 (20130101) Apparatus for Enzymology or Microbiology; C12M 23/16 (20130101) C12M 23/28 (20130101) C12M 27/00 (20130101) C12M 29/04 (20130101) C12M 33/00 (20130101) C12M 35/08 (20130101) C12M 41/14 (20130101) C12M 41/48 (20130101) Original (OR) Class Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0639 (20130101) C12N 2501/22 (20130101) C12N 2501/25 (20130101) C12N 2501/2306 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282208 | Palmer et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Douglas C. PALMER (North Bethesda, Maryland); Anna PASETTO (Stockholm, Sweden); Nicholas P. RESTIFO (Chevy Chase, Maryland); Steven A. ROSENBERG (Potomac, Maryland); THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (Bethesda, Maryland) |
| ASSIGNEE(S) | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (Bethesda, Maryland) |
| INVENTOR(S) | Douglas C. Palmer (North Bethesda, Maryland); Anna Pasetto (Stockholm, Sweden); Nicholas P. Restifo (Chevy Chase, Maryland); Steven A. Rosenberg (Potomac, Maryland) |
| ABSTRACT | Provided are methods of producing an isolated population of cells for adoptive cell therapy comprising use of at least one cell permeable Ca2+ dye. Further embodiments of the invention provide isolated populations of cells produced by the methods, related pharmaceutical compositions, and related methods of treating or preventing cancer in a patient. |
| FILED | Friday, September 18, 2020 |
| APPL NO | 17/636206 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 35/17 (20130101) Peptides C07K 14/7051 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0087 (20130101) C12N 5/0093 (20130101) Original (OR) Class C12N 5/0634 (20130101) C12N 2501/2302 (20130101) C12N 2501/2307 (20130101) C12N 2501/2312 (20130101) C12N 2501/2315 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/582 (20130101) G01N 33/5094 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282218 | Leen et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Baylor College of Medicine (Houston, Texas); Wilson Wolf Manufacturing (New Brighton, Minnesota) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ann Marie Leen (Houston, Texas); Ulrike Gerdemann (Cambridge, Massachusetts); Cliona M. Rooney (Bellaire, Texas); Juan F. Vera Valdes (Houston, Texas); John R. Wilson (New Brighton, Minnesota) |
| ABSTRACT | The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and/or that employ a particular bioreactor having a gas permeable membrane. |
| FILED | Thursday, May 26, 2022 |
| APPL NO | 17/804239 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/0011 (20130101) A61K 39/12 (20130101) A61K 39/155 (20130101) A61K 39/245 (20130101) A61K 2039/54 (20130101) A61K 2039/572 (20130101) A61K 2039/5158 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0636 (20130101) C12N 5/0638 (20130101) Original (OR) Class C12N 2501/23 (20130101) C12N 2501/2302 (20130101) C12N 2501/2306 (20130101) C12N 2501/2307 (20130101) C12N 2501/2312 (20130101) C12N 2501/2315 (20130101) C12N 2502/11 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282238 | Parkinson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| ASSIGNEE(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| INVENTOR(S) | Elizabeth I. Parkinson (West Lafayette, Indiana); Matthew A. Hostetler (Huntington, West Virginia) |
| ABSTRACT | The present disclosure reaches a method of a unique combination of bioinformatic technical tools together with chemical synthesis for identification of bioactive peptide molecules based on non-ribosomal peptide synthetases. Those bioactive cyclic peptide molecules are useful as antimicrobials, anticancer agents, antiparasitic, immunosuppressants, and others. Series of useful cyclic peptides and the pharmaceutical compositions thereof are within the scope of this disclosure. |
| FILED | Thursday, February 24, 2022 |
| APPL NO | 17/679249 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/93 (20130101) Original (OR) Class Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 21/02 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282286 | Tamiev et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Iowa State University Research Foundation, Inc. (Ames, Iowa) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Denis Tamiev (Ames, Iowa); Nigel Forest Reuel (Ames, Iowa) |
| ABSTRACT | Various aspects relate to a cell-free protein expression method. The method includes exposing a microorganism to substantially anaerobic growth conditions to produce a conditioned microorganism. The method further includes lysing the conditioned microorganism to produce a lysate. The method further includes combining the lysate with a nucleic acid and producing a protein of interest a metabolic pathway, a molecule, or a mixture thereof from the lysate. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/689586 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 1/205 (20210501) C12N 2500/05 (20130101) C12N 2500/34 (20130101) C12N 2500/46 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 1/04 (20130101) Original (OR) Class C12P 21/00 (20130101) Indexing Scheme Associated With Subclasses C12C - C12Q, Relating to Microorganisms C12R 2001/19 (20210501) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282295 | Tyo |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | Northwestern University (Evanston, Illinois) |
| INVENTOR(S) | Keith E.J. Tyo (Evanston, Illinois) |
| ABSTRACT | The present disclosure provides a DNA-synthesis based recording system that, in combination with CRISPR-Cas9 or other CRISPR systems, can establish single-cell level connectivity for densely packed cells, for example in the brain. |
| FILED | Friday, March 04, 2022 |
| APPL NO | 17/687276 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 9/1264 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 19/34 (20130101) Original (OR) Class Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6869 (20130101) Enzymes C12Y 207/07031 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282300 | Pierce et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | California Institute of Technology (Pasadena, California); Molecular Instruments, Inc. (Los Angeles, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Niles A. Pierce (Pasadena, California); Harry Ming Tak Choi (Los Angeles, California) |
| ABSTRACT | Methods of analysis of a sample using hybridization chain reaction (HCR) are provided herein. Some embodiments involve one, two, or all three of the following aspects: 1) repeated signal detection, 2) overlapping binding sites, and 3) catalytic reporter deposition (CARD). Compositions and kits relating to these are also provided. Some embodiments encompass a method for repeated signal detection with reporter-labeled HCR hairpins involving providing a sample possibly containing one or more targets as well as possibly other molecules that are not targets, providing one or more probe sets each comprising either: a)one or more HCR initiator-labeled probes, or b) one or more probe units each comprising two or more HCR fractional initiator probes, providing one or more HCR amplifiers (each labeled with one or more reporters), detecting one or more signals from one or more reporters. In some embodiments, a probe unit comprises two or more HCR fractional initiator probes, wherein an HCR fractional initiator probe comprises a target-binding region and a fractional initiator, wherein the target-binding regions within a probe unit are configured to bind to overlapping or non-overlapping binding sites on the target, and wherein the fractional initiators on the probes within each probe unit are configured to bind to overlapping or non-overlapping binding sites on an HCR hairpin. Some embodiments encompass a method for HCR-mediated catalytic reporter deposition (CARD) for signal detection with hapten-labeled HCR hairpins involving providing a sample possibly containing one or more targets as well as possibly other molecules that are not targets, providing one or more probe sets each comprising either: a) one or more HCR initiator-labeled probes, or b) one or more probe units each comprising two or more HCR fractional initiator probes, providing one or more HCR amplifiers (each labeled with one or more haptens), providing one or more anti-haptens labeled with one or more reporter entities, wherein the reporter entity is an enzyme that mediates CARD, providing one or more CARD-substrates leading to deposition of one or more reporters, and detecting one or more signals from one or more reporters. |
| FILED | Thursday, March 04, 2021 |
| APPL NO | 17/637253 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/682 (20130101) Original (OR) Class C12Q 1/6825 (20130101) C12Q 1/6841 (20130101) C12Q 2600/16 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282301 | Levner et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | President and Fellows of Harvard College (Cambridge, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Daniel Levner (Boston, Massachusetts); Je-hyuk Lee (Allston, Massachusetts); George M. Church (Brookline, Massachusetts); Michael Super (Lexington, Massachusetts) |
| ABSTRACT | The inventions provided herein relate to detection reagents, compositions, methods, and kits comprising the detection reagents for use in detection, identification, and/or quantification of analytes in a sample. Such detection reagents and methods described herein allow multiplexing of many more labeled species in the same procedure than conventional methods, in which multiplexing is limited by the number of available and practically usable colors. |
| FILED | Thursday, May 19, 2022 |
| APPL NO | 17/664095 |
| CURRENT CPC | Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 19/34 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6804 (20130101) C12Q 1/6806 (20130101) Original (OR) Class C12Q 1/6816 (20130101) C12Q 1/6837 (20130101) C12Q 1/6844 (20130101) C12Q 1/6869 (20130101) C12Q 1/6874 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/53 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282303 | Willey et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The University of Toledo (Toledo, Ohio) |
| ASSIGNEE(S) | The University of Toledo (Toledo, Ohio) |
| INVENTOR(S) | James C. Willey (Toledo, Ohio); Thomas Blomquist (Waterville, Ohio); Erin Crawford (Rossford, Ohio) |
| ABSTRACT | Methods for controlling for non-systematic error in an amplification-based next generation sequencing (NGS) library preparation are described, which method includes using an internal amplification control (IAC) sharing identical priming sites to a native nucleic acid target template of interest in a NGS library preparation. |
| FILED | Monday, April 25, 2022 |
| APPL NO | 17/728463 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6806 (20130101) Original (OR) Class C12Q 1/6851 (20130101) C12Q 1/6869 (20130101) Combinatorial Chemistry; Libraries, e.g Chemical Libraries C40B 20/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282321 | SABETI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE BROAD INSTITUTE, INC. (Cambridge, Massachusetts); PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Pardis SABETI (Cambridge, Massachusetts); Bronwyn MACINNIS (Cambridge, Massachusetts); Erica NORMANDIN (Cambridge, Massachusetts); Katie SIDDLE (Cambridge, Massachusetts); Steven REILLY (Cambridge, Massachusetts); Matthew BAUER (Cambridge, Massachusetts); Kim LAGERBORG (Cambridge, Massachusetts) |
| ABSTRACT | Embodiments disclosed herein provide methods of using synthetic DNA spike-ins (SDSIs) to detect, prevent, and quantify contamination in amplicon sequencing. These embodiments may, but are not limited to, reveal sample swaps, intra-batch contamination, and, on a larger scale, intra-laboratory contamination. Embodiments disclosed herein also provide synthetic DNA spike-ins for use in amplicon-based sequencing methods. |
| FILED | Tuesday, March 01, 2022 |
| APPL NO | 17/684328 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/1096 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/686 (20130101) C12Q 1/6809 (20130101) C12Q 1/6855 (20130101) Original (OR) Class C12Q 2527/101 (20130101) C12Q 2600/16 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282325 | BERNSTEIN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The General Hospital Corporation (Boston, Massachusetts); President and Fellows of Harvard College (Cambridge, Massachusetts) |
| ASSIGNEE(S) | The General Hospital Corporation (Boston, Massachusetts); President and Fellows of Harvard College (Cambridge, Massachusetts) |
| INVENTOR(S) | Bradley BERNSTEIN (Boston, Massachusetts); Sarah SHAREEF (Cambridge, Massachusetts); Volker HOVESTADT (Boston, Massachusetts) |
| ABSTRACT | The present invention features compositions and methods for assaying DNA methylation. |
| FILED | Thursday, May 12, 2022 |
| APPL NO | 17/743041 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/686 (20130101) C12Q 1/6869 (20130101) Original (OR) Class C12Q 1/6876 (20130101) C12Q 2600/154 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282334 | Weiss et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| INVENTOR(S) | Ron Weiss (Newton, Massachusetts); Jin Huh (Watertown, Massachusetts) |
| ABSTRACT | Provided herein are genetic circuits and cell state classifiers for detecting the microRNA profile of a cell. The cell state classifiers of the present disclosure are designed to incorporate multiple genetic circuits integrated together by transcriptional or translational control. Multiple inputs can be sensed simultaneously by coupling their detection to different portions of the genetic circuit such that the output molecule is produced only when the correct input profile of miRNAs is detected. The genetic circuits and cell state classifiers may be used in various applications (e.g., therapeutic or diagnostic applications). |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/688985 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/7125 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/113 (20130101) C12N 2310/14 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6811 (20130101) C12Q 1/6886 (20130101) Original (OR) Class C12Q 1/6897 (20130101) C12Q 2525/204 (20130101) C12Q 2525/207 (20130101) C12Q 2600/136 (20130101) C12Q 2600/178 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283126 | Wu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Regents of the University of Oklahoma (Oklahoma City, Oklahoma) |
| ASSIGNEE(S) | The Board of Regents of the University of Oklahoma (Oklahoma City, Oklahoma) |
| INVENTOR(S) | Si Wu (Norman, Oklahoma); Lushuang Huang (Norman, Oklahoma); Zhe Wang (San Francisco, California) |
| ABSTRACT | A spray-capillary device is configured to process ultra-low-volume samples. The spray-capillary device includes a capillary tube that includes a lumen, an inner surface, an outer surface, an inlet end for receiving a fluid, and a discharge end having a porous section. A polymer material may be applied to the inner surface to form a polymer coating thereon. A downstream connector provides an interface between the porous section of the capillary tube, a conductive fluid, and a high voltage electrical source. The application of voltage to the downstream connector causes electrospray ionization, which can be used to draw ultra-low-volume samples into the inlet end. A gas injection assembly can be used to increase the pressure on the inlet end of the capillary tube to encourage movement of the sample therethrough. The spray-capillary device may be used to provide the ultra-low-volume samples to a mass spectrometer or other suitable analytic device. |
| FILED | Friday, May 20, 2022 |
| APPL NO | 17/750022 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 30/16 (20130101) Original (OR) Class G01N 30/7233 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283140 | Wanunu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northeastern University (Boston, Massachusetts); The Board of Trustees of the University of Illinois (Urbana, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Meni Wanunu (Sharon, Massachusetts); Luning Yu (Brookline, Massachusetts); Aleksei Aksimentiev (Urbana, Illinois); Behzad Mehrafrooz (Urbana, Illinois) |
| ABSTRACT | A method and system for performing single molecule proteomics utilizing a nanopore sensor to measure an electronic signature of protein or peptide being transported through the nanopore from a first chamber to a second chamber. The protein's electronic signature is a function of ionic current over time. The method and system utilizing an agent, such as guanidinium chloride, to bind to the nanopore's interior and provide an electroosmotic force within the nanopore. The electroosmotic force, in some embodiments, enables stretching and unfolding of the protein during transport through the nanopore. The agent may also or alternatively induce the unfolding of the protein before transport through the nanopore and/or provide force moving the protein through the nanopore. |
| FILED | Thursday, December 23, 2021 |
| APPL NO | 17/645943 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502715 (20130101) B01L 3/502761 (20130101) B01L 2200/0663 (20130101) B01L 2300/0645 (20130101) B01L 2300/0663 (20130101) B01L 2400/0418 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/34 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6818 (20130101) G01N 33/48721 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283144 | Qi et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California) |
| ASSIGNEE(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California) |
| INVENTOR(S) | Lei S. Qi (Stanford, California); Yanxia Liu (Stanford, California) |
| ABSTRACT | Provided herein are compositions and methods for identifying and using stem cell regulation factors. For example, in some embodiments, provided herein are compositions and methods for identifying stem cell regulation factors using marker gene expression libraries. Also provided herein are compositions and methods for generating differentiated cells lines and uses of such cell lines. |
| FILED | Thursday, October 07, 2021 |
| APPL NO | 17/496275 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0697 (20130101) C12N 9/22 (20130101) C12N 9/1276 (20130101) C12N 15/65 (20130101) C12N 2310/20 (20170501) C12N 2502/1323 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5073 (20130101) Original (OR) Class G01N 33/6887 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283157 | Glezer et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Meso Scale Technologies, LLC. (Rockville, Maryland) |
| ASSIGNEE(S) | Meso Scale Technologies, LLC. (Rockville, Maryland) |
| INVENTOR(S) | Eli N. Glezer (Del Mar, California); Mikayla Higgins (Gaithersburg, Maryland); John Kenten (Boyds, Maryland); George Sigal (Rockville, Maryland) |
| ABSTRACT | The present disclosure relates to multiplexed assay formats configured to measure the level of a plurality of biomarkers that include a protein array for detecting autoreactive antibody levels against autoantigens. |
| FILED | Monday, November 22, 2021 |
| APPL NO | 17/531868 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/564 (20130101) Original (OR) Class G01N 2800/52 (20130101) G01N 2800/104 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283160 | Pirovano et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | MEMORIAL SLOAN KETTERING CANCER CENTER (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Giacomo Pirovano (New York, New York); Naga Vara Kishore Pillarsetty (New York, New York); Thomas Reiner (New York, New York) |
| ABSTRACT | The present disclosure relates to methods and kits for detecting SARS-CoV-2 virus in a patient. For example, a method is disclosed that includes contacting at least a portion of a diluted saliva sample, the diluted saliva sample including a saliva sample from a patient and a saline solution, with a radiolabeled SARS-CoV-2-targeted antibody to form a first solution that includes target bound antibody and unbound antibody; separating at least a portion of the target bound antibody from the unbound antibody in the first solution to form a separated target bound antibody solution; and detecting a radiation level in the separated target bound antibody sample indicating the presence of the target bound antibody in the separated target bound antibody sample. |
| FILED | Friday, November 19, 2021 |
| APPL NO | 17/531165 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 1/10 (20130101) G01N 23/00 (20130101) G01N 33/60 (20130101) G01N 33/56988 (20130101) Original (OR) Class G01N 2001/1056 (20130101) G01N 2333/165 (20130101) G01N 2469/10 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283161 | Kinchen et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Johns Hopkins University (Baltimore, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Valerie Kinchen (Baltimore, Maryland); Guido Massaccesi (Baltimore, Maryland); Stuart C. Ray (Baltimore, Maryland); Andrea Lynn Cox (Baltimore, Maryland); Justin R. Bailey (Baltimore, Maryland) |
| ABSTRACT | Provided herein are, inter alia, methods, compositions and kits for HCV antigen and vaccine design. Preferred methods include measuring neutralization of HCV pseudoparticles (HCVpp) by antibodies specific for an HCV in the biological sample, generating a neutralizations profile of each biological sample; deconvoluting the HCV-specific neutralizing antibodies by generating reference antibody neutralization profiles; correlating the reference antibody neutralization profiles to the biological sample's neutralization profile; and, identifying the HCV neutralizing antibodies. |
| FILED | Friday, July 24, 2020 |
| APPL NO | 17/630104 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 39/29 (20130101) A61K 2039/575 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 7/00 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5767 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283165 | Felsher et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Board of Trustees of the Leland Stanford Junior University (Stanford, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Dean Felsher (San Mateo, California); Carolyn R. Bertozzi (Menlo Park, California); Anja Deutzmann (Redwood City, California); Benjamin Smith (Redwood City, California); Simon Wisnovsky (Redwood City, California) |
| ABSTRACT | Provided are methods of enhancing immunogenicity of cancers. In certain aspects, the methods include administering an effective amount of a sialic acid modulator to an individual identified as having a cancer comprising dysregulated Myc. According to some aspects, the methods include administering an effective amount of a disialyl-T modulator to an individual identified as having a cancer comprising cell surface expression of disialyl-T. In certain aspects, the methods include administering an effective amount of an agent to an individual identified as having a cancer comprising cell surface expression of a glycoprotein comprising an O-glycosylated mucin-like domain, where the agent modulates the glycoprotein. Also provided are methods of assessing whether a cancer of an individual comprises dysregulated Myc. |
| FILED | Friday, July 10, 2020 |
| APPL NO | 17/625264 |
| CURRENT CPC | Peptides C07K 16/2896 (20130101) C07K 2317/76 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/57426 (20130101) Original (OR) Class G01N 33/57492 (20130101) G01N 2333/82 (20130101) G01N 2333/91091 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283172 | Parikh |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE JOHNS HOPKINS UNIVERSITY (Baltimore, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Chirag Parikh (Baltimore, Maryland) |
| ABSTRACT | The present invention relates to the field of organ transplantation. More specifically, the present invention provides compositions and methods useful for reducing the discard of kidney for transplantation after brain death. In a specific embodiment, a method for assessing viability of a kidney for transplantation comprises the step of measuring the amount of UMOD and OPN in a urine sample obtained from a deceased donor using a point-of-care lateral flow device, wherein ratio of UMOD:OPN of ≤3 indicates the kidney is viable for transplantation. |
| FILED | Friday, August 07, 2020 |
| APPL NO | 17/633292 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/68 (20130101) Original (OR) Class G01N 33/54388 (20210801) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283175 | OKERBERG et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Encodia, Inc. (San Diego, California) |
| ASSIGNEE(S) | Encodia, Inc. (San Diego, California) |
| INVENTOR(S) | Eric OKERBERG (San Diego, California); Stephen VERESPY, III (San Diego, California); Jason C. KLIMA (San Diego, California); Soumya GANGULY (San Diego, California); Zachary MILES (San Diego, California); Jason Duarte JACINTHO (San Diego, California); Aaron WISE (San Diego, California) |
| ABSTRACT | The present disclosure relates to a metalloprotein binder that specifically binds to a N-terminally modified peptide. Also provided herein is a method and related kits for treating or analyzing a peptide using the metalloprotein binder and/or modified cleavase. In some embodiments, the method provided herein comprises binding metalloprotein binder-coding tag conjugates to a modified N-terminal amino acid residue of an immobilized peptide associated with a recording tag, transferring identifying information from the coding tag to the recording tag using a ligation or primer extension, and cleaving the modified N-terminal amino acid residue. The method and metalloprotein binders provided herein are useful for de novo peptide identification or sequencing. |
| FILED | Friday, April 22, 2022 |
| APPL NO | 17/727677 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/573 (20130101) G01N 33/6818 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283180 | Wong et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE JOHNS HOPKINS UNIVERSITY (Baltimore, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Philip C. Wong (Lutherville, Maryland); Jonathan P. Ling (Baltimore, Maryland) |
| ABSTRACT | Chimeric proteins comprising an N-terminal domain derived from an N-terminal nucleotide binding domain of TDP-43 and a C-terminal domain derived from a splicing repressor are described. These proteins may be administered to a subject to treat or prevent disease manifesting TDP-43 proteinopathy such as inclusion body myocytosis, amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD). |
| FILED | Tuesday, March 02, 2021 |
| APPL NO | 17/189967 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Peptides C07K 14/4703 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6883 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6875 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283183 | Johnson |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Massachusetts (Boston, Massachusetts) |
| ASSIGNEE(S) | University of Massachusetts (Boston, Massachusetts) |
| INVENTOR(S) | Mark D. Johnson (Sudbury, Massachusetts) |
| ABSTRACT | Aspects of the disclosure relate to methods and compositions for diagnosing and/or treating idiopathic Normal Pressure Hydrocephalus (iNPH). In some embodiments, the methods comprise detecting a level of Cwh43 gene expression or Cwh43 protein in a subject and administering to the subject one or more therapies to treat iNPH based upon the level of the Cwh43 gene expression or Cwh43 protein compared to a control sample. |
| FILED | Wednesday, August 12, 2020 |
| APPL NO | 17/634586 |
| CURRENT CPC | Animal Husbandry; Care of Birds, Fishes, Insects; Fishing; Rearing or Breeding Animals, Not Otherwise Provided For; New Breeds of Animals A01K 67/0276 (20130101) A01K 2217/075 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6883 (20130101) C12Q 2600/156 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6896 (20130101) Original (OR) Class G01N 2800/2814 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283185 | Sweeney et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Melanie D. Sweeney (Los Angeles, California); Abhay P. Sagare (Los Angeles, California); Berislav V. Zlokovic (Los Angeles, California) |
| ABSTRACT | A highly sensitive immunoassay has been developed and validated. In various embodiments, the assay comprises an immunoassay usable to measure soluble PDGFRβ (sPDGFR-β) in a human biofluid sample such as cerebrospinal fluid (CSF). In various embodiments, elevated sPDGFR-β in a human biofluid sample reflects pericyte and blood-brain barrier (BBB) injury, and is therefore an early biomarker of human cognitive dysfunction, dementia, and/or Alzheimer's disease. |
| FILED | Thursday, August 27, 2020 |
| APPL NO | 17/637700 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/66 (20130101) G01N 21/76 (20130101) G01N 33/577 (20130101) G01N 33/6896 (20130101) Original (OR) Class G01N 2333/49 (20130101) G01N 2800/2821 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283192 | Czarnecki et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NanoCytomics, LLC (Evanston, Illinois); Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jarema Czarnecki (Evanston, Illinois); Justin Derbas (Evanston, Illinois); Sergey Rozhok (Evanston, Illinois); Hariharan Subramanian (Mundelein, Illinois); Parvathi Viswanathan (Evanston, Illinois) |
| ABSTRACT | Systems and methods that enable automated spray deposition of biological specimens carried on microscope slides are described herein. Aspects of the technology are directed, for example, to automated specimen deposition systems and methods of generating high-quality, reproducible specimen-bearing microscope slides in automated processing systems. |
| FILED | Monday, May 23, 2022 |
| APPL NO | 17/751127 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 1/312 (20130101) G01N 1/2813 (20130101) G01N 35/00029 (20130101) Original (OR) Class G01N 35/00871 (20130101) G01N 35/1011 (20130101) G01N 2001/317 (20130101) G01N 2035/00138 (20130101) G01N 2035/00168 (20130101) G01N 2035/00881 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283443 | Xu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| ASSIGNEE(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| INVENTOR(S) | Fan Xu (West Lafayette, Indiana); Fang Huang (West Lafayette, Indiana); Donghan Ma (West Lafayette, Indiana) |
| ABSTRACT | A method of in situ point spread function (PSF) retrieval is disclosed which includes encoding 3D location of molecules into PSFs, receiving molecule-generated images containing PSFs, segmenting the images into sub-PSFs, initializing template PSFs from a pupil function, determining a maximum normalized cross correlation (NCC) coefficient (NCCmax) between the sub- and template PSFs, associating each of the sub-PSFs with a template PSF based on the NCCmax and storing the sub-PSFs in associated bins, aligning and averaging the binned sub-PSFs, applying a phase retrieval algorithm to the averaged sub-PSFs to update the pupil function, regenerating the template PSFs, repeating until a difference between a new and a prior generation pupil function is below a predetermined threshold, generating in situ PSFs from the last pupil function, and applying a maximum likelihood estimation algorithm based on the in situ PSFs and the sub-PSFs to thereby generate lateral and axial locations of molecules. |
| FILED | Thursday, August 06, 2020 |
| APPL NO | 17/628140 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/6458 (20130101) Optical Elements, Systems, or Apparatus G02B 21/367 (20130101) G02B 26/0825 (20130101) G02B 27/58 (20130101) Original (OR) Class G02B 27/0068 (20130101) Image Data Processing or Generation, in General G06T 2207/10056 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283510 | Lee et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| ASSIGNEE(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| INVENTOR(S) | Ki-Bum Lee (Monmouth, New Jersey); Letao Yang (Piscataway, New Jersey) |
| ABSTRACT | A dynamic interference lithography (DIL) device is provided. The device includes a laser source configured for providing a laser beam, a substrate stage configured for mounting a substrate, an at least partially convex curved mirror, and a spatial filter configured to divide the laser beam into a first beam portion directed towards the at least partially convex curved mirror and a second beam portion directed towards the substrate. The first beam portion is reflected by the at least partially convex curved mirror towards the substrate to form an interference pattern on the substrate. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/653357 |
| CURRENT CPC | Photomechanical Production of Textured or Patterned Surfaces, e.g for Printing, for Processing of Semiconductor Devices; Materials Therefor; Originals Therefor; Apparatus Specially Adapted Therefor; G03F 7/2053 (20130101) G03F 7/70025 (20130101) G03F 7/70316 (20130101) G03F 7/70408 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284643 | Jha et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Abhinav Kumar Jha (St. Louis, Missouri); Ziping Liu (St. Louis, Missouri); Hae Sol Moon (St. Louis, Missouri); Zitong Yu (St. Louis, Missouri); Md Ashequr Rahman (St. Louis, Missouri) |
| ASSIGNEE(S) | Washington University (St. Louis, Missouri) |
| INVENTOR(S) | Abhinav Kumar Jha (St. Louis, Missouri); Ziping Liu (St. Louis, Missouri); Hae Sol Moon (St. Louis, Missouri); Zitong Yu (St. Louis, Missouri); Md Ashequr Rahman (St. Louis, Missouri) |
| ABSTRACT | Among the various aspects of the present disclosure is the provision of methods for estimation-based segmentation of nuclear medicine images, as well as methods of transmission-less attenuation and scatter compensation of nuclear medicine images. |
| FILED | Friday, February 26, 2021 |
| APPL NO | 17/187727 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 6/037 (20130101) A61B 6/5247 (20130101) A61B 6/5282 (20130101) Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers G06K 9/00147 (20130101) G06K 9/00201 (20130101) G06K 2209/05 (20130101) Image Data Processing or Generation, in General G06T 7/11 (20170101) G06T 7/0012 (20130101) G06T 11/005 (20130101) Original (OR) Class G06T 11/008 (20130101) G06T 2207/10104 (20130101) G06T 2207/10108 (20130101) G06T 2207/20081 (20130101) G06T 2207/30096 (20130101) G06T 2211/424 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285005 | Noble et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | VANDERBILT UNIVERSITY (Nashville, Tennessee) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jack H. Noble (Nashville, Tennessee); Ahmet Cakir (Nashville, Tennessee); Benoit M. Dawant (Nashville, Tennessee); Robert F. Labadie (Nashville, Tennessee); Rene H. Gifford (Franklin, Tennessee) |
| ABSTRACT | Systems and methods are provided for performing model-based cochlear implant programming (MOCIP) on a living subject with a cochlear implant (CI) to determine stimulation settings of a patient-customized electro-neural interface (ENI) model. The method includes: localizing an electrode array of the CI and intracochlear structures of the living subject to determine patient-specific electrode positions of the CI and a patient-specific anatomy shape; generating a CI electric field model based on the patient-specific electrodes positions of the CI and the patient-specific anatomy shape; and establishing an auditory nerve fiber (ANF) bundle model using the CI electric field model, and estimating neural health of the living subject using the ANF bundle model applications of the same. |
| FILED | Wednesday, August 26, 2020 |
| APPL NO | 17/637875 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 6/12 (20130101) A61B 6/032 (20130101) A61B 6/501 (20130101) A61B 6/506 (20130101) A61B 2034/102 (20160201) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 1/0541 (20130101) Electric Digital Data Processing G06F 30/23 (20200101) Image Data Processing or Generation, in General G06T 7/33 (20170101) G06T 7/55 (20170101) G06T 7/73 (20170101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 20/40 (20180101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Defense (DOD)
| US 20220280051 | Redkar et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Arizona Board of Regents on behalf of Arizona State University (Scottsdale, Arizona); The United States of America as represented by the Secretary of the Navy (Indian Head, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sangram Redkar (Mesa, Arizona); Kevin Nichols (Gilbert, Arizona); Prabha Dwivedi (Port Tobacco, Maryland) |
| ABSTRACT | Systems and methods for monitoring physiological parameter(s) and environmental condition(s) of a subject include an in-ear wearable apparatus. The in-ear wearable apparatus includes a housing, a controller coupled to the housing, a first plurality of physiological sensors coupled to the housing and configured to detect a plurality of physiological parameters, and at least one environmental sensor coupled to the housing and configured to detect at least one environmental condition. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/685914 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/0022 (20130101) A61B 5/02055 (20130101) Original (OR) Class Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 40/67 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280081 | ANDESHMAND et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | TALIS BIOMEDICAL CORPORATION (Menlo Park, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sayeed ANDESHMAND (Dublin, California); Thomas H. CAULEY, III (Redwood City, California); John DIXON (Moss Beach, California); David GLADE (San Ramon, California); Hédia MAAMAR (El Dorado Hills, California); Michael John McADAMS (Los Gatos, California); Dzam-Si Jesse NG (Fremont, California); David Alexander ROLFE (San Francisco, California) |
| ABSTRACT | Methods and systems are provided for point-of-care nucleic acid amplification and detection. One embodiment of the point-of-care molecular diagnostic system includes a cartridge and an instrument. The cartridge can accept a biological sample, such as a urine or blood sample. The cartridge, which can comprise one or more of a loading module, lysis module, purification module and amplification module, is inserted into the instrument which acts upon the cartridge to facilitate various sample processing steps that occur in order to perform a molecular diagnostic test. |
| FILED | Monday, August 17, 2020 |
| APPL NO | 17/635044 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/150755 (20130101) A61B 5/150961 (20130101) Original (OR) Class Chemical or Physical Laboratory Apparatus for General Use B01L 3/502761 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/689 (20130101) C12Q 1/6888 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280423 | Nedergaard et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Rochester (New York, New York) |
| ASSIGNEE(S) | University of Rochester (New York, New York) |
| INVENTOR(S) | Maiken Nedergaard (Rochester, New York); Benjamin Plog (New York, New York); Humberto Mestre (New York, New York); Tuomas O. Lilius (Helsinki, Finland); Andreas I. Jensen (Virum, Denmark); Steven A. Goldman (Webster, New York) |
| ABSTRACT | This invention relates to improving delivery of agents (e.g., one or more nanoparticles) to the central nervous system. |
| FILED | Monday, March 21, 2022 |
| APPL NO | 17/699953 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0085 (20130101) Original (OR) Class A61K 9/5115 (20130101) A61K 9/5146 (20130101) A61K 47/02 (20130101) Peptides C07K 16/18 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280525 | BORRERO-GARCÍA et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF PUERTO RICO (San Juan, Puerto Rico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Luis D. BORRERO-GARCÍA (San Juan, Puerto Rico); Suranganie DHARMAWARDHANE FLANAGAN (San Juan, Puerto Rico) |
| ABSTRACT | Targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), however acquired or intrinsic resistance often confounds therapy success. Common mechanisms of therapy resistance involve activating receptor point mutations and (or) upregulation of signaling downstream of EGFR/HER2 to Akt and (or) mitogen activated protein kinase (MAPK) pathways. However, additional pathways of resistance may exist thus, confounding successful therapy. To determine novel mechanisms of EGFR/HER2 therapy resistance in breast cancer, Gefitinib® or Lapatinib® resistant variants were created from SKBR3 breast cancer cells. Syngenic therapy sensitive and resistant SKBR3 variants were characterized for mechanisms of resistance by mammosphere assays, viability assays, and western blotting for total and phospho proteins. Combinations of treatments focused on RGFR/HER2 and Rac inhibitors (1,5-disubstituted 1, 2, 3-triazoles, e.g. Ehop-16 and MBQ-167) are proposed as viable strategies for treatment of EGFR/HER2 targeted therapy resistant breast cancer. |
| FILED | Wednesday, March 02, 2022 |
| APPL NO | 17/685174 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/517 (20130101) A61K 31/4192 (20130101) A61K 31/5377 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280649 | Gray et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, Massachusetts) |
| ASSIGNEE(S) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, Massachusetts) |
| INVENTOR(S) | Nathanael S. Gray (Boston, Massachusetts); Guangyan Du (Jamaica Plain, Massachusetts); Tinghu Zhang (Brookline, Massachusetts); Zhixiang He (Brookline, Massachusetts); Nicholas Kwiatkowski (Brookline, Massachusetts); Jie Jiang (Brookline, Massachusetts) |
| ABSTRACT | Disclosed are bispecific compounds (degraders) that target CDK7 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease. |
| FILED | Tuesday, August 04, 2020 |
| APPL NO | 17/631774 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 47/54 (20170801) A61K 47/55 (20170801) Original (OR) Class A61K 47/545 (20170801) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280661 | Evans et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | The Regents of the University of California (Oakland, California) |
| INVENTOR(S) | Michael Evans (Oakland, California); Yangjie Huang (Oakland, California); Christopher Drake (Oakland, California) |
| ABSTRACT | Disclosed herein are compounds useful for detection of glucocorticoid receptor expression and activity via positron emission tomography and related techniques. Methods for preparation and use of the compounds are also described. |
| FILED | Thursday, May 05, 2022 |
| APPL NO | 17/737649 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 51/0455 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280742 | Kitchin et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Naval Information Warfare Center Pacific (San Diego, California) |
| ASSIGNEE(S) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (San Diego, California) |
| INVENTOR(S) | Tristan Charles Kitchin (San Diego, California); Palmer Duston Hayward (San Diego, California); Daniel Sean Jennings (San Diego, California); Chandler James Petrovich Flynn (San Diego, California); Annie Yu-wen Lin (San Diego, California); Eric William Goulet (San Diego, California) |
| ABSTRACT | A ventilator airflow splitter is described herein that includes two to four connectors extending axially through two to four channels starting from a port insert of a single inlet connector and terminating at a port of each of the two to four connectors. The two to four connectors merge into the single inlet connector where the single inlet connector includes an internal cross-splitter individually dividing each of the two to four connectors internally, thereby separating the airflow between each of the two to four connectors such that the air is incapable of moving between connectors. The ventilator airflow splitter also includes gussets where each of the two to four connectors have a gusset individually attached and the gussets merge at the single inlet connector. Each of the two to four connectors are configured to be operatively connected to medical equipmentor a ventilator at the ports and the port insert of the single inlet connector. |
| FILED | Tuesday, March 02, 2021 |
| APPL NO | 17/189382 |
| CURRENT CPC | Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor A61M 16/20 (20130101) A61M 16/0875 (20130101) Original (OR) Class Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering B33Y 80/00 (20141201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281214 | Huang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NUtech Ventures (Lincoln, Nebraska) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jinsong Huang (Lincoln, Nebraska); Wei Wei (Lincoln, Nebraska) |
| ABSTRACT | Perovskite single crystal X-ray radiation detector devices including an X-ray wavelength-responsive active layer including an organolead trihalide perovskite single crystal, a substrate layer comprising an oxide, and a binding layer disposed between the active layer and the substrate layer. The binding layer including a binding molecule having a first functional group that bonds to the organolead trihalide perovskite single crystal and a second functional group that bonds with the oxide. Inclusion of the binding layer advantageously reduces device noise while retaining signal intensity. |
| FILED | Monday, May 16, 2022 |
| APPL NO | 17/745598 |
| CURRENT CPC | Layered Products, i.e Products Built-up of Strata of Flat or Non-flat, e.g Cellular or Honeycomb, Form B32B 27/08 (20130101) Original (OR) Class Techniques for Handling Particles or Ionising Radiation Not Otherwise Provided For; Irradiation Devices; Gamma Ray or X-ray Microscopes G21K 4/00 (20130101) G21K 2004/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281477 | Coyle et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Government of the United States, as represented by the Secretary of the Air Force (Wright-Patterson AFB, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David Coyle (Surprise, Arizona); Daniel Treece (Buckeye, Arizona); Wylie Standage-Beier (Phoenix, Arizona) |
| ABSTRACT | A threat emitter system comprising a threat emitter comprising a main power supply, an external power source, a first sequencer, a driver amp, a second sequencer, a main amp, and a radio; a three-way power supply; a mixer, synthesizer, pre-amp, and cooling fans receiving electrical power from the three-way power supply; and an antenna in communication with the main amp; a user interface in communication with radio; the radio in communication with the mixer; the mixer in communication with the synthesizer; a filter in communication between the mixer and the pre-amp; the driver amp in communication with the pre-amp; the first sequencer in communication with the driver amp; the driver amp in communication with the main amp; a second sequencer in communication with the main amp; and a processor with access to a memory storing instructions executable by the processor. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/653294 |
| CURRENT CPC | Conjoint Control of Vehicle Sub-units of Different Type or Different Function; Control Systems Specially Adapted for Hybrid Vehicles; Road Vehicle Drive Control Systems for Purposes Not Related to the Control of a Particular Sub-unit B60W 50/14 (20130101) B60W 60/001 (20200201) Original (OR) Class B60W 2540/215 (20200201) B60W 2556/45 (20200201) B60W 2710/22 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281749 | Yeh et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | California Institute of Technology (Pasadena, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nai-Chang Yeh (Pasadena, California); Chen-Chih Hsu (Pasadena, California); Jiaqing Wang (Pasadena, California); Marcus L. Teague (Pasadena, California) |
| ABSTRACT | A strain engineered material including a monolayer graphene sheet comprising an array of wrinkles induced by deformations in the graphene sheet, the deformations formed by a lattice of underlying nanostructures on a substrate. The lattice of nanostructures comprises rows of the nanostructures and each of the wrinkles comprise a ridge aligned on top of a different one of the rows and along an alignment direction defined by the rows. The deformations pattern a strain distribution in the graphene sheet that induces a periodically varying pseudo magnetic field distribution ranging between a positive value and a negative values, The periodically varying pseudo magnetic field distribution has field magnitude minima located parallel to and between the ridges and field magnitude maxima located near to and parallel to each of the ridges and can be designed for various valleytronic and spintronic device applications. |
| FILED | Friday, May 07, 2021 |
| APPL NO | 17/314873 |
| CURRENT CPC | Non-metallic Elements; Compounds Thereof; C01B 32/186 (20170801) Original (OR) Class Measuring Electric Variables; Measuring Magnetic Variables G01R 33/072 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/1606 (20130101) H01L 43/04 (20130101) H01L 43/065 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281774 | Aguilar-Mendoza et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Guillermo Aguilar-Mendoza (Corona, California); Javier E. Garay (San Diego, California); Elias Penilla (Upland, California) |
| ABSTRACT | Ceramic welding methods and welded articles are disclosed. The present disclosure shows that transparent and diffuse ceramics can be successfully joined using lasers. The diffuse ceramic welding can be aided by introducing a small gap for optical penetration while no gap is necessary in the transparent ceramics case. Laser welding is more versatile on transparent ceramics since one can focus through the material allowing the joining of more complex geometries and over multiple interaction zones, increasing the ultimate weld volumes. |
| FILED | Sunday, July 26, 2020 |
| APPL NO | 17/630151 |
| CURRENT CPC | Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone C04B 35/4885 (20130101) C04B 37/005 (20130101) Original (OR) Class C04B 2235/665 (20130101) C04B 2235/781 (20130101) C04B 2235/3225 (20130101) C04B 2235/6567 (20130101) C04B 2235/9653 (20130101) C04B 2237/59 (20130101) C04B 2237/82 (20130101) C04B 2237/343 (20130101) C04B 2237/348 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281874 | Zhang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Dana-Farber Cancer Institure, Inc. (Boston, Massachusetts) |
| ASSIGNEE(S) | Dana-Farber Cancer Institure, Inc. (Boston, Massachusetts) |
| INVENTOR(S) | Tinghu Zhang (Brookline, Massachusetts); Nicholas Paul Kwiatkowski (Brookline, Massachusetts); Nathanael S. Gray (Stanford, California); Zhixiang He (Brookline, Massachusetts); Yanke Liang (Belmont, Massachusetts) |
| ABSTRACT | The present disclosure provides compounds of Formula (I), (II-1), (II-2), (II-3), or (II-4). The compounds of the present disclosure may be inhibitors of kinases (e.g., a cyclin-dependent kinase (CDK) (e.g., CDK7)). In some embodiments, the compounds disclosed herein are selective for inhibiting the activity of a kinase (e.g., CDK7) over certain other kinases (e.g., CDK2, CDK9, CDK12). In certain embodiments, the compounds do not bind or inhibit a 5-hydroxytryptamine (5-HT) receptor. Also provided are pharmaceutical compositions, kits, methods of use, and uses that involve the compounds disclosed herein. In some embodiments, the compounds are useful in inhibiting the activity of a kinase, inhibiting the growth of a cell, inducing apoptosis of a cell, treating a disease, and/or preventing a disease (e.g., proliferative disease, cystic fibrosis). |
| FILED | Wednesday, July 22, 2020 |
| APPL NO | 17/628794 |
| CURRENT CPC | Heterocyclic Compounds C07D 487/04 (20130101) Original (OR) Class C07D 519/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281955 | WATTERS et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts) |
| ASSIGNEE(S) | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts) |
| INVENTOR(S) | Alexander WATTERS (North Andover, Massachusetts); Brendon Dusel (West Roxbury, Massachusetts); Michael SUPER (Lexington, Massachusetts); Mark CARTWRIGHT (West Newton, Massachusetts); Donald E. INGBER (Boston, Massachusetts) |
| ABSTRACT | Described herein are engineered microbe-targeting molecules, microbe-targeting articles, kits comprising the same, and uses thereof. Such microbe-targeting molecules, microbe-targeting articles, or the kits comprising the same can not only bind or capture of a microbe or microbial matter thereof, but they also have improved capability (e g, enhanced sensitivity or signal intensity) of detecting a microbe or microbial matter. Thus, the microbe-targeting molecules, microbe-targeting articles, and/or the kit described herein can be used in various applications, e.g., but not limited to assays for detection of a microbe or microbial matter, diagnostic and/or therapeutic agents for diagnosis and/or treatment of an infection caused by microbes in a subject or any environmental surface, and/or devices for removal of a microbe or microbial matter from a fluid. |
| FILED | Thursday, December 16, 2021 |
| APPL NO | 17/552662 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/00 (20130101) Peptides C07K 14/00 (20130101) C07K 14/78 (20130101) Original (OR) Class C07K 14/4726 (20130101) C07K 19/00 (20130101) C07K 2319/30 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/569 (20130101) G01N 2400/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281958 | CROWE, JR. et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Vanderbilt University (Nashville, Tennessee) |
| ASSIGNEE(S) | Vanderbilt University (Nashville, Tennessee) |
| INVENTOR(S) | James E. CROWE, JR. (Nashville, Tennessee); Seth ZOST (Nashville, Tennessee); Robert CARNAHAN (Nashville, Tennessee); Pavlo GILCHUK (Nashville, Tennessee) |
| ABSTRACT | The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof. |
| FILED | Friday, March 18, 2022 |
| APPL NO | 17/655503 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 2039/505 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 31/14 (20180101) Peptides C07K 16/10 (20130101) Original (OR) Class Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/56983 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282029 | FISCHER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (OAKLAND, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | FELIX RAOUL FISCHER (BERKELEY, California); JEFFREY BOKOR (PIEDMONT, California); ZAFER MUTLU (WALNUT CREEK, California); JUAN PABLO LLINAS (OAKLAND, California); RYAN DAVID MCCURDY (BERKELEY, California); GREGORY CLINTON VEBER (BERKELEY, California); DHARATI JOSHI KOENIGS (PEARLAND, Texas) |
| ABSTRACT | Various chemical structures of precursors for armchair graphene nanoribbons (AGNRs) are disclosed, along with a C method of manufacturing. |
| FILED | Friday, May 29, 2020 |
| APPL NO | 17/608355 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 40/00 (20130101) Non-metallic Elements; Compounds Thereof; C01B 32/184 (20170801) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 61/10 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282042 | Swager et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| ASSIGNEE(S) | Massachusetts Institute of Technology (Cambridge, Massachusetts) |
| INVENTOR(S) | Timothy Manning Swager (Newton, Massachusetts); Richard Liu (Cambridge, Massachusetts); Sheng Guo (Brookline, Massachusetts) |
| ABSTRACT | Compositions and methods related to the synthesis and application of poly(aryl ether)s are generally described. |
| FILED | Thursday, December 23, 2021 |
| APPL NO | 17/560983 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 23/44 (20130101) B01J 35/1019 (20130101) B01J 37/12 (20130101) B01J 37/16 (20130101) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 65/48 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282265 | Tracewell et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Zymergen Inc. (Emeryville, California) |
| ASSIGNEE(S) | Zymergen Inc. (Emeryville, California) |
| INVENTOR(S) | Cara Ann Tracewell (Walnut Creek, California); Alexander Glennon Shearer (San Francisco, California) |
| ABSTRACT | The present disclosure describes the engineering of microbial cells for fermentative production of 3-amino-4-hydroxybenzoic acid and provides novel engineered microbial cells and cultures, as well as related 3-amino-4-hydroxybenzoic acid production methods. Embodiments 1: An engineered microbial cell that produces 3-amino-4-hydroxybenzoic acid, wherein the engineered microbial cell expresses: (a) a non-native 2-amino-4,5-dihydroxy-6-oxo-7-(phosphooxy) heptanoate synthase; and (b) a non-native 3-amino-4-benzoic acid synthase. |
| FILED | Monday, August 10, 2020 |
| APPL NO | 17/632497 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/77 (20130101) Original (OR) Class C12N 15/81 (20130101) C12N 2510/02 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 13/14 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282300 | Pierce et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | California Institute of Technology (Pasadena, California); Molecular Instruments, Inc. (Los Angeles, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Niles A. Pierce (Pasadena, California); Harry Ming Tak Choi (Los Angeles, California) |
| ABSTRACT | Methods of analysis of a sample using hybridization chain reaction (HCR) are provided herein. Some embodiments involve one, two, or all three of the following aspects: 1) repeated signal detection, 2) overlapping binding sites, and 3) catalytic reporter deposition (CARD). Compositions and kits relating to these are also provided. Some embodiments encompass a method for repeated signal detection with reporter-labeled HCR hairpins involving providing a sample possibly containing one or more targets as well as possibly other molecules that are not targets, providing one or more probe sets each comprising either: a)one or more HCR initiator-labeled probes, or b) one or more probe units each comprising two or more HCR fractional initiator probes, providing one or more HCR amplifiers (each labeled with one or more reporters), detecting one or more signals from one or more reporters. In some embodiments, a probe unit comprises two or more HCR fractional initiator probes, wherein an HCR fractional initiator probe comprises a target-binding region and a fractional initiator, wherein the target-binding regions within a probe unit are configured to bind to overlapping or non-overlapping binding sites on the target, and wherein the fractional initiators on the probes within each probe unit are configured to bind to overlapping or non-overlapping binding sites on an HCR hairpin. Some embodiments encompass a method for HCR-mediated catalytic reporter deposition (CARD) for signal detection with hapten-labeled HCR hairpins involving providing a sample possibly containing one or more targets as well as possibly other molecules that are not targets, providing one or more probe sets each comprising either: a) one or more HCR initiator-labeled probes, or b) one or more probe units each comprising two or more HCR fractional initiator probes, providing one or more HCR amplifiers (each labeled with one or more haptens), providing one or more anti-haptens labeled with one or more reporter entities, wherein the reporter entity is an enzyme that mediates CARD, providing one or more CARD-substrates leading to deposition of one or more reporters, and detecting one or more signals from one or more reporters. |
| FILED | Thursday, March 04, 2021 |
| APPL NO | 17/637253 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/682 (20130101) Original (OR) Class C12Q 1/6825 (20130101) C12Q 1/6841 (20130101) C12Q 2600/16 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282304 | ISMAGILOV et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CALIFORNIA INSTITUTE OF TECHNOLOGY (Pasadena, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Rustem F. ISMAGILOV (Pasadena, California); Eric LIAW (Pasadena, California); Anna E. ROMANO (Pasadena, California) |
| ABSTRACT | Provided herein is an antibiotic susceptibility and related compositions, methods and systems based on nucleic acid detection based on detected intracellular and extracellular nucleic acid from a same sample, which allows determination of antibiotic susceptibility of microorganisms as well as the diagnosis and/or treatment of related infections in individuals. |
| FILED | Monday, February 28, 2022 |
| APPL NO | 17/683246 |
| CURRENT CPC | Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/18 (20130101) C12Q 1/689 (20130101) Original (OR) Class C12Q 1/6806 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283260 | Kassas et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Zak M. Kassas (Irvine, California); Kimia Shamaei (Irvine, California); Joe Khalife (Costa Mesa, California) |
| ABSTRACT | A software-defined receiver (SDR) using real long term evolution (LTE) signals may be used for navigation. The LTE SDR leverages the structure of the downlink LTE signal, and provides signal acquisition, navigation-relevant high-level system information extraction, and signal tracking. The LTE SDR also provides the ability to obtain a time-of-arrival (TOA) estimate from received LTE signals, which provides a navigation solution comparable to a GPS-only navigation solution. |
| FILED | Friday, October 29, 2021 |
| APPL NO | 17/515063 |
| CURRENT CPC | Aeroplanes; Helicopters B64C 39/02 (20130101) B64C 2201/145 (20130101) Cosmonautics; Vehicles or Equipment Therefor B64G 1/1014 (20130101) Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 5/145 (20130101) G01S 5/0221 (20130101) Original (OR) Class G01S 19/48 (20130101) Wireless Communication Networks H04W 56/006 (20130101) H04W 64/006 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283315 | Allen |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Aerospace Corporation (El Segundo, California) |
| ASSIGNEE(S) | The Aerospace Corporation (El Segundo, California) |
| INVENTOR(S) | David W. Allen (Fairfax, Virginia) |
| ABSTRACT | Systems and methods for simulating performance of receivers in realistic interference scenarios are provided herein. A method for simulating the performance of a receiver may include (a) generating a set of observables that a receiver in a truth state would ideally see; (b) adding interference to the set of observables to generate a set of corrupted observables; and (c) generating a position, navigation, and timing (PNT) solution using the set of corrupted observables. |
| FILED | Monday, March 08, 2021 |
| APPL NO | 17/194797 |
| CURRENT CPC | Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 19/21 (20130101) G01S 19/23 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283317 | LANGEL et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The MITRE Corporation (McLean, Virginia) |
| ASSIGNEE(S) | The MITRE Corporation (McLean, Virginia) |
| INVENTOR(S) | Steven Edward LANGEL (Bedford, Massachusetts); John David QUARTARARO (Tynsgboro, Massachusetts); Joseph Samuel CISNEROS (Pomona, California); Kevin Francis GRECO (Hermosa Beach, California) |
| ABSTRACT | An apparatus that performs spoof detection of satellite signals based on clock information derived from the satellite signals. The apparatus may include a position, velocity, time (PVT) component that derives the clock information from the satellite signals and provides the clock information to a spoof detection mechanism. In some embodiments, the clock frequency estimate is modeled as a Wiener process. |
| FILED | Thursday, March 04, 2021 |
| APPL NO | 17/192445 |
| CURRENT CPC | Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 19/11 (20130101) G01S 19/23 (20130101) G01S 19/37 (20130101) Original (OR) Class G01S 19/243 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283411 | DEVLIN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts) |
| ASSIGNEE(S) | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, Massachusetts) |
| INVENTOR(S) | Robert C. DEVLIN (Cambridge, Massachusetts); Mohammadreza KHORASANINEJAD (Cambridge, Massachusetts); Federico CAPASSO (Cambridge, Massachusetts); Hongkun PARK (Cambridge, Massachusetts); Alexander Arthur HIGH (Cambridge, Massachusetts) |
| ABSTRACT | A method of fabricating a visible spectrum optical component includes: providing a substrate; forming a resist layer over a surface of the substrate; patterning the resist layer to form a patterned resist layer defining openings exposing portions of the surface of the substrate; performing deposition to form a dielectric film over the patterned resist layer and over the exposed portions of the surface of the substrate, wherein a top surface of the dielectric film is above a top surface of the patterned resist layer; removing a top portion of the dielectric film to expose the top surface of the patterned resist layer and top surfaces of dielectric units within the openings of the patterned resist layer; and removing the patterned resist layer to retain the dielectric units over the substrate. |
| FILED | Wednesday, May 25, 2022 |
| APPL NO | 17/824823 |
| CURRENT CPC | Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General C23C 16/042 (20130101) C23C 16/56 (20130101) C23C 16/45525 (20130101) C23C 16/45555 (20130101) Optical Elements, Systems, or Apparatus G02B 1/002 (20130101) G02B 1/02 (20130101) G02B 1/005 (20130101) G02B 13/14 (20130101) Original (OR) Class Photomechanical Production of Textured or Patterned Surfaces, e.g for Printing, for Processing of Semiconductor Devices; Materials Therefor; Originals Therefor; Apparatus Specially Adapted Therefor; G03F 7/0005 (20130101) G03F 7/40 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 31/02 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283443 | Xu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| ASSIGNEE(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| INVENTOR(S) | Fan Xu (West Lafayette, Indiana); Fang Huang (West Lafayette, Indiana); Donghan Ma (West Lafayette, Indiana) |
| ABSTRACT | A method of in situ point spread function (PSF) retrieval is disclosed which includes encoding 3D location of molecules into PSFs, receiving molecule-generated images containing PSFs, segmenting the images into sub-PSFs, initializing template PSFs from a pupil function, determining a maximum normalized cross correlation (NCC) coefficient (NCCmax) between the sub- and template PSFs, associating each of the sub-PSFs with a template PSF based on the NCCmax and storing the sub-PSFs in associated bins, aligning and averaging the binned sub-PSFs, applying a phase retrieval algorithm to the averaged sub-PSFs to update the pupil function, regenerating the template PSFs, repeating until a difference between a new and a prior generation pupil function is below a predetermined threshold, generating in situ PSFs from the last pupil function, and applying a maximum likelihood estimation algorithm based on the in situ PSFs and the sub-PSFs to thereby generate lateral and axial locations of molecules. |
| FILED | Thursday, August 06, 2020 |
| APPL NO | 17/628140 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 21/6458 (20130101) Optical Elements, Systems, or Apparatus G02B 21/367 (20130101) G02B 26/0825 (20130101) G02B 27/58 (20130101) Original (OR) Class G02B 27/0068 (20130101) Image Data Processing or Generation, in General G06T 2207/10056 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283565 | Kalyanam et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Palo Alto Research Center Incorporated (Palo Alto, California) |
| ASSIGNEE(S) | Palo Alto Research Center Incorporated (Palo Alto, California) |
| INVENTOR(S) | Krishna M. Kalyanam (Campbell, California); Morad Behandish (Foster City, California) |
| ABSTRACT | Embodiments described herein provide a system for facilitating a process plan for manufacturing an object. During operation, the system can determine a target search space based on a set of constraints. The target search space can include a set of manufacturing actions associated with a manufacturing process of the object. A respective manufacturing action can include an additive or subtractive manufacturing operation corresponding to the addition or removal of a predefined region of the object, respectively. The system can then traverse a set of sequence of actions in the target search space based on a search operation and select a sequence of actions satisfying a target objective as the process plan. A respective sequence of actions can include one or more manufacturing operations capable of producing the object. Subsequently, the system can provide the process plan to a controller configured to manage the manufacturing process of the object. |
| FILED | Wednesday, March 03, 2021 |
| APPL NO | 17/191583 |
| CURRENT CPC | Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing B29C 64/386 (20170801) Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering B33Y 50/00 (20141201) Control or Regulating Systems in General; Functional Elements of Such Systems; Monitoring or Testing Arrangements for Such Systems or Elements G05B 19/4099 (20130101) Original (OR) Class G05B 2219/32423 (20130101) G05B 2219/35134 (20130101) Data Processing Systems or Methods, Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes; Systems or Methods Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes, Not Otherwise Provided for G06Q 10/06316 (20130101) G06Q 50/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283943 | Grayver et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Aerospace Corporation (El Segundo, California) |
| ASSIGNEE(S) | The Aerospace Corporation (El Segundo, California) |
| INVENTOR(S) | Eugene Grayver (Manhattan Beach, California); Mark Kubiak (Redondo Beach, California) |
| ABSTRACT | High-throughput software-defined convolutional interleavers and de-interleavers are provided herein. In some examples, a method for generating convolutionally interleaved samples on a general purpose processor with cache is provided. Memory is represented as a three dimensional array, indexed by block number, row, and column. Input samples may be written to the cache according to an indexing scheme. Output samples may be generated every MN samples by reading out the samples from the cache in a transposed and vectorized order. |
| FILED | Friday, March 05, 2021 |
| APPL NO | 17/193354 |
| CURRENT CPC | Electric Digital Data Processing G06F 12/0813 (20130101) Original (OR) Class G06F 17/18 (20130101) G06F 2212/603 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284115 | Tang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of Columbia University in the City of New York (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Adrian Tang (New York, New York); Salvatore Stolfo (New York, New York); Lakshminarasimhan Sethumadhavan (New York, New York) |
| ABSTRACT | Disclosed are devices, systems, apparatus, methods, products, and other implementations, including a method that includes determining whether an operation to access a memory location containing executable code comprises a general-purpose memory access operation, and changing content of the memory location in response to a determination that the operation to access the memory location containing the executable code comprises the general-purpose memory access operation to the memory location. |
| FILED | Tuesday, December 14, 2021 |
| APPL NO | 17/550559 |
| CURRENT CPC | Electric Digital Data Processing G06F 9/45558 (20130101) G06F 12/1009 (20130101) G06F 12/1475 (20130101) G06F 21/52 (20130101) G06F 21/604 (20130101) G06F 21/6218 (20130101) Original (OR) Class G06F 2009/45583 (20130101) G06F 2009/45595 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284261 | Lillo |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Aerospace Corporation (El Segundo, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Walter Engevald Lillo (Westlake Village, California) |
| ABSTRACT | Machine learning models are provided that consider, during the process of producing output, various aspects of the training data and/or training process from which the models are created. A machine learning model may generate output (e.g., classification determinations or regression output) that is augmented with information regarding the distribution(s) of the corpus of training data upon which the model was trained, the features extracted from the training data, the resulting determinations made by the model, and/or other information. The augmentation may occur internally while generating the model output, or the output itself may be augmented to include distribution-based data in addition to a model output. |
| FILED | Friday, March 05, 2021 |
| APPL NO | 17/249604 |
| CURRENT CPC | Computer Systems Based on Specific Computational Models G06N 3/04 (20130101) Original (OR) Class G06N 3/08 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284589 | Mathai et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Carnegie Mellon University (Pittsburgh, Pennsylvania); University of Pittsburgh - Of the Commonwealth System of Higher Education (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Tejas Sudharshan Mathai (Seattle, Washington); John Galeotti (Pittsburgh, Pennsylvania); Vijay Saradhi Gorantla (Winston Salem, North Carolina) |
| ABSTRACT | Provided is a system, method, and computer program product for segmenting vessels in an ultrasound image. The method includes detecting edges of a vessel in the ultrasound image; detecting a vessel contour of the vessel in the ultrasound image based on the detected edges and a distance regularized level set evolution; and tracking the vessel contour with a Kalman Filter. |
| FILED | Friday, June 12, 2020 |
| APPL NO | 17/618151 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 6/504 (20130101) Image Data Processing or Generation, in General G06T 7/0012 (20130101) G06T 7/12 (20170101) G06T 7/149 (20170101) Original (OR) Class G06T 2207/10081 (20130101) G06T 2207/30101 (20130101) Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data G16H 30/40 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284706 | Rowe et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Carnegie Mellon University (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Anthony Rowe (Pittsburgh, Pennsylvania); Michael Farb (Pittsburgh, Pennsylvania); Ivan Liang (Pittsburgh, Pennsylvania); Edward Lu (Pittsburgh, Pennsylvania); Nuno Pereira (Pittsburgh, Pennsylvania); Eric Riebling (Pittsburgh, Pennsylvania) |
| ABSTRACT | Some embodiments of the present inventive concept provide for improved telepresence and other virtual sessions using localized projection of audible noises and/or dynamic adjustment of audio and/or video qualities based on spatial relationships between users. An XR telepresence platform can allow for immersive multi-user video conferencing from within a web browser or other medium. The platform can support spatial audio and/or user video. The platform can scale to hundreds or thousands of users concurrently in a single or multiple virtual environments. Disclosed herein are quality-of-service techniques for dynamically selecting or modifying audio and/or video traffic. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/685816 |
| CURRENT CPC | Image Data Processing or Generation, in General G06T 15/10 (20130101) G06T 19/006 (20130101) G06T 2219/024 (20130101) Image or Video Recognition or Understanding G06V 20/20 (20220101) Original (OR) Class Transmission of Digital Information, e.g Telegraphic Communication H04L 65/60 (20130101) Stereophonic Systems H04S 7/303 (20130101) H04S 2400/11 (20130101) H04S 2400/13 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285499 | Morgan et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The United States of America, as represented by the Secretary of the Navy (Crane, Indiana) |
| ASSIGNEE(S) | The United States of America, as represented by the Secretary of the Navy (Arlington, Virginia) |
| INVENTOR(S) | Timothy Allen Morgan (Ellettsville, Indiana); Matthew J Gadlage (Bloomington, Indiana); Kevin Goodman (Ellettsville, Indiana); Morgan E Ware (Fayetteville, Arkansas); Pijush Kanti Ghosh (Dallas, Texas) |
| ABSTRACT | A microelectronic device that is radiation hardened through the incorporation of a quantum structure getter (QSG) is provided. The device, such as a field effect transistor (FET) includes a conductive channel and a material stack comprising: a capping layer, one or more barrier layers comprising a high band gap, one or more quantum structures comprising a small band gap, and a substrate. The quantum structures are positioned in close proximity to the conductive channel to form a quantum well charge getter. The getter forms a low energy area beneath the FET, which traps and confines electron-hole pair wave functions produced from ionizing radiation, causing the wave functions overlap, recombine, and produce light emission. The quantum structures getter the wave functions, which reduces the ionized photocurrent that reaches the conducting channel, thereby hardening the microelectronic device against ionizing radiation. |
| FILED | Thursday, December 16, 2021 |
| APPL NO | 17/553038 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 27/085 (20130101) H01L 29/155 (20130101) Original (OR) Class H01L 29/205 (20130101) H01L 29/7786 (20130101) H01L 29/66462 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285526 | Brueck et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNM RAINFOREST INNOVATIONS (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Steven R.J. Brueck (Albuquerque, New Mexico); Stephen D. Hersee (Albuquerque, New Mexico); Seung-Chang Lee (Albuquerque, New Mexico); Daniel Feezell (Albuquerque, New Mexico) |
| ABSTRACT | A method for making a heteroepitaxial layer. The method comprises providing a semiconductor substrate. A seed area delineated with a selective growth mask is formed on the semiconductor substrate. The seed area comprises a first material and has a linear surface dimension of less than 100 nm. A heteroepitaxial layer is grown on the seed area, the heteroepitaxial layer comprising a second material that is different from the first material. Devices made by the method are also disclosed. |
| FILED | Tuesday, May 24, 2022 |
| APPL NO | 17/752228 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 10/00 (20130101) B82Y 40/00 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 21/02107 (20130101) H01L 21/02381 (20130101) H01L 21/02532 (20130101) H01L 21/02538 (20130101) H01L 21/02639 (20130101) H01L 27/1211 (20130101) H01L 29/04 (20130101) H01L 29/16 (20130101) H01L 29/20 (20130101) H01L 29/0665 (20130101) H01L 29/0673 (20130101) H01L 29/0676 (20130101) H01L 29/775 (20130101) H01L 29/785 (20130101) H01L 29/7783 (20130101) H01L 29/7827 (20130101) H01L 29/7851 (20130101) H01L 29/66462 (20130101) Original (OR) Class H01L 29/66469 (20130101) H01L 29/66666 (20130101) H01L 29/66795 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285635 | Leem et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| ASSIGNEE(S) | Purdue Research Foundation (West Lafayette, Indiana) |
| INVENTOR(S) | Jung Woo Leem (West Lafayette, Indiana); Seung Ho Choi (West Lafayette, Indiana); Young L. Kim (West Lafayette, Indiana) |
| ABSTRACT | A method of disinfection of a surface of a subject of harmful microorganisms including pathogenic bacteria and viruses upon visible light irradiation using a hybridized fluorescent silk is provided. The method includes placing a predetermined quantity of the hybridized fluorescent silk i) directly on to a skin surface of a subject; or ii) on a medium and then placing the medium on the skin surface of the subject. The method further includes applying light in the visible spectrum for a predetermined amount of time to the placed quantity of hybridized fluorescent silk, wherein the hybridized fluorescent silk is one of KillerRed, SuperNova, KillerOrange, Dronpa, TurboGFP, mCherry, or any combination thereof. |
| FILED | Friday, March 25, 2022 |
| APPL NO | 17/704222 |
| CURRENT CPC | Preserving, e.g by Canning, Meat, Fish, Eggs, Fruit, Vegetables, Edible Seeds; Chemical Ripening of Fruit or Vegetables; the Preserved, Ripened, or Canned Products A23B 7/015 (20130101) A23B 7/154 (20130101) Indexing Scheme Relating to Foods, Foodstuffs or Non-alcoholic Beverages A23V 2002/00 (20130101) Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles A61L 2/0052 (20130101) A61L 2/0076 (20130101) A61L 2/084 (20130101) A61L 2/088 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 5/062 (20130101) A61N 5/0624 (20130101) A61N 2005/0663 (20130101) Separation B01D 29/62 (20130101) B01D 46/66 (20220101) Peptides C07K 14/43504 (20130101) C07K 14/43586 (20130101) C07K 19/00 (20130101) C07K 2319/00 (20130101) Materials for Miscellaneous Applications, Not Provided for Elsewhere C09K 11/06 (20130101) C09K 2211/14 (20130101) Capacitors; Capacitors, Rectifiers, Detectors, Switching Devices or Light-sensitive Devices, of the Electrolytic Type H01G 9/2018 (20130101) H01G 9/2059 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 51/0093 (20130101) Original (OR) Class H01L 51/442 (20130101) H01L 51/4253 (20130101) H01L 2251/301 (20130101) H01L 2251/306 (20130101) H01L 2251/308 (20130101) Reduction of Greenhouse Gas [GHG] Emissions, Related to Energy Generation, Transmission or Distribution Y02E 10/549 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285642 | Ma et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Florida State University Research Foundation, Inc. (Tallahassee, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Biwu Ma (Tallahassee, Florida); Qingquan He (Tallahassee, Florida) |
| ABSTRACT | Methods of passivating a surface. The methods may include providing a mixture including a liquid and a derivative of quinacridone, applying the mixture to a first surface of a film that includes a metal halide perovskite, and annealing the film for a time and a temperature effective to convert the derivative of quinacridone to quinacridone. Composite materials and electronic devices also are provided. |
| FILED | Tuesday, March 02, 2021 |
| APPL NO | 17/189662 |
| CURRENT CPC | Processes for Applying Fluent Materials to Surfaces, in General B05D 1/005 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 51/448 (20130101) Original (OR) Class H01L 51/4213 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285817 | Darwish |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | U.S. Army Combat Capabilities Development Command, Army Research Laboratory (Adelphi, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ali M. Darwish (Highland, Maryland) |
| ABSTRACT | Switch circuits for electrical power are formed of a hybrid coupler configured to receive a signal as an input, and output first and second pulsed wave signals along first and second signal paths, respectively; in a plurality of time frames, wherein the phases of the first and second pulsed wave signals along first and second signal paths are aligned. The switch circuits may be incorporated in time folding power circuits as an exemplary application. |
| FILED | Wednesday, January 19, 2022 |
| APPL NO | 17/578525 |
| CURRENT CPC | Waveguides; Resonators, Lines, or Other Devices of the Waveguide Type H01P 5/19 (20130101) Original (OR) Class Impedance Networks, e.g Resonant Circuits; Resonators H03H 11/16 (20130101) Pulse Technique H03K 17/56 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285944 | Drummond et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Arizona Board of Regents on behalf of Arizona State University (Scottsdale, Arizona) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Zachary Drummond (Mesa, Arizona); Kevin Claytor (Columbia, Maryland) |
| ABSTRACT | A subspace-based approach to synchrophasor estimation is provided. Embodiments described herein provide two improvements to subspace-based phasor measurement unit (PMU) algorithms based on estimation of signal parameters via rotational invariance techniques (ESPRIT) frequency estimation. The first is a dynamic, real-time thresholding method to determine the size of the signal subspace. This allows for accurate ESPRIT-based frequency estimates of the nominal system frequency as well as the frequencies of any out-of-band interference or harmonic frequencies. Since other frequencies are included in the least squares (LS) estimate, the interference from frequencies other than nominal can be excluded. This results in a near flat estimation error over changes in a) nominal system frequency, b) harmonic distortion, and c) out-of-band interference. Second, the computational burden of ESPRIT is reduced and the proposed algorithm runs in real time on resource-constrained platforms. |
| FILED | Thursday, December 23, 2021 |
| APPL NO | 17/561062 |
| CURRENT CPC | Circuit Arrangements or Systems for Supplying or Distributing Electric Power; Systems for Storing Electric Energy H02J 3/242 (20200101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220286166 | Pham |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Govt of US as Rep by the Secy of the Air Force (Wright Patterson AFB, Ohio) |
| ASSIGNEE(S) | Govt of the US as rep by the Secy of the Air Force (Wright Patterson AFB, Ohio) |
| INVENTOR(S) | Khanh Dai Pham (Albuquerque, New Mexico) |
| ABSTRACT | A method of precoding the power of a channel of a ground terminal in communication with a satellite. The ground terminal is subject to limitations in terrestrial mobile network rates and other congestion conditions. An actual signal-to-interference-plus-noise ratio is calculated and adjusted according to a desired signal-to-interference-plus-noise ratio for a predetermined time epoch. The actual signal-to-interference-plus-noise ratio is adjusted while considering the competing requirements of both: the energy of the difference between the successive actual/desired signal-to-interference-plus-noise ratio levels and the energy of the control sequences. The actual signal-to-interference-plus-noise ratio is autonomously converged with the desired with the signal-to-interference-plus-noise ratio, subject to the limitations in terrestrial mobile network rates and other congestion conditions, by dynamically minimizing covariance error and predicting gain for the epoch. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/653346 |
| CURRENT CPC | Transmission H04B 7/0456 (20130101) Original (OR) Class H04B 7/0857 (20130101) Wireless Communication Networks H04W 28/0268 (20130101) H04W 28/0289 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220286311 | Rowe et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Carnegie Mellon University (Pittsburgh, Pennsylvania) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Anthony Rowe (Pittsburgh, Pennsylvania); Michael Farb (Pittsburgh, Pennsylvania); Ivan Liang (Pittsburgh, Pennsylvania); Edward Lu (Pittsburgh, Pennsylvania); Nuno Pereira (Pittsburgh, Pennsylvania); Eric Riebling (Pittsburgh, Pennsylvania) |
| ABSTRACT | Some embodiments of the present inventive concept provide for improved telepresence and other virtual sessions dynamic scaling and/or assignment of computing resources. An XR telepresence platform can allow for immersive multi-user video conferencing from within a web browser or other medium. The platform can support spatial audio and/or user video. The platform can scale to hundreds or thousands of users concurrently in a single or multiple virtual environments. Disclosed herein are resource allocation techniques for dynamically allocating client connections across multiple servers. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/685869 |
| CURRENT CPC | Image Data Processing or Generation, in General G06T 19/006 (20130101) Transmission of Digital Information, e.g Telegraphic Communication H04L 12/1827 (20130101) Original (OR) Class H04L 65/403 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220286616 | Watnik et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Government of the United States, as represented by the Secretary of the Navy (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Abbie Watnik (Washington, District of Columbia); Dennis Gardner (Washington, District of Columbia); Theodore DuBose (Washington, District of Columbia) |
| ABSTRACT | A system and method for correcting distorted wavefronts is provided. A wavefront sensor, or an image sensor, receives a distorted wavefront and generates intensity data, x-slope data, and y-slope data corresponding to the distorted wavefront. A controller receives the intensity data, x-slope data, and y-slope data from the wavefront sensor and generates a reconstructed wavefront using a trained neural network based on the intensity data, x-slope data, and y-slope data. |
| FILED | Friday, March 04, 2022 |
| APPL NO | 17/686973 |
| CURRENT CPC | Pictorial Communication, e.g Television H04N 5/23258 (20130101) H04N 5/23287 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Energy (DOE)
| US 20220280113 | Sonnon et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Mission Support and Test Services, LLC (Las Vegas, Nevada) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Scott B. Sonnon (North Las Vegas, Nevada); Erik Stassinos (North Las Vegas, Nevada) |
| ABSTRACT | A respiration monitor configured as a patching having adhesive on one side to allow adhesive attachment of the patch to a person. The patch includes a transmitter which generates a reference signal that is provided to a signal path. The signal path is configured to receive and conduct a transmitted reference signal such that the signal path has a length that increases when the person inhales and contracts when the person exhales. A receiver is configured to receive a received reference signal from the signal path. A controller is configured to control generation and transmission of the reference signal and processing the transmitted reference signal and the received reference signal to identify changes in the received reference signal due to transmission through the signal path as the signal path expands and contracts. This is done to generate respiration data that reflects respiration characteristics of the person. |
| FILED | Monday, March 07, 2022 |
| APPL NO | 17/688535 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/0873 (20130101) A61B 5/6833 (20130101) Original (OR) Class A61B 2562/223 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280424 | MCDEVITT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | MEMORIAL SLOAN KETTERING CANCER CENTER (New York, New York) |
| ASSIGNEE(S) | MEMORIAL SLOAN KETTERING CANCER CENTER (New York, New York) |
| INVENTOR(S) | Michael R. MCDEVITT (Bronx, New York); Simone ALIDORI (Ardmore, Pennsylvania); Nima AKHAVEIN (Philadelphia, Pennsylvania); David A. SCHEINBERG (New York, New York) |
| ABSTRACT | Pharmaceutical compositions for preventing or reducing kidney injury are disclosed, where the pharmaceutical compositions include (1) siRNAs non-covalently conjugated to functionalized single walled carbon nanotubes (f-SWCNTs) and (2) a pharmaceutically acceptable carrier, where the siRNAs inhibit expression of one or more genes selected from the group consisting of MEP1B and p53 genes. |
| FILED | Wednesday, October 27, 2021 |
| APPL NO | 17/512280 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 9/0019 (20130101) A61K 9/0092 (20130101) Original (OR) Class A61K 31/711 (20130101) A61K 31/713 (20130101) A61K 31/7105 (20130101) A61K 47/52 (20170801) A61K 47/6925 (20170801) A61K 47/6929 (20170801) A61K 51/1248 (20130101) Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/113 (20130101) C12N 15/1135 (20130101) C12N 15/1137 (20130101) C12N 2310/14 (20130101) C12N 2310/351 (20130101) C12N 2320/32 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280900 | FREEMAN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Benny FREEMAN (Austin, Texas); Theodore J. DILENSCHNEIDER (Elgin, Texas); Kevin REIMUND (Austin, Texas) |
| ABSTRACT | Disclosed herein are mixed matrix membranes, the mixed matrix membranes comprising a metal organic framework CA dispersed in a continuous polymer phase and methods of making and use thereof. The mixed matrix membranes can comprise a plurality of metal organic framework particles comprising UiO-66-(COOH)2 dispersed in a continuous polymer phase. The mixed matrix membranes can comprise a plurality of metal organic framework particles dispersed in a continuous polymer phase comprising polyethersulfone, polyphenylsulfone, Matrimid, Torlon, cellulose acetate, or combinations thereof. Also disclosed herein are mixed matrix membranes for separating a target ion from a non-target ion in a liquid medium. Also described herein methods of separating a target ion from a non-target ion in a liquid medium using a mixed matrix membrane, wherein the mixed matrix membrane comprises a plurality of metal organic framework particles dispersed in a continuous polymer phase. |
| FILED | Wednesday, August 26, 2020 |
| APPL NO | 17/637918 |
| CURRENT CPC | Separation B01D 69/02 (20130101) B01D 69/148 (20130101) Original (OR) Class B01D 71/16 (20130101) B01D 71/64 (20130101) B01D 71/68 (20130101) B01D 2325/02 (20130101) B01D 2325/04 (20130101) Treatment of Water, Waste Water, Sewage, or Sludge C02F 1/44 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280918 | Hopkinson et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Battelle Memorial Institute (Columbus, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David P. Hopkinson (Morgantown, West Virginia); Lingxiang Zhu (Bethel Park, Pennsylvania); James S. Baker (South Park, Pennsylvania); Patrick F. Muldoon (Pittsburgh, Pennsylvania) |
| ABSTRACT | Sorbent polymer composites and a solution-casting method of making hydrophobic sorbent polymer composites for CO2 adsorption applications are described. The sorbent polymer composites are comprised of a polymer matrix, a dispersed CO2 sorbent, and an optional filler particle for hydrophobicity modification. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/686349 |
| CURRENT CPC | Separation B01D 53/02 (20130101) B01D 67/0011 (20130101) B01D 67/0013 (20130101) B01D 67/0095 (20130101) B01D 69/02 (20130101) B01D 69/12 (20130101) B01D 71/32 (20130101) B01D 2253/25 (20130101) B01D 2257/504 (20130101) B01D 2323/08 (20130101) B01D 2323/12 (20130101) B01D 2323/22 (20130101) B01D 2325/12 (20130101) B01D 2325/38 (20130101) Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 20/103 (20130101) B01J 20/226 (20130101) B01J 20/261 (20130101) B01J 20/324 (20130101) B01J 20/327 (20130101) B01J 20/3225 (20130101) Original (OR) Class B01J 20/3238 (20130101) B01J 20/3285 (20130101) B01J 20/28026 (20130101) B01J 20/28033 (20130101) B01J 2220/46 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281455 | SARLASHKAR et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Southwest Research Institute (San Antonio, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Jayant V. SARLASHKAR (San Antonio, Texas); Sankar B. RENGARAJAN (San Antonio, Texas); Scott R. HOTZ (Pinckney, Michigan); Stanislav A. GANKOV (San Antonio, Texas) |
| ABSTRACT | The present disclosure provides vehicle controller circuitry for a subject vehicle. The vehicle controller circuitry includes vehicle constraint determination circuitry to determine vehicle constraints including predicted values for vehicle speed of at least one other vehicle and predicted values of for vehicle position of the at least one other vehicle relative to the subject vehicle, wherein the vehicle constraints are determined at predetermined time steps (k) over a time horizon (Th). The vehicle controller circuitry also includes traffic signal constraint determination circuitry to determine, within a distance horizon (Dh) from the subject vehicle, traffic signal constraints including a green signal state of at least one traffic signal, a distance to the at least one traffic signal relative to the subject vehicle, and a time remaining in the green signal state of the at least one traffic signal; wherein the traffic signal constraints are determined at the predetermined time steps (k) over the time horizon (Th). The vehicle controller circuitry also includes acceleration profile (AP) determination circuitry to determine at least one AP for the subject vehicle based on the vehicle constraints, the traffic signal constraints and a minimum safe distance from the at least one other vehicle; wherein the at least one AP comprising k number of acceleration values, which when applied to the subject vehicle at each time step k will cause the subject vehicle to travel at a target velocity that is sufficient to pass through the at least one traffic signal while in the green signal state and while maintaining at least the minimum safe distance to the at least one other vehicle. |
| FILED | Thursday, March 04, 2021 |
| APPL NO | 17/249545 |
| CURRENT CPC | Conjoint Control of Vehicle Sub-units of Different Type or Different Function; Control Systems Specially Adapted for Hybrid Vehicles; Road Vehicle Drive Control Systems for Purposes Not Related to the Control of a Particular Sub-unit B60W 30/0956 (20130101) B60W 30/18159 (20200201) Original (OR) Class B60W 30/18163 (20130101) B60W 40/04 (20130101) B60W 40/105 (20130101) B60W 40/107 (20130101) B60W 2554/802 (20200201) B60W 2554/4041 (20200201) B60W 2556/65 (20200201) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281743 | Fathalizadeh et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Aidin Fathalizadeh (Berkeley, California); Thang Pham (Berkeley, None); William Mickelson (Albany, California); Alexander Zettl (Kensington, California) |
| ABSTRACT | This disclosure provides systems, methods, and apparatus related to boron nitride nanomaterials. In one aspect, a method includes generating a directed flow of plasma. A boron-containing species is introduced to the directed flow of the plasma. Boron nitride nanostructures are formed in a chamber. In another aspect, a method includes generating a directed flow of plasma using nitrogen gas. A boron-containing species is introduced to the directed flow of the plasma. The boron-containing species can consist of boron powder, boron nitride powder, and/or boron oxide powder. Boron nitride nanostructures are formed in a chamber, with a pressure in the chamber being about 3 atmospheres or greater. |
| FILED | Tuesday, May 03, 2022 |
| APPL NO | 17/661805 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 19/08 (20130101) B01J 2219/0879 (20130101) B01J 2219/0894 (20130101) Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 30/00 (20130101) B82Y 40/00 (20130101) Non-metallic Elements; Compounds Thereof; C01B 21/064 (20130101) C01B 21/0641 (20130101) Original (OR) Class Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds C01P 2002/82 (20130101) C01P 2004/04 (20130101) C01P 2004/24 (20130101) Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone C04B 35/583 (20130101) C04B 35/622 (20130101) C04B 2235/95 (20130101) C04B 2235/767 (20130101) C04B 2235/5276 (20130101) C04B 2235/5284 (20130101) C04B 2235/5454 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282017 | Appelhans et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Leah Appelhans (Tijeras, New Mexico); Samuel Leguizamon (Albuquerque, New Mexico); Brad Howard Jones (Albuquerque, New Mexico); Adam Wade Cook (Albuquerque, New Mexico) |
| ABSTRACT | The invention is directed to latent metathesis-active resin compositions and additive manufacturing approaches. The latent metathesis-active compositions comprise at least one latent metathesis catalyst, at least one curable metathesis-active monomer, and optional fillers, photosensitizers, and/or a secondary monomer resin system for dual-cure. A method comprises extruding a latent metathesis-active resin from a dispensing apparatus and spatially triggering a ring-opening metathesis polymerization by directed irradiation with light or directed application of a thermal stimuli for direct-ink write printing of objects. Another method uses a latent metathesis-active resin for vat photopolymerization and stereolithographic printing of objects. |
| FILED | Tuesday, February 22, 2022 |
| APPL NO | 17/677558 |
| CURRENT CPC | Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing B29C 64/124 (20170801) Indexing Scheme Associated With Subclasses B29B, B29C or B29D, Relating to Moulding Materials or to Materials for Reinforcements, Fillers or Preformed Parts, e.g Inserts B29K 2105/0002 (20130101) Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering B33Y 10/00 (20141201) B33Y 40/20 (20200101) B33Y 70/00 (20141201) Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds C08F 236/20 (20130101) Original (OR) Class Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor C09D 147/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282029 | FISCHER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (OAKLAND, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | FELIX RAOUL FISCHER (BERKELEY, California); JEFFREY BOKOR (PIEDMONT, California); ZAFER MUTLU (WALNUT CREEK, California); JUAN PABLO LLINAS (OAKLAND, California); RYAN DAVID MCCURDY (BERKELEY, California); GREGORY CLINTON VEBER (BERKELEY, California); DHARATI JOSHI KOENIGS (PEARLAND, Texas) |
| ABSTRACT | Various chemical structures of precursors for armchair graphene nanoribbons (AGNRs) are disclosed, along with a C method of manufacturing. |
| FILED | Friday, May 29, 2020 |
| APPL NO | 17/608355 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 40/00 (20130101) Non-metallic Elements; Compounds Thereof; C01B 32/184 (20170801) Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds C08G 61/10 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282289 | Garg et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | LanzaTech, Inc. (Skokie, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Shivani Garg (Park Ridge, Illinois); Michael Koepke (Chicago, Illinois) |
| ABSTRACT | Microorganisms are genetically engineered to produce various chemicals for industrial use. The microorganisms are carboxydotrophic acetogens. The microorganisms produce acetyl-CoA using the Wood-Ljungdahl Pathway for fixing CO/CO2. A reverse beta-oxidation pathway cycle from a microorganism that contains such a group of enzymes is introduced. Additionally, primers and extenders, and/or genes encoding for enzymes that generate primers and extenders may also be introduced. Product synthesis can be effected by improved promoters or enzyme designs that are catalytically more efficient. Similarly, product synthesis may also be improved by deleting competing reactions. |
| FILED | Tuesday, March 08, 2022 |
| APPL NO | 17/653913 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 15/52 (20130101) C12N 15/74 (20130101) C12N 2800/101 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 7/6409 (20130101) Original (OR) Class Enzymes C12Y 101/0133 (20150701) C12Y 103/01009 (20130101) C12Y 203/01009 (20130101) C12Y 402/01017 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282317 | Wright et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Battelle Memorial Institute (Richland, Washington) |
| ASSIGNEE(S) | Battelle Memorial Institute (Richland, Washington) |
| INVENTOR(S) | Aaron T. Wright (Richland, Washington); Susan Ramos-Hunter (Madison, Wisconsin); Christopher Whidbey (Seattle, Washington) |
| ABSTRACT | Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes described specifically label only their target active enzymes involved in xenobiotic metabolism and therefore provide a measurement of true protein functional activity rather than transcript or protein abundance. The activity-based probes also provide multimodal profiling of these active enzymes. Methods for preparing the activity based probes and exemplary methods for their use also are disclosed. |
| FILED | Tuesday, April 26, 2022 |
| APPL NO | 17/730004 |
| CURRENT CPC | Acyclic or Carbocyclic Compounds C07C 203/04 (20130101) C07C 233/20 (20130101) C07C 233/33 (20130101) C07C 247/00 (20130101) C07C 247/12 (20130101) C07C 271/28 (20130101) C07C 305/22 (20130101) C07C 317/40 (20130101) Heterocyclic Compounds C07D 203/26 (20130101) C07D 311/16 (20130101) C07D 405/04 (20130101) C07D 405/12 (20130101) Sugars; Derivatives Thereof; Nucleosides; Nucleotides; Nucleic Acids C07H 15/203 (20130101) C07H 19/067 (20130101) Peptides C07K 1/13 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/34 (20130101) C12Q 1/48 (20130101) C12Q 1/6837 (20130101) Original (OR) Class C12Q 1/6841 (20130101) C12Q 2565/514 (20130101) C12Q 2600/106 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/582 (20130101) G01N 33/583 (20130101) G01N 2333/91177 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282520 | Bratton et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Battelle Energy Alliance, LLC (Idaho Falls, Idaho) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Kenneth R. Bratton (Idaho Falls, Idaho); Teddy R. Reed (Idaho Falls, Idaho); Henry S. Chu (Idaho Falls, Idaho); Todd L. Johnson (Shelley, Idaho) |
| ABSTRACT | Corner assemblies for protective barriers for protecting assets (e.g., electrical power transformers and other substation components). The corner assembly includes two guide structures oriented perpendicular to each other. The corner assembly includes at least two protective member assemblies disposed within the two guide structures. Each protective member assembly includes two side members within protective members extending horizontally between the two side members. |
| FILED | Wednesday, March 03, 2021 |
| APPL NO | 17/249510 |
| CURRENT CPC | Buildings or Like Structures for Particular Purposes; Swimming or Splash Baths or Pools; Masts; Fencing; Tents or Canopies, in General E04H 17/009 (20210101) E04H 17/1413 (20130101) Original (OR) Class Boards, Substations, or Switching Arrangements for the Supply or Distribution of Electric Power H02B 1/00 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282970 | WOJTSEKHOWSKI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | JEFFERSON SCIENCE ASSOCIATES, LLC (Newport News, Virginia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | BOGDAN WOJTSEKHOWSKI (Yorktown, Virginia); GUY RON (Mevaseret Zion, Israel) |
| ABSTRACT | A high precision magnetic compass based on a Hall probe. The probe is oriented at an angle of 90 degrees to the rotation axis of the device. An oscillating component of the signal from the probe, synchronized with the device rotation, is transferred to the non-rotation frame and is used to align the axis of rotation to be parallel to the magnetic field. The device does not require prior calibration. It is insensitive to drift of the probe parameters and can provide an angle with precision equal to or better than a 0.05 degree. |
| FILED | Monday, February 14, 2022 |
| APPL NO | 17/671112 |
| CURRENT CPC | Measuring Distances, Levels or Bearings; Surveying; Navigation; Gyroscopic Instruments; Photogrammetry or Videogrammetry G01C 17/32 (20130101) Original (OR) Class Measuring Electric Variables; Measuring Magnetic Variables G01R 33/07 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283171 | COLEMAN et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (Livemore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Matthew A. COLEMAN (OAKLAND, California); Paul D. HOEPRICH (PLEASANTON, California); Brent W. SEGELKE (SAN RAMON, California) |
| ABSTRACT | Provided herein are methods and systems for the production of a nanolipoprotein particle (NLP) that includes a scaffold protein a membrane forming lipid and optionally a target protein. At least one of the scaffold protein and target protein can be provided through an IVT system. The membrane forming lipid, scaffold protein and optionally the target protein can be assembled for a time and under conditions that allow obtaining high yield NLPs, NPLs with an increased solubility, an NLP of a controlled size, and/or an NLP having a size predetermined to include a pre-selected target protein. |
| FILED | Monday, March 21, 2022 |
| APPL NO | 17/700145 |
| CURRENT CPC | Peptides C07K 14/705 (20130101) C07K 17/02 (20130101) Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture C12P 21/02 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/582 (20130101) G01N 33/587 (20130101) Original (OR) Class G01N 33/54346 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283285 | Lehman et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sean Kenneth Lehman (Pleasanton, California); Emeraldo V. Baluyot (Mountain House, California); Jae Jeon (Livermore, California) |
| ABSTRACT | Multistatic radar systems and associated methods are disclosed herein. In some embodiments, a multistatic radar system can include multiple radar transmitters and multiple radar receivers. The transmitters are configured to generate radio-frequency (RF) signals in a target volume, and the receivers are configured to receive the RF signals after the RF signals are reflected off an object moving through the target volume. The transmitters and the receivers can be spaced apart and aperiodically positioned about the target volume. The receivers can sample and digitize the reflected RF signals at an RF frequency. The radar system further includes a processing device configured to determine a property of the object based on the sampled reflected RF signals. |
| FILED | Wednesday, March 10, 2021 |
| APPL NO | 17/197585 |
| CURRENT CPC | Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 13/0209 (20130101) G01S 13/581 (20130101) Original (OR) Class G01S 13/9029 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285057 | PARKER et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UT-Battelle, LLC (Oak Ridge, Tennessee); Iowa State University Research Foundation, Inc. (Ames, Iowa) |
| ASSIGNEE(S) | |
| INVENTOR(S) | David S. PARKER (Oak Ridge, Tennessee); Tribhuwan PANDEY (Oak Ridge, Tennessee); Ikenna C. NLEBEDIM (Ames, Iowa); Xubo LIU (Ames, Iowa) |
| ABSTRACT | Permanent magnet materials are provided. The permanent magnet materials are cerium based materials including zirconium and iron in combination with cobalt. The permanent magnet materials may have the formula Ce2ZrFe15−xCox wherein 6≤x≤15. In some embodiments, the permanent magnet materials have the formula Ce2+yZr1−yFe(15−x)(2−z)/2)CoxCu((15−x)z/2) wherein 6≤x≤15, 0≤y≤0.4, and z=0 or 1. In other embodiments, the permanent magnet materials have the formula Ce2Zrx(Fe1−yCoy)17−2x, where 0<x≤1 and 0.4≤y≤1. Permanent magnets including the permanent magnet materials are also provided. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/685672 |
| CURRENT CPC | Magnets; Inductances; Transformers; Selection of Materials for Their Magnetic Properties H01F 1/055 (20130101) Original (OR) Class H01F 41/0293 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285411 | Ma et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Wisconsin Alumni Research Foundation (Madison, Wisconsin); The Research Foundation for the State University of New York (Amherst, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Zhenqiang Ma (Middleton, Wisconsin); Zhenyang Xia (Madison, Wisconsin); Ming Zhou (Middleton, Wisconsin); Qiaoqiang Gan (Buffalo, New York); Zongfu Yu (Madison, Wisconsin) |
| ABSTRACT | Hyperspectral resonant cavity imaging spectrometers and imaging systems incorporating the resonant cavity spectrometers are provided. The spectrometers include an array of photodetectors based on photosensitive semiconductor nanomembranes disposed between two dielectric spacers, each of the dielectric spacers having a thickness gradient along a lateral direction, such that the resonant cavity height differs for different photodetectors in the array. |
| FILED | Tuesday, March 02, 2021 |
| APPL NO | 17/189394 |
| CURRENT CPC | Measurement of Intensity, Velocity, Spectral Content, Polarisation, Phase or Pulse Characteristics of Infra-Red, Visible or Ultra-violet Light; Colorimetry; Radiation Pyrometry G01J 3/021 (20130101) G01J 3/2803 (20130101) G01J 3/2823 (20130101) G01J 2003/2813 (20130101) G01J 2003/2826 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 27/14605 (20130101) Original (OR) Class H01L 27/14629 (20130101) Pictorial Communication, e.g Television H04N 5/332 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285603 | El-Kady et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ihab Fathy El-Kady (Albuquerque, New Mexico); Rupert M. Lewis (Albuquerque, New Mexico); Michael David Henry (Albuquerque, New Mexico); Matt Eichenfield (Albuquerque, New Mexico) |
| ABSTRACT | The invention is directed to a device and method to engineer the superconducting transition width by suppressing the phonon populations responsible for the Cooper-pair decoherence below the superconducting transition temperature via phononic bandgap engineering. The device uses phononic crystals to engineer a phononic frequency gap that suppresses the decohering thermal phonon population just below the Cooper-frequency, and thus the normal conduction electron population. For example, such engineering can relax the cooling requirements for a variety of circuits yielding higher operational quality factors for superconducting electronics and interconnects. |
| FILED | Wednesday, March 06, 2019 |
| APPL NO | 16/294011 |
| CURRENT CPC | Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 39/08 (20130101) H01L 39/12 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285666 | Zhu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of Indiana University (Indianapolis, Indiana); Argonne National Laboratory (Lemont, Illinois) |
| ASSIGNEE(S) | The Trustees of Indiana University (Indianapolis, Indiana) |
| INVENTOR(S) | Likun Zhu (Zionsville, Indiana); Shengfeng Yang (Carmel, Indiana); Xinwei Zhou (Zionsville, Indiana); Yuzi Liu (Lemont, Illinois) |
| ABSTRACT | A porous microstructure includes: a solid material, wherein the solid material allows conductivity of ions; and a plurality of nanopores defined within the solid material. |
| FILED | Tuesday, September 08, 2020 |
| APPL NO | 17/632490 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 4/13 (20130101) Original (OR) Class H01M 10/054 (20130101) H01M 10/0525 (20130101) H01M 2004/021 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285692 | Manthiram et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Board of Regents, The University of Texas System (Austin, Texas) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Arumugam Manthiram (Austin, Texas); Brian Theodore Heligman (Austin, Texas); Karl Joseph Kreder, III (Austin, Texas); Kevin Scanlan (Austin, Texas) |
| ABSTRACT | Described herein are multilayer composite foil materials, as well as methods of making and using multilayer composite foil materials. The composite foil materials can comprise different layers of different metals which may have differing activity toward an active metal, such as lithium. The different layers may allow the composite foil material to include layers that are more active towards the active metal, providing for electrochemical activity, and other layers that are less active towards the active metal, and serving as structural layers. The multilayer composite foils are useful as anodes of electrochemical cells, such as lithium ion cells. |
| FILED | Friday, July 24, 2020 |
| APPL NO | 17/629726 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 4/382 (20130101) H01M 4/662 (20130101) H01M 4/667 (20130101) Original (OR) Class H01M 10/0525 (20130101) H01M 2004/027 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285704 | Barnett et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Scott A. Barnett (Evanston, Illinois); Travis Schmauss (Evanston, Illinois); Matthew Lu (Evanston, Illinois) |
| ABSTRACT | Motorized vehicles are provided which may a device configured to convert a fuel comprising a hydrocarbon, an alcohol, or both, to an exhaust comprising CO2; and a tank configured to store, under pressure, the exhaust comprising CO2 and an inlet port configured to receive the exhaust from the device. The device may be a solid oxide fuel cell (SOFC). The tank may be a co-storage tank configured to store, under pressure, the fuel comprising the hydrocarbon, the alcohol, or both, and the exhaust comprising CO2, the co-storage tank further comprising an outlet port configured to deliver the fuel to the device. Methods of using the motorized vehicle are also provided. |
| FILED | Tuesday, August 04, 2020 |
| APPL NO | 17/630212 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 8/12 (20130101) H01M 8/04111 (20130101) H01M 8/04179 (20130101) Original (OR) Class H01M 8/04201 (20130101) H01M 2008/1293 (20130101) H01M 2250/20 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285729 | Bheemireddy et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UChicago Argonne, LLC (Chicago, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Sambasiva Reddy Bheemireddy (Woodridge, Illinois); Lu Zhang (Naperville, Illinois); Zhengcheng Zhang (Naperville, Illinois) |
| ABSTRACT | An electrochemical device includes a compound that is an isatin derivative. The electrochemical device may be a lithium ion battery, a sodium ion battery, or a redox flow battery, and the isatin derivative may be a bipolar redox active material. |
| FILED | Thursday, March 04, 2021 |
| APPL NO | 17/191872 |
| CURRENT CPC | Heterocyclic Compounds C07D 209/38 (20130101) Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 8/188 (20130101) H01M 10/0525 (20130101) H01M 10/0567 (20130101) Original (OR) Class H01M 2300/0025 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285732 | LUCHT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Rhode Island Board of Trustees (Independnce, Ohio); GOTION, INC. (Independence, Ohio) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Brett LUCHT (Kingston, Rhode Island); Jongjung KIM (Warwick, Rhode Island); Venkata A.K. ADIRAJU (Warwick, Rhode Island); Jennifer HOFFMANN (Elyria, Ohio); Martin PAYNE (Avon, Ohio) |
| ABSTRACT | This work investigates the beneficial roles of lithium bis(trimethylsilyl) phosphate (LiTMSP) which may act as a novel bifunctional additive for lithium ion batteries, in particular, LiNi0.5Mn1.5O4 (LNMO)/graphite cells. The cycle performance of LNMO/graphite cells is significantly improved with incorporation of LiTMSP. Trimethylsilyl functional group therein can react with HF generated through hydrolysis of LiPF6 by residual water in electrolyte solution, followed by a decrease in the concentration of metal ions dissolution from the electrode. The generation of superior passivating surface film derived by LiTMSP on graphite electrode, suppressing further electrolyte reductive decomposition and deterioration/reformation caused by migrated metal ions, is confirmed. Furthermore, LiTMSP derived surface film is likely to have better lithium ions conductivity with a decrease in resistance of the graphite electrode, improving rate performance of cells. The HF scavenging and film-forming effects of LTMPS are responsible for the less polarization of cells enabling to improve cycle performance. |
| FILED | Wednesday, March 02, 2022 |
| APPL NO | 17/685076 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 4/505 (20130101) H01M 4/583 (20130101) H01M 10/0525 (20130101) H01M 10/0567 (20130101) Original (OR) Class H01M 10/0568 (20130101) H01M 2004/027 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285922 | Fitzpatrick et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | TRANSIENT PLASMA SYSTEMS, INC. (Torrance, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Joseph F. Fitzpatrick (Glendale, California); Mark A. Thomas (Redondo Beach, California); Alonzo Gomez (Los Angeles, California); Jason M. Sanders (La Crescenta, California) |
| ABSTRACT | A system and method for differentiating between different modes of pulsed electrical discharges via of an amplitude to time (ATC) conversion circuit is described. A bipolar ATC circuit is used to add together the positive and negative portions of an attenuated and filtered signal derived either from the voltage or current of a pulse. Alternatively, a unipolar ATC circuit may be employed. The resulting processed signal is compared against a reference voltage to generate an output signal that is active for the amount of time that the processed signal exceeds the reference voltage. Discharge mode is determined based on three factors: did a pulse occur, if a pulse occurred when did the pulse start relative to the original pulse event, and what is the duty cycle of the pulse. Subsequent pulse generated may be controlled accordingly |
| FILED | Tuesday, March 01, 2022 |
| APPL NO | 17/684085 |
| CURRENT CPC | Spark Gaps; Overvoltage Arresters Using Spark Gaps; Sparking Plugs; Corona Devices; Generating Ions to be Introduced into Non-enclosed Gases H01T 15/00 (20130101) Original (OR) Class Impedance Networks, e.g Resonant Circuits; Resonators H03H 7/06 (20130101) Pulse Technique H03K 3/017 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220286845 | Vanoss et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California); Avian, Inc. (Lexington Park, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Vincent M. Vanoss (Leonardtown, Maryland); Faranak Nekoogar (San Ramon, California); Farid U. Dowla (Castro Valley, California) |
| ABSTRACT | A networking architecture that incorporates the security of Blockchain distributed ledgers as an authentication layer, while connecting mesh nodes using secure, pulse-based wide-band and ultra wide-band communication technology to provide a nearly undetectable, unbreakable, and dynamic wireless communication mesh architecture that can securely transmit data, voice and video over short ranges, in one embodiment, up to 1 Km, is disclosed. |
| FILED | Thursday, April 29, 2021 |
| APPL NO | 17/244763 |
| CURRENT CPC | Transmission of Digital Information, e.g Telegraphic Communication H04L 9/3236 (20130101) H04L 9/3271 (20130101) H04L 2209/38 (20130101) Wireless Communication Networks H04W 12/06 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220287155 | Pang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Lawrence Livermore National Security, LLC (Livermore, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Simon Hoching Pang (Fremont, California); Jeffery J. Haslam (Livermore, California); James Patrick Kelly (San Francisco, California); Joshuah K. Stolaroff (Oakland, California) |
| ABSTRACT | A product includes a three-dimensional resistive heating element formed by additive manufacturing and a catalytic component on at least an external surface of the resistive heating element. The resistive heating element has a pre-defined geometric arrangement of features, and the resistive heating element includes a conductive ceramic material. |
| FILED | Friday, March 05, 2021 |
| APPL NO | 17/193937 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 19/0053 (20130101) B01J 35/023 (20130101) B01J 35/026 (20130101) Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering B33Y 40/20 (20200101) B33Y 70/00 (20141201) B33Y 80/00 (20141201) Electric Heating; Electric Lighting Not Otherwise Provided for H05B 3/141 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
National Science Foundation (NSF)
| US 20220280625 | GIANNESCHI et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | Northwestern University (Evanston, Illinois) |
| INVENTOR(S) | Nathan C. GIANNESCHI (Evanston, Illinois); Jeremy A. LAVINE (Evanston, Illinois); Bin ZHANG (Evanston, Illinois); Or BERGER (Evanston, Illinois); Wonmin CHOI (Evanston, Illinois); Max Mu WANG (Evanston, Illinois); Claudia BATTISTELLA (Evanston, Illinois); Hao SUN (Evanston, Illinois) |
| ABSTRACT | In an aspect, the invention provides therapeutic agents comprising brush polymers that address challenges associated with conventional administration of free therapeutic peptides. In an embodiment, for example, the invention provides brush polymers incorporating one or more therapeutic peptides as side chain moieties. Therapeutic agents of the invention comprising brush polymers include high-density brush polymers including cross-linked brush polymers and brush block copolymers. In an embodiment, brush polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration. The invention also includes methods of making and using therapeutic agents comprising brush polymers. |
| FILED | Tuesday, August 11, 2020 |
| APPL NO | 17/634497 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/095 (20190101) A61K 39/001192 (20180801) Original (OR) Class A61K 47/58 (20170801) A61K 47/64 (20170801) A61K 47/6845 (20170801) A61K 2039/627 (20130101) A61K 2039/6031 (20130101) A61K 2039/6056 (20130101) A61K 2039/6093 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 9/12 (20180101) A61P 35/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280777 | Humayun et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Mark S. Humayun (Glendale, California); Gianluca Lazzi (Los Angeles, California); Bodour Salhia (Los Angeles, California); Manjunath Machnoor (Los Angeles, California); Javad Paknahad (Los Angeles, California); Alejandra Gonzalez-Calle (Los Angeles, California); Ben Yi Tew (Los Angeles, California) |
| ABSTRACT | Bioelectronic lens (E-lens) systems for inducing neuroprotective changes in neurons, in particular the retina. A system may include a stimulating electrode configured to be placed on an eye or skin around the eye. The system may further include a return electrode configured such that voltage distribution is focalized to the eye and induced electric fields to an area of interest on the eye or on the skin around the eye are maximized. The electric fields provide neuroprotection and reinnervation. |
| FILED | Wednesday, March 02, 2022 |
| APPL NO | 17/685186 |
| CURRENT CPC | Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 1/14 (20130101) A61N 1/40 (20130101) A61N 1/0456 (20130101) A61N 1/0464 (20130101) Original (OR) Class A61N 1/0492 (20130101) A61N 1/0543 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281743 | Fathalizadeh et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Aidin Fathalizadeh (Berkeley, California); Thang Pham (Berkeley, None); William Mickelson (Albany, California); Alexander Zettl (Kensington, California) |
| ABSTRACT | This disclosure provides systems, methods, and apparatus related to boron nitride nanomaterials. In one aspect, a method includes generating a directed flow of plasma. A boron-containing species is introduced to the directed flow of the plasma. Boron nitride nanostructures are formed in a chamber. In another aspect, a method includes generating a directed flow of plasma using nitrogen gas. A boron-containing species is introduced to the directed flow of the plasma. The boron-containing species can consist of boron powder, boron nitride powder, and/or boron oxide powder. Boron nitride nanostructures are formed in a chamber, with a pressure in the chamber being about 3 atmospheres or greater. |
| FILED | Tuesday, May 03, 2022 |
| APPL NO | 17/661805 |
| CURRENT CPC | Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus B01J 19/08 (20130101) B01J 2219/0879 (20130101) B01J 2219/0894 (20130101) Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 30/00 (20130101) B82Y 40/00 (20130101) Non-metallic Elements; Compounds Thereof; C01B 21/064 (20130101) C01B 21/0641 (20130101) Original (OR) Class Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds C01P 2002/82 (20130101) C01P 2004/04 (20130101) C01P 2004/24 (20130101) Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone C04B 35/583 (20130101) C04B 35/622 (20130101) C04B 2235/95 (20130101) C04B 2235/767 (20130101) C04B 2235/5276 (20130101) C04B 2235/5284 (20130101) C04B 2235/5454 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281749 | Yeh et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | California Institute of Technology (Pasadena, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nai-Chang Yeh (Pasadena, California); Chen-Chih Hsu (Pasadena, California); Jiaqing Wang (Pasadena, California); Marcus L. Teague (Pasadena, California) |
| ABSTRACT | A strain engineered material including a monolayer graphene sheet comprising an array of wrinkles induced by deformations in the graphene sheet, the deformations formed by a lattice of underlying nanostructures on a substrate. The lattice of nanostructures comprises rows of the nanostructures and each of the wrinkles comprise a ridge aligned on top of a different one of the rows and along an alignment direction defined by the rows. The deformations pattern a strain distribution in the graphene sheet that induces a periodically varying pseudo magnetic field distribution ranging between a positive value and a negative values, The periodically varying pseudo magnetic field distribution has field magnitude minima located parallel to and between the ridges and field magnitude maxima located near to and parallel to each of the ridges and can be designed for various valleytronic and spintronic device applications. |
| FILED | Friday, May 07, 2021 |
| APPL NO | 17/314873 |
| CURRENT CPC | Non-metallic Elements; Compounds Thereof; C01B 32/186 (20170801) Original (OR) Class Measuring Electric Variables; Measuring Magnetic Variables G01R 33/072 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 29/1606 (20130101) H01L 43/04 (20130101) H01L 43/065 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220281782 | Agrawal et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana) |
| ASSIGNEE(S) | PURDUE RESEARCH FOUNDATION (West Lafayette, Indiana) |
| INVENTOR(S) | Rakesh Agrawal (West Lafayette, Indiana); Yiru Li (West Lafayette, Indiana) |
| ABSTRACT | Processes and systems for upgrading natural gas liquids. At least a portion of the natural gas liquid components in a shale gas stream can be dehydrogenated to their corresponding olefin derivatives prior to separating any methane from the liquids. Further processing subsequent to dehydrogenation could include various separations, oligomerizing olefins produced in the dehydrogenation step, recovering desired products, etc. The order of the processing steps subsequent to dehydrogenation could be adjusted in various cases. |
| FILED | Wednesday, May 18, 2022 |
| APPL NO | 17/747637 |
| CURRENT CPC | Acyclic or Carbocyclic Compounds C07C 2/06 (20130101) C07C 5/333 (20130101) Original (OR) Class Cracking Hydrocarbon Oils; Production of Liquid Hydrocarbon Mixtures, e.g by Destructive Hydrogenation, Oligomerisation, Polymerisation; Recovery of Hydrocarbon Oils From Oil-shale, Oil-sand, or Gases; Refining Mixtures Mainly Consisting of Hydrocarbons; Reforming of Naphtha; Mineral Waxes C10G 5/00 (20130101) Fuels Not Otherwise Provided for; Natural Gas; Synthetic Natural Gas Obtained by Processes Not Covered by Subclasses C10G, C10K; Liquefied Petroleum Gas; Adding Materials to Fuels or Fires to Reduce Smoke or Undesirable Deposits or to Facilitate Soot Removal; Firelighters C10L 3/102 (20130101) C10L 3/106 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282056 | Manas-Zloczower et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | CASE WESTERN RESERVE UNIVERSITY (, None) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Ica Manas-Zloczower (Cleveland, Ohio); Liang Yue (Cleveland, Ohio); Mehrad Amirkhosravi (Cleveland, Ohio) |
| ABSTRACT | Thermosetting plastics are recycled by process that begins with grinding the plastic into small pieces. This particulate is then mixed with a catalyst and ball mill milled to a fine powder, which can then be reprocessed via molding (e.g., hot-press, injection, etc.). |
| FILED | Monday, May 23, 2022 |
| APPL NO | 17/750730 |
| CURRENT CPC | Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H C08J 11/26 (20130101) Original (OR) Class C08J 2363/02 (20130101) C08J 2367/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220282266 | WANG et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (GAINESVILLE, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nian WANG (Auburndale, Florida); Xiaoen HUANG (Lake Alfred, Florida); Tirtha LAMICHHANE (Winter Haven, Florida); Ali PARSAEIMEHR (Winter Haven, Florida); Su HANG (Winter Haven, Florida); Shumig WANG (Gainesville, Florida) |
| ABSTRACT | Disclosed herein are methods and materials for editing genes in citrus cells. Specifically exemplified is the implementation of an optimized Cas9 and the CRISPR type II class nuclease. Also exemplified is the use of a U6-1 promoter for driving expressing of editing constructs in citrus cells. Various protocols and sequences for editing genes are disclosed as well. |
| FILED | Monday, August 03, 2020 |
| APPL NO | 17/632371 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0025 (20130101) C12N 9/22 (20130101) C12N 15/11 (20130101) C12N 15/8205 (20130101) C12N 15/8213 (20130101) Original (OR) Class C12N 15/8281 (20130101) C12N 2310/20 (20170501) C12N 2800/80 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283013 | Reuel et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Skroot Laboratory, Inc. (Ames, Iowa) |
| ASSIGNEE(S) | Skroot Laboratory, Inc. (Ames, Iowa) |
| INVENTOR(S) | Nigel F. Reuel (Ames, Iowa); Cameron Greenwalt (Kalamazoo, Michigan); Samuel Rothstein (Ames, Iowa); Charu Gupta (Ames, Iowa) |
| ABSTRACT | A system is provided for monitoring foam levels within a vessel wherein one or more chemical reactions or biological growths are occurring. The system includes a resonant sensor positioned outside of the vessel at a position to measure foam level within the vessel, the resonant sensor having an inductive element and a capacitive element and tuned to provide for enhanced sensitivity of changes in local permittivity to resonate. In a frequency range which permits penetration through a sidewall of the vessel, at least one antenna positioned outside of the vessel, a scattering parameter measurement device electrically connected to the at least one antenna positioned outside of the vessel to measure transmitted or reflected power, and a controller operatively connected to the scattering parameter measurement device to receive a signal from the scattering parameter measurement device, the controller configured to correlate resonant frequency based on the signal from the vector network analyzer with foam level in the vessel, |
| FILED | Friday, March 05, 2021 |
| APPL NO | 17/193480 |
| CURRENT CPC | Measuring Volume, Volume Flow, Mass Flow or Liquid Level; Metering by Volume G01F 23/265 (20130101) G01F 23/266 (20130101) G01F 23/2845 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283140 | Wanunu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northeastern University (Boston, Massachusetts); The Board of Trustees of the University of Illinois (Urbana, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Meni Wanunu (Sharon, Massachusetts); Luning Yu (Brookline, Massachusetts); Aleksei Aksimentiev (Urbana, Illinois); Behzad Mehrafrooz (Urbana, Illinois) |
| ABSTRACT | A method and system for performing single molecule proteomics utilizing a nanopore sensor to measure an electronic signature of protein or peptide being transported through the nanopore from a first chamber to a second chamber. The protein's electronic signature is a function of ionic current over time. The method and system utilizing an agent, such as guanidinium chloride, to bind to the nanopore's interior and provide an electroosmotic force within the nanopore. The electroosmotic force, in some embodiments, enables stretching and unfolding of the protein during transport through the nanopore. The agent may also or alternatively induce the unfolding of the protein before transport through the nanopore and/or provide force moving the protein through the nanopore. |
| FILED | Thursday, December 23, 2021 |
| APPL NO | 17/645943 |
| CURRENT CPC | Chemical or Physical Laboratory Apparatus for General Use B01L 3/502715 (20130101) B01L 3/502761 (20130101) B01L 2200/0663 (20130101) B01L 2300/0645 (20130101) B01L 2300/0663 (20130101) B01L 2400/0418 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/34 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/6818 (20130101) G01N 33/48721 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283431 | Hua et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Arizona Board of Regents on Behalf of the University of Arizona (Tucson, Arizona) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Hong Hua (Tucson, Arizona); Hekun Huang (Tucson, Arizona) |
| ABSTRACT | Methods and frameworks for designing and optimizing of high-performance light field displays, such as integral imaging head-mounted displays, are disclosed. The disclosed techniques enable user-defined metrics for characterizing the performance and optimization of such systems. One design method relates to an integral-imaging based three-dimensional (3D) display system that includes an arrayed optics, an arrayed display device to produce a plurality of elemental images, a first reference plane representing a virtual central depth plane (CDP), a second reference plane representing a viewing window for viewing a reconstructed 3D scene, and an optical subsection representing a model of a human eye. The method includes tracing rays starting at the arrayed display device, through the arrayed optics, and to the optical subsection for each element of the arrayed display device and arrayed optics, and adjusting one or more parameters to obtain at least a first metric value within a predetermined value. |
| FILED | Wednesday, August 12, 2020 |
| APPL NO | 17/634734 |
| CURRENT CPC | Optical Elements, Systems, or Apparatus G02B 27/0012 (20130101) Original (OR) Class G02B 30/10 (20200101) Electric Digital Data Processing G06F 30/10 (20200101) Image Data Processing or Generation, in General G06T 15/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220283510 | Lee et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| ASSIGNEE(S) | Rutgers, The State University of New Jersey (New Brunswick, New Jersey) |
| INVENTOR(S) | Ki-Bum Lee (Monmouth, New Jersey); Letao Yang (Piscataway, New Jersey) |
| ABSTRACT | A dynamic interference lithography (DIL) device is provided. The device includes a laser source configured for providing a laser beam, a substrate stage configured for mounting a substrate, an at least partially convex curved mirror, and a spatial filter configured to divide the laser beam into a first beam portion directed towards the at least partially convex curved mirror and a second beam portion directed towards the substrate. The first beam portion is reflected by the at least partially convex curved mirror towards the substrate to form an interference pattern on the substrate. |
| FILED | Thursday, March 03, 2022 |
| APPL NO | 17/653357 |
| CURRENT CPC | Photomechanical Production of Textured or Patterned Surfaces, e.g for Printing, for Processing of Semiconductor Devices; Materials Therefor; Originals Therefor; Apparatus Specially Adapted Therefor; G03F 7/2053 (20130101) G03F 7/70025 (20130101) G03F 7/70316 (20130101) G03F 7/70408 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284115 | Tang et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of Columbia University in the City of New York (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Adrian Tang (New York, New York); Salvatore Stolfo (New York, New York); Lakshminarasimhan Sethumadhavan (New York, New York) |
| ABSTRACT | Disclosed are devices, systems, apparatus, methods, products, and other implementations, including a method that includes determining whether an operation to access a memory location containing executable code comprises a general-purpose memory access operation, and changing content of the memory location in response to a determination that the operation to access the memory location containing the executable code comprises the general-purpose memory access operation to the memory location. |
| FILED | Tuesday, December 14, 2021 |
| APPL NO | 17/550559 |
| CURRENT CPC | Electric Digital Data Processing G06F 9/45558 (20130101) G06F 12/1009 (20130101) G06F 12/1475 (20130101) G06F 21/52 (20130101) G06F 21/604 (20130101) G06F 21/6218 (20130101) Original (OR) Class G06F 2009/45583 (20130101) G06F 2009/45595 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284154 | Yavari et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | NUtech Ventures (Lincoln, Nebraska) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Reza Yavari (Lincoln, Nebraska); Prahalada Rao (Lincoln, Nebraska); Kevin D. Cole (Lincoln, Nebraska) |
| ABSTRACT | Systems for simulating temperature during an additive manufacturing process. A system can access a computer-modelled part representing a physical part, populate first nodes within a first region of the part with temperature values, the first region having a first density of the first nodes, populate second nodes within a second region of the part with temperature values, the second region having a second density of the second nodes less than the first density of the first nodes and being distal the surface of the part where material is added, remove first nodes from part of the first region proximate the second region, simulate adding material on the surface of the part to form a new layer, the new layer being part of the first region and having first nodes distributed according to the first density, and populate the first nodes within the new layer of the part with temperature values. |
| FILED | Wednesday, February 09, 2022 |
| APPL NO | 17/668025 |
| CURRENT CPC | Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering B33Y 50/00 (20141201) Electric Digital Data Processing G06F 30/20 (20200101) Original (OR) Class G06F 2113/10 (20200101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285526 | Brueck et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNM RAINFOREST INNOVATIONS (Albuquerque, New Mexico) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Steven R.J. Brueck (Albuquerque, New Mexico); Stephen D. Hersee (Albuquerque, New Mexico); Seung-Chang Lee (Albuquerque, New Mexico); Daniel Feezell (Albuquerque, New Mexico) |
| ABSTRACT | A method for making a heteroepitaxial layer. The method comprises providing a semiconductor substrate. A seed area delineated with a selective growth mask is formed on the semiconductor substrate. The seed area comprises a first material and has a linear surface dimension of less than 100 nm. A heteroepitaxial layer is grown on the seed area, the heteroepitaxial layer comprising a second material that is different from the first material. Devices made by the method are also disclosed. |
| FILED | Tuesday, May 24, 2022 |
| APPL NO | 17/752228 |
| CURRENT CPC | Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures B82Y 10/00 (20130101) B82Y 40/00 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 21/02107 (20130101) H01L 21/02381 (20130101) H01L 21/02532 (20130101) H01L 21/02538 (20130101) H01L 21/02639 (20130101) H01L 27/1211 (20130101) H01L 29/04 (20130101) H01L 29/16 (20130101) H01L 29/20 (20130101) H01L 29/0665 (20130101) H01L 29/0673 (20130101) H01L 29/0676 (20130101) H01L 29/775 (20130101) H01L 29/785 (20130101) H01L 29/7783 (20130101) H01L 29/7827 (20130101) H01L 29/7851 (20130101) H01L 29/66462 (20130101) Original (OR) Class H01L 29/66469 (20130101) H01L 29/66666 (20130101) H01L 29/66795 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285642 | Ma et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Florida State University Research Foundation, Inc. (Tallahassee, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Biwu Ma (Tallahassee, Florida); Qingquan He (Tallahassee, Florida) |
| ABSTRACT | Methods of passivating a surface. The methods may include providing a mixture including a liquid and a derivative of quinacridone, applying the mixture to a first surface of a film that includes a metal halide perovskite, and annealing the film for a time and a temperature effective to convert the derivative of quinacridone to quinacridone. Composite materials and electronic devices also are provided. |
| FILED | Tuesday, March 02, 2021 |
| APPL NO | 17/189662 |
| CURRENT CPC | Processes for Applying Fluent Materials to Surfaces, in General B05D 1/005 (20130101) Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for H01L 51/448 (20130101) Original (OR) Class H01L 51/4213 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285666 | Zhu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of Indiana University (Indianapolis, Indiana); Argonne National Laboratory (Lemont, Illinois) |
| ASSIGNEE(S) | The Trustees of Indiana University (Indianapolis, Indiana) |
| INVENTOR(S) | Likun Zhu (Zionsville, Indiana); Shengfeng Yang (Carmel, Indiana); Xinwei Zhou (Zionsville, Indiana); Yuzi Liu (Lemont, Illinois) |
| ABSTRACT | A porous microstructure includes: a solid material, wherein the solid material allows conductivity of ions; and a plurality of nanopores defined within the solid material. |
| FILED | Tuesday, September 08, 2020 |
| APPL NO | 17/632490 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 4/13 (20130101) Original (OR) Class H01M 10/054 (20130101) H01M 10/0525 (20130101) H01M 2004/021 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220285704 | Barnett et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Northwestern University (Evanston, Illinois) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Scott A. Barnett (Evanston, Illinois); Travis Schmauss (Evanston, Illinois); Matthew Lu (Evanston, Illinois) |
| ABSTRACT | Motorized vehicles are provided which may a device configured to convert a fuel comprising a hydrocarbon, an alcohol, or both, to an exhaust comprising CO2; and a tank configured to store, under pressure, the exhaust comprising CO2 and an inlet port configured to receive the exhaust from the device. The device may be a solid oxide fuel cell (SOFC). The tank may be a co-storage tank configured to store, under pressure, the fuel comprising the hydrocarbon, the alcohol, or both, and the exhaust comprising CO2, the co-storage tank further comprising an outlet port configured to deliver the fuel to the device. Methods of using the motorized vehicle are also provided. |
| FILED | Tuesday, August 04, 2020 |
| APPL NO | 17/630212 |
| CURRENT CPC | Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy H01M 8/12 (20130101) H01M 8/04111 (20130101) H01M 8/04179 (20130101) Original (OR) Class H01M 8/04201 (20130101) H01M 2008/1293 (20130101) H01M 2250/20 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Veterans Affairs (DVA)
| US 20220280360 | Hansen et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Government as Represented by the Department of Veterans Affairs (Washington, District of Columbia); Regents of the University of Minnesota (St. Paul, Minnesota) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Andrew Hansen (Apple Valley, Minnesota); Gregory Owen Voss (Apple Valley, Minnesota); Eric Nickel (Minneapolis, Minnesota); Gary D. Goldish (Plymouth, Minnesota); John M. Looft (Minneapolis, Minnesota) |
| ABSTRACT | A wheelchair having a frame and a drive wheel coupled to the frame. The drive wheel rotates relative to the frame about a first axis of rotation. A first push rim is coupled to the frame. The first push rim rotates relative to the frame about a second axis of rotation that extends substantially parallel to the first axis of rotation. A second push rim is coupled to the frame. The second push rim rotates relative to the frame about a third axis of rotation that extends substantially parallel to the first axis of rotation. A transmission transmits rotation of each of the first and second push rims to the drive wheel. Movement of the first push rim by a first arc length causes the drive wheel to rotate by a first angular displacement, and movement of the second push rim by the first arc length causes the drive wheel to rotate by a second angular displacement that is greater than the first angular displacement. |
| FILED | Wednesday, March 02, 2022 |
| APPL NO | 17/684990 |
| CURRENT CPC | Transport, Personal Conveyances, or Accommodation Specially Adapted for Patients or Disabled Persons; Operating Tables or Chairs; Chairs for Dentistry; Funeral Devices A61G 5/022 (20130101) Original (OR) Class A61G 5/026 (20130101) Gearing F16H 1/28 (20130101) F16H 7/02 (20130101) F16H 7/06 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280370 | Higgins |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNITED STATES GOVERNMENT AS REPRESENTE BY THE DEPARTMENT OF VETERANS AFFAIRE (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Brian Higgins (Washington, District of Columbia) |
| ABSTRACT | Methods, systems, and apparatuses are described that are configured for determining a path of an apparatus, engaging a motor to cause the apparatus to proceed along the path, receiving one or more of LIDAR data, ultrasonic data, or optical flow data, determining, based on one or more of the LIDAR data, the ultrasonic data, or the optical flow data, one or more objects in the path of the apparatus, and engaging the motor to cause the apparatus to avoid the one or more objects. |
| FILED | Monday, September 28, 2020 |
| APPL NO | 17/632228 |
| CURRENT CPC | Physical Therapy Apparatus, e.g Devices for Locating or Stimulating Reflex Points in the Body; Artificial Respiration; Massage; Bathing Devices for Special Therapeutic or Hygienic Purposes or Specific Parts of the Body A61H 3/061 (20130101) Original (OR) Class A61H 3/068 (20130101) A61H 2003/063 (20130101) A61H 2201/0157 (20130101) A61H 2201/0173 (20130101) A61H 2201/1207 (20130101) A61H 2201/5012 (20130101) A61H 2201/5048 (20130101) A61H 2201/5058 (20130101) A61H 2201/5092 (20130101) Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves G01S 15/86 (20200101) G01S 15/93 (20130101) G01S 17/93 (20130101) G01S 19/01 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280472 | Goldblum et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Maryland, Baltimore (Baltimore, Maryland); The Governors of the University of Alberta (Edmonton, Canada); The United States Government as represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Simeon E. Goldblum (Baltimore, Maryland); Sergei P. Atamas (Ellicott City, Maryland); Irina G. Luzina (Ellicott City, Maryland); Christopher W. Cairo (Edmonton, Canada) |
| ABSTRACT | The present invention provides a method for treating a fibrotic lung disease or fibrotic lung condition in a subject that involves an increase in NEU1 expression and/or activity, comprising administering to the subject an effective amount of an agent that inhibits the activity of NEU 1 sialidase, thereby treating the fibrotic lung disease or fibrotic lung condition in the subject. |
| FILED | Wednesday, July 08, 2020 |
| APPL NO | 17/625059 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/351 (20130101) Original (OR) Class A61K 31/713 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 11/00 (20180101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280535 | ADAMS et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF IOWA RESEARCH FOUNDATION (Iowa City, Iowa); THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (Washington, District of Columbia) |
| ASSIGNEE(S) | UNIVERSITY OF IOWA RESEARCH FOUNDATION (IOWA CITY, Iowa); THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (WASHINGTON, District of Columbia) |
| INVENTOR(S) | Christopher M. ADAMS (Rochester, Minnesota); Steven D. KUNKEL (West Richland, Washington); Michael WELSH (Riverside, Iowa) |
| ABSTRACT | The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula: or a stereoisomer, solvate, or pharmaceutically acceptable salt thereof, thereby accomplishing one or more of (a)-(f). |
| FILED | Monday, May 17, 2021 |
| APPL NO | 17/321923 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 31/36 (20130101) A61K 31/56 (20130101) A61K 31/58 (20130101) Original (OR) Class A61K 31/215 (20130101) A61K 31/352 (20130101) A61K 31/353 (20130101) A61K 31/382 (20130101) A61K 31/404 (20130101) A61K 31/407 (20130101) A61K 31/435 (20130101) A61K 31/436 (20130101) A61K 31/437 (20130101) A61K 31/438 (20130101) A61K 31/473 (20130101) A61K 31/565 (20130101) A61K 31/4164 (20130101) A61K 31/4166 (20130101) A61K 31/4355 (20130101) A61K 31/4365 (20130101) A61K 31/4375 (20130101) A61K 31/4706 (20130101) Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes C12Q 1/6809 (20130101) C12Q 2600/136 (20130101) Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 33/5023 (20130101) G01N 2800/10 (20130101) G01N 2800/52 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280609 | DUBINETT et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); United States Government Represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| ASSIGNEE(S) | The Regents of the University of California (Oaklandca, None); United States Government Represented by the Department of Veterans Affairs (Washington, District of Columbia) |
| INVENTOR(S) | Steven M. DUBINETT (Los Angeles, California); Bin LIU (Woodland Hills, California); Raymond LIM (Tustin, California); Ramin SALEHI-RAD (Encino, California) |
| ABSTRACT | The present disclosure relates, in general, to methods for treating cancer comprising administering to a subject in need thereof an effective amount of CXCL9, CXCL10 or the combination, in combination with an immune checkpoint inhibitor. The CXCL9, CXCL10 or combination may be administered as a polypeptide, a polynucleotide or cells comprising a polynucleotide encoding CXCL9, CXCL10 or both. In one aspect, the treatment is amenable to patients with low or high mutational burden tumors. |
| FILED | Friday, July 17, 2020 |
| APPL NO | 17/625062 |
| CURRENT CPC | Preparations for Medical, Dental, or Toilet Purposes A61K 38/195 (20130101) Original (OR) Class A61K 45/06 (20130101) Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Peptides C07K 16/2818 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220280792 | GANGULY et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of California (Oakland, California); U.S. Government Represented by the Department of Veterans Affairs (Washington, District of Columbia); LightSide MD, LLC (Los Altos, California) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Karunesh GANGULY (San Francisco, California); Adelyn TSU (San Francisco, California); Nikhilesh NATRAJ (San Francisco, California); Gabriel Philip HOWLES-BANERJI (Oakland, California); Rajiv DOSHI (Los Altos, California); Kondapavulur T. VENKATESWARA-RAO (San Jose, California) |
| ABSTRACT | Methods and apparatuses for sensory electrical stimulation of the peripheral nervous system to improve human motor function and performance are described. Methods and devices may be used to enhance physical performance of athletes, professionals, and gamers or improve motor function (hand, finger and limb movement) in patients rehabilitating from neurological deficits and impairments caused by stroke, traumatic brain injury and other neurologic or non-neurologic conditions. These apparatuses and methods may be used for physical training and mental training (to improve memory and functional performance including motor coordination, limb-eye coordination, occupational and recreational skills) through periodic or sustained sensory electrical stimulation. Treatment plans may be based on biomarkers and may be used alone or in combination with other apparatuses. Learning and feedback techniques individualize treatment parameters depending on the subject's neurologic and motor function in diseased patients and healthy users. |
| FILED | Wednesday, March 23, 2022 |
| APPL NO | 17/702621 |
| CURRENT CPC | Diagnosis; Surgery; Identification A61B 5/002 (20130101) A61B 5/30 (20210101) A61B 5/375 (20210101) A61B 5/4047 (20130101) A61B 5/4824 (20130101) A61B 5/4848 (20130101) A61B 5/7275 (20130101) A61B 5/7455 (20130101) A61B 2505/09 (20130101) Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy A61N 1/378 (20130101) A61N 1/0456 (20130101) A61N 1/0484 (20130101) A61N 1/0492 (20130101) A61N 1/36021 (20130101) A61N 1/36031 (20170801) Original (OR) Class A61N 1/36034 (20170801) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Office of the Director of National Intelligence (ODNI)
| US 20220284106 | Stolfo et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Trustees of Columbia University in the City of New York (New York, New York) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Salvatore J. Stolfo (New York, New York); Preetam Kumar Dutta (New York, New York) |
| ABSTRACT | Methods, systems, and media for testing insider threat detection systems are provided. In some embodiments, the method comprises: receiving, using a hardware processor, a first plurality of actions in a computing environment that are associated with one of a plurality of user accounts; generating a plurality of models of user behavior based at least in part on the first plurality of actions, wherein each of the plurality of models of user behavior is associated with each of the plurality of user accounts; selecting a model of user behavior from the plurality of models of user behavior, wherein the model of user behavior is associated with a malicious user type; generating a simulated user bot based on the selected model of user behavior; executing the simulated user bot in the computing environment, wherein the simulated user bot injects a second plurality of actions in the computing environment; determining whether an insider threat detection system executing within the computing environment identifies the simulated user bot as a malicious user; and transmitting a notification indicating an efficacy of the insider threat detection system based on the determination. |
| FILED | Tuesday, October 26, 2021 |
| APPL NO | 17/511253 |
| CURRENT CPC | Electric Digital Data Processing G06F 21/577 (20130101) Original (OR) Class G06F 2221/034 (20130101) Transmission of Digital Information, e.g Telegraphic Communication H04L 67/306 (20130101) H04L 67/535 (20220501) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284288 | TOLIAS et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | BAYLOR COLLEGE OF MEDICINE (HOUSTON, Texas); UNIVERSITY OF TUBINGEN (TUBINGEN, Germany) |
| ASSIGNEE(S) | BAYLOR COLLEGE OF MEDICINE (HOUSTON, Texas); UNIVERSITY OF TUBINGEN (TUBINGEN, Germany) |
| INVENTOR(S) | ANDREAS TOLIAS (HOUSTON, Texas); ZHE LI (HOUSTON, Texas); ZACHARY PITKOW (HOUSTON, Texas); JOSUE ORTEGA CARO (HOUSTON, Texas); ANKIT PATEL (HOUSTON, Texas); JACOB REIMER (HOUSTON, Texas); MATTHIAS BETHGE (TUBINGEN, Germany); FABIAN SINZ (TUBINGEN, Germany) |
| ABSTRACT | The present disclosure relates to machine-learning generalization, and in particular to techniques for regularizing machine-learning The present disclosure relates to machine-learning generalization, and in particular to techniques for regularizing machine-learning models using biological systems (e.g. brain data) to engineer machine-learning-algorithms that can generalize better. Particularly, aspects are directed to a computer implemented method that includes measuring a plurality of biological responses (e.g. neural responses to stimuli or other variables such body movements); generating data (e.g. responses to stimuli) using the predictive model which can denoise biological data and extract task relevant information; scaling and transforming these predictions (e.g. measure representational similarities between stimuli); and using the biologically derived data to regularize machine-learning-algorithms. The method is applicable in many domains of computer science and artificial intelligence such as perception, learning, memory, cognition, decision making. |
| FILED | Thursday, September 24, 2020 |
| APPL NO | 17/641259 |
| CURRENT CPC | Computer Systems Based on Specific Computational Models G06N 3/08 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
United States Postal Service (USPS)
| US 20220280977 | Bombaugh et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Postal Service (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Scott R. Bombaugh (Burke, Virginia); Thomas J. Foti (Annandale, Virginia); David E. Loyd (Stafford, Virginia); Sarvang D. Shah (Fairfax, Virginia) |
| ABSTRACT | Embodiments of a system and method for sorting and delivering articles in a processing facility. Delivery endpoints are divided and grouped into stop groups. A first sorter sorts items according to stop group and outputs the items to trays. The output trays from the first sorter are loaded to a second sorter. The second sorter sorts items for each stop group into trays based on carrier route segments. A manifest is created that comprises a list of the items in a tray. A mobile computing device alerts a delivery carrier when there is an item that needs to be delivered. |
| FILED | Tuesday, May 24, 2022 |
| APPL NO | 17/664846 |
| CURRENT CPC | Postal Sorting; Sorting Individual Articles, or Bulk Material Fit to be Sorted Piece-meal, e.g by Picking B07C 3/00 (20130101) B07C 3/005 (20130101) Original (OR) Class B07C 3/14 (20130101) B07C 2301/0041 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
| US 20220284388 | Jones et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | United States Postal Service (Washington, District of Columbia) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Anthony Cramer Jones (Brooklyn, New York); Dominik Heinrich (New York, New York); Caspar Serge Ouvaroff (New York, New York) |
| ABSTRACT | Systems, methods, and media for the delivery of physical items using a digital stamp. Various implementations include operations such as receiving a request from a user to deliver an item to a destination using a digital stamp, wherein the item includes destination information and lacks any physical indicator that the delivery fee for the item has been paid or will be paid; receiving a destination address from the user; determining a delivery fee for the item; and generating a digital stamp using the destination address, the delivery fee, and user account information for the user. The operations may also include obtaining an image of the item including the destination information; determining, from the image, that the item lacks any physical indicator regarding the delivery fee; checking for a digital stamp corresponding to the item; and directing the item for delivery to the destination information, if the digital stamp is found. |
| FILED | Tuesday, May 24, 2022 |
| APPL NO | 17/752121 |
| CURRENT CPC | Data Processing Systems or Methods, Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes; Systems or Methods Specially Adapted for Administrative, Commercial, Financial, Managerial, Supervisory or Forecasting Purposes, Not Otherwise Provided for G06Q 10/0832 (20130101) Original (OR) Class G06Q 20/3223 (20130101) G06Q 50/32 (20130101) Ticket-issuing Apparatus; Fare-registering Apparatus; Franking Apparatus G07B 17/00508 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Agriculture (USDA)
| US 20220282266 | WANG et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (GAINESVILLE, Florida) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Nian WANG (Auburndale, Florida); Xiaoen HUANG (Lake Alfred, Florida); Tirtha LAMICHHANE (Winter Haven, Florida); Ali PARSAEIMEHR (Winter Haven, Florida); Su HANG (Winter Haven, Florida); Shumig WANG (Gainesville, Florida) |
| ABSTRACT | Disclosed herein are methods and materials for editing genes in citrus cells. Specifically exemplified is the implementation of an optimized Cas9 and the CRISPR type II class nuclease. Also exemplified is the use of a U6-1 promoter for driving expressing of editing constructs in citrus cells. Various protocols and sequences for editing genes are disclosed as well. |
| FILED | Monday, August 03, 2020 |
| APPL NO | 17/632371 |
| CURRENT CPC | Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media C12N 5/0025 (20130101) C12N 9/22 (20130101) C12N 15/11 (20130101) C12N 15/8205 (20130101) C12N 15/8213 (20130101) Original (OR) Class C12N 15/8281 (20130101) C12N 2310/20 (20170501) C12N 2800/80 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Department of Commerce (DOC)
| US 20220283059 | Friss et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | The Regents of the University of Colorado, a body corporate (Denver, Colorado); Government of the United States of America, as represented by the Secretary of Commerce, National In (Gaithersburg, Maryland) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Adam J. Friss (Louisville, Colorado); Megan E. Harries (Boulder, Colorado); Tara M. Lovestead (Louisville, Colorado) |
| ABSTRACT | Portable dynamic vapor micro-extraction systems for use in real-time trace vapor collection in the field. The system includes one or more wafer collection modules or cartridges that include a plurality of sample collection capillaries, each cartridge being receivable into an associated vapor collection device of the system, for collecting a vapor sample in the field. The vapor collection device includes a thermoelectric cooler providing a cold plate directly thermally coupled to an installed cartridge. The thermoelectric cooler provides cooling to a temperature below ambient temperature, while vapor sampling occurs. A pump draws the vapor sample through a sample port of the device, and into the received cartridge, such that target molecules to be detected are adsorbed. The system can further include a cartridge storage compartment, for storing the cartridges. |
| FILED | Friday, March 04, 2022 |
| APPL NO | 17/687155 |
| CURRENT CPC | Investigating or Analysing Materials by Determining Their Chemical or Physical Properties G01N 1/2214 (20130101) G01N 1/2273 (20130101) Original (OR) Class G01N 2001/2276 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
National Aeronautics and Space Administration (NASA)
| US 20220286874 | Barsoum et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | Constellation Designs, LLC (Anaheim, California) |
| ASSIGNEE(S) | Constellation Designs, LLC (Anaheim, California) |
| INVENTOR(S) | Maged F. Barsoum (San Jose, California); Christopher R. Jones (Pacific Palisades, California) |
| ABSTRACT | Communication systems are described that use unequally spaced constellations that have increased capacity compared to conventional constellations operating within a similar SNR band. One embodiment is a digital communications system including a transmitter transmitting signals via a communication channel, the transmitter including a coder capable of receiving user bits and outputting encoded bits at a rate, a mapper capable of mapping encoded bits to symbols in a constellation, and a modulator capable of generating a modulated signal for transmission via the communication channel using symbols generated by the mapper, wherein the constellation is unequally spaced and characterizable by assignment of locations and labels of constellation points to maximize parallel decode capacity of the constellation at a given signal-to-noise ratio so that the constellation provides a given capacity at a reduced signal-to-noise ratio compared to a uniform constellation that maximizes the minimum distance between constellation points of the uniform constellation. |
| FILED | Thursday, May 26, 2022 |
| APPL NO | 17/804305 |
| CURRENT CPC | Coding; Decoding; Code Conversion in General H03M 13/255 (20130101) H03M 13/6325 (20130101) Transmission H04B 15/00 (20130101) H04B 17/336 (20150115) Transmission of Digital Information, e.g Telegraphic Communication H04L 1/0003 (20130101) H04L 1/0009 (20130101) H04L 27/3405 (20130101) H04L 27/3483 (20130101) H04L 27/3809 (20130101) Wireless Communication Networks H04W 24/02 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
Small Business Administration (SBA)
| US 20220281862 | Liu et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | KUDA Therapeutics, Inc. (Salt Lake City, Utah) |
| ASSIGNEE(S) | |
| INVENTOR(S) | Xiaohui Liu (Salt Lake City, Utah); Mei Yee Koh (Salt Lake City, Utah) |
| ABSTRACT | Novel substituted imidazopyridine and oxazolopyridine compounds that are useful as inhibitors of HIF-2α and inducers of ferroptosis through perturbations in iron metabolism, synthetic methods for making said compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat disorders associated with dysfunction of HIF-2α or iron metabolism. |
| FILED | Friday, February 14, 2020 |
| APPL NO | 16/791148 |
| CURRENT CPC | Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations A61P 35/00 (20180101) Heterocyclic Compounds C07D 417/12 (20130101) Original (OR) Class C07D 471/04 (20130101) C07D 487/04 (20130101) C07D 498/04 (20130101) C07D 513/04 (20130101) |
| VIEW PATENT | @ USPTO: Full Text PDF |
Smithsonian Institution (SI)
| US 20220281816 | Luesch et al. |
|---|---|
| FUNDED BY |
|
| APPLICANT(S) | University of Florida Research Foundation, Incorporation (Gainesville, Florida); Smithsonian Institution (Washington, District of Columbia) |
| ASSIGNEE(S) | University of Florida Research Foundation, Incorporation (Gainesville, Florida); Smithsonian Institution (Washington, District of Columbia) |
| INVENTOR(S) | Hendrik Luesch (Gainesville, Florida); Xiao Liang (Gainesville, Florida); Susan Matthew (Houston, Texas); Jason C. Kwan (Gainesville, Florida); Qi-Yin Chen (Gainesville, Florida); Valerie J. Paul (Fort Pierce, Florida) |
| ABSTRACT | The invention is directed towards compounds (e.g., Formulae (I)-(IX)), their mechanism of action, processes to prepare the compounds, methods of activating quorum sensing signaling activity, and methods of treating diseases and disorders using the compounds described herein (e.g., Formulae (I)-(IX)). |
| FILED | Friday, July 24, 2020 |
| APPL NO | 17/630138 |
| CURRENT CPC | Heterocyclic Compounds C07D 207/38 (20130101) Original (OR) Class |
| VIEW PATENT | @ USPTO: Full Text PDF |
Government Rights Acknowledged
How To Use This Page
THE FEDINVENT PATENT APPLICATION DETAILS PAGE
Each week, FedInvent analyzes newly granted patents and published patent applications whose origins lead back to funding by the US Federal Government. The FedInvent Patent Details page is a companion to the weekly FedInvents Patents Report.
This week's information is published in the FedInvent Patents report for Thursday, September 08, 2022.
The FedInvent Weekly Patent Details Page contains a subset of patent information to provide a deeper dive into the week's taxpayer-funded patents to help the reader better understand where a patent fits in the federal innovation ecosphere.
HOW IS THE INFORMATION ORGANIZED?
Patents are organized by the funding agency. Within each group, the patents are organized in numeric order. A patent funded by more than one agency will appear in the section of each of the agencies that funded the research and development that resulted in the invention. This approach gives the reader a complete view of the department or agency activity for the week.
WHAT INFORMATION WILL I FIND?
THE PANEL
There is a panel for each patent that contains the patent number and the title of the patent. When you click the panel, it opens to reveal the following information:
FUNDED BY
The agencies that funded the grants, contracts, or other research agreements that resulted in the patent. FedInvent includes as much information on the source of the funding as possible. The information is presented in a hierarchy going from the Federal Department down to the agencies, subagencies, and offices that funded the work. Here are two examples:
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Army Research Office (ARO)
We do our best to provide detailed information about the funding. In some cases, the patent only reports limited information on the origins of the funding. FedInvents presents what it can confirm. We add the patents without the information required by the Bayh-Dole Act to our list of patents worthy of further investigation.
APPLICANT(S) and ASSIGNEES
FedInvent includes both the Applicants and the Assignees because having both provides more information about where the inventive work was done and by what organizations. Many organizations — universities, corporations, and federal agencies — standardize the Assignee/Owner information by the time a patent is granted. In the case of federal patents, many of the patents use the agency headquarters information for patent assignment.
Showing just the headquarters address would make Washington, DC the epicenter of all taxpayer-funded research and development. Providing both the applicant information and the assignee information provides a more accurate picture of where important taxpayer-funded innovation is happening in America. Here are two examples from two different patents:
APPLICANT: U.S. Army Research Laboratory, Adelphi, MD
ASSIGNEE: The United States of America as represented by the Secretary of the Army Washington, DC
APPLICANT: Optech Ventures, LLC (Torrance, California)
ASSIGNEE(S): The Regents of the University of California (Oakland, California); Optech Ventures, LLC (Torrance, California)
INVENTOR(S)
The inventors appear in the same order as they appear on the patent. FedInvents presents the names in first name/last name order because they are easier to read than the last name/first name order of the names on the USPTO patent documents.
ABSTRACT
The abstract is presented as it appears on the patent.
FILED
The date the patent application including the day of the week.
APPL NO
This is the patent application serial number. If you’d like to learn more about how application serial numbers work you can go to the Lists Page.
ART UNIT
Patent data includes the Art Unit where a patent was examined. (The Art Unit isn’t available for published patent applications.) The Art Unit provides insight into what group of patent examiners prosecuted the patent application and the subject matter that the examiners work on. For example:
3793 — Medical Instruments, Diagnostic Equipment, and Treatment Devices
You can learn more about ART UNITS on the FedInvent Patents Weekly panel called About Tech Center or you can find information on the FedInvent Lists Page.
CURRENT CPC
Current CPC provides a list of the Cooperative Patent Classification symbols assigned to the patent. These are the CPC symbols assigned at the time the patent was granted.
The FedInvent Project is a patent classification maximalist endeavor or put another way, we believe that the more you understand about patent classification the more you'll learn about the nature of the invention and the types of work that the federal government is funding.
The symbol presented in BOLD is the symbol identified as the "first" classification which is the most relevant classification on the patent. The date that follows the symbol is the date of the most recent revision to the art classed there.
- A61B 1/149 (20130101)
- A61B 1/71 (20130101)
- A61B 1/105 (20130101)
The CPC symbols match the classifications found on the PDF version of the patent. Over time, the classifications on the full text version of the patent change to reflect how USPTO organizes patent art to support its examiners. The two sets of CPCs don’t always match.
VIEW PATENT
As of June 2021, we include two ways to view a patent at USPTO. FedInvent provides a link to the Full-Text Version of the patent and a link to the PDF version of the patent.
HOW DO I FIND A SPECIFIC PATENT ON A PAGE?
You can use the Command F or Control F to find a specific patent you are interested in.
HOW DO I GET HERE?
You navigate to the details of a patent by clicking the information icon that follows a patent on the FedInvent Patents Weekly Report.
You can also reach this page using the weekly page link that looks like this:
https://wayfinder.digital/fedinvent/patents-2022/fedinvent-applications-20220908.html
Just update the date portion of the URL. Tuesdays for patents. Thursdays for pre-grant publication of patent applications.
Download a copy of the How To Use This Page